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   HYPOTHESIS	  AND	  SPECIFIC	  AIMS:	   	  The	  aim	  of	  this	  study	  is	  to	  characterize	  the	  incidence	  and	  outcomes	  of	  various	  groups	  within	  a	  novel	  classification	  system	  of	  severe	   sepsis	   and	   septic	   shock,	   for	   the	   purpose	   of	   informing	   more	   accurate	   risk	  prediction	  in	  the	  proximal	  phases	  of	  care.	   	  Our	  primary	  hypothesis	  is	  that	  an	  early	  classification	   system	   of	   septic	   patients	   categorized	   by	   organ	   dysfunction,	   initial	  emergency	  department	  (ED)	  serum	  lactate,	  and	  ED	  vasopressor	  utilization	  will	  offer	  accurate	  mortality	  prognostication	  in	  patients	  with	  severe	  sepsis	  and	  septic	  shock.	  
	   METHODS:	   	   We	   performed	   a	   retrospective	   analysis	   of	   a	   prospectively-­‐gathered	  registry	  of	  severe	  sepsis	  and	  septic	  shock	  patients	  presenting	  to	  a	  dual-­‐site	  academic	   emergency	   department	   (ED).	   	   In	   the	   primary	   analysis,	   registry	   subjects	  were	  categorized	  into	  five	  groups	  by	  initial	  ED	  serum	  lactate	  level	  and	  vasopressor	  requirement	   in	   the	   ED:	   dysoxic	   shock	   (vasopressor	   use	   +	   lactate	   >4	   mmol/L),	  vasoplegic	   shock	   (vasopressor	   use	   +	   lactate	   ≤4	  mmol/L),	   cryptic	   shock	  major	   (no	  vasopressor	  use	  +	   lactate	  >4	  mmol/L),	   cryptic	  shock	  minor	   (no	  vasopressor	  use	  +	  lactate	   >2	   and	   ≤4	   mmol/L),	   and	   severe	   sepsis	   without	   lactate	   elevation	   (no	  vasopressor	  use	  +	  lactate	  ≤2	  mmol/L	  +	  evidence	  of	  ≥1	  organ	  dysfunction).	  	  For	  each	  group,	  the	  28-­‐day	  mortality	  rate	  was	  evaluated	  by	  logistic	  regression	  controlling	  for	  specific	  factors	  associated	  with	  sepsis	  severity.	  
	   RESULTS:	   	  Of	   521	   registry	   subjects,	   85.6%	   (n=446)	  met	   inclusion	   criteria.	  	  4.9%	  (n=22)	  subjects	  presented	  in	  dysoxic	  shock,	  11.7%	  (n=52)	  in	  vasoplegic	  shock,	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12.1%	   (n=54)	   in	   cryptic	   shock	  major,	   30.9%	   (n=138)	   in	   cryptic	   shock	  minor,	   and	  40.4%	   (n=180)	   in	   severe	   sepsis	   without	   lactate	   elevation.	   	   The	   28-­‐day	   mortality	  rates	   for	   these	   groups	  were	  50.0%,	  21.1%,	  18.5%,	  12.3%,	   and	  7.2%,	   respectively;	  this	  stepwise	  trend	  was	  paralleled	  by	  metrics	  of	  critical	  care	  utilization	  such	  as	  ICU	  admission,	   mechanical	   ventilation,	   and	   vasopressor	   use	   within	   72	   hours	   of	  admission.	   	   After	   controlling	   for	   known	   risk	   factors	   for	   sepsis	   severity,	   the	   odds	  ratios	   for	   death	   before	   28	   days	  were	   15.06	   for	   dysoxic	   shock,	   3.61	   for	   vasoplegic	  shock,	  3.77	  for	  cryptic	  shock	  major,	  and	  1.93	  for	  cryptic	  shock	  minor,	  as	  compared	  to	  severe	  sepsis	  without	  lactate	  elevation.	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  Sepsis	  is	  a	  clinical	  syndrome	  of	  immense	  complexity,	  an	  understanding	  of	  which	  is	  essential	   for	   clinicians	   and	   researchers	   who	   hope	   to	   improve	   sepsis	   care.	   	   The	  following	   literature	   review	   explores	   the	   key	   epidemiologic	   and	   clinical	   aspects	   of	  sepsis	   that	   informed	   the	   current	   research	   project.	   	   After	   a	   review	   of	   the	  epidemiology	   and	   pathophysiology	   of	   sepsis,	   we	   summarize	   the	   current	   widely-­‐utilized	   system	   for	   classifying	   sepsis.	   	   This	   is	   followed	   by	   an	   appraisal	   of	   the	  literature	   on	   sepsis	   severity,	   evidencing	   the	   need	   for	   both	   simpler	   and	   more	  accurate	   sepsis	   classification	   systems.	   	   We	   conclude	   with	   a	   summary	   of	   various	  alternative	   classification	   systems	   for	   severe	   sepsis	   and	   septic	   shock,	   to	  which	   our	  system,	  described	  in	  this	  thesis,	  can	  be	  compared.	  	  
Epidemiology	  
	  The	  clinical	  entity	  of	  sepsis,	  a	  systemic	  inflammatory	  response	  to	  infection,	  is	  one	  of	  the	  greatest	  causes	  of	  morbidity	  and	  mortality	  in	  the	  United	  States.	  	  Sepsis	  is	  the	  6th	  most	   common	   admitting	   diagnosis	   in	   the	  US	   [1].	   	   In	   2009,	   836,000	  hospital	   stays	  were	   attributed	   to	   a	   principal	   diagnosis	   of	   sepsis,	  with	   another	   829,500	   having	   a	  secondary	  diagnosis	  of	  sepsis	  during	  the	  course	  of	  hospitalization;	  when	  combined,	  sepsis	  is	  implicated	  in	  4.2%	  of	  all	  hospitalizations	  [1].	  	  In	  addition,	  the	  incidence	  of	  sepsis	  has	  been	  trending	  upward.	  	  Hospital	  stays	  with	  a	  principal	  diagnosis	  of	  sepsis	  increased	   by	   153%	   between	   1993	   and	   2009:	   a	   six	   percent	   increase	   in	  hospitalizations	  due	   to	   sepsis	   every	   year	   [1].	   	   This	   trend	   is	   likely	   due	   to	   an	   aging	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population,	   increasing	   burden	   of	   other	   health	   conditions,	   a	   higher	   proportion	   of	  immunocompromised	  patients	  from	  any	  cause,	  and	  perhaps	  an	  increased	  awareness	  and	  documentation	  of	  sepsis	  by	  providers.	  	  Sepsis	  is	  also	  extremely	  costly,	  in	  terms	  of	  lives	  as	  well	  as	  care	  delivered.	  	  The	  mortality	  rate	  of	  all	  patients	  with	  a	  diagnosis	  of	   sepsis	   in	   the	  US	  was	  around	  16%	   in	  2009:	   eight	   times	  higher	   than	   the	  average	  mortality	   rate	   of	   all	   other	   hospital	   stays	   [1].	   	   Sepsis	   remains	   the	  most	   expensive	  reason	   for	   hospitalization	   in	   the	   US,	   with	   estimates	   of	   $15.4	   billion	   in	   aggregate	  hospital	  costs	  per	  year,	  representing	  4.0%	  of	  all	  hospital	  costs	  [1].	  	  	   Sepsis	   may	   also	   be	   increasing	   in	   severity.	   	   The	   incidence	   of	   severe	   sepsis	  (defined	   as	   sepsis-­‐induced	   organ	   dysfunction,	   hypoperfusion	   or	   hypotension)	   is	  reportedly	   between	   256,000-­‐700,000	   per	   year	   [2-­‐4],	   with	   an	   increase	   of	   around	  13%	  per	  year	   [5]:	   far	   faster	   than	   the	   rate	  of	   increase	  of	  all	   sepsis	  diagnoses.	   	  One	  study	  documented	  that	  the	  percentage	  of	  sepsis	  presentations	  qualifying	  as	  severe	  sepsis	   increased	   from	   26%	   to	   44%	   between	   1993	   and	   2003	   [2].	   	   Severe	   sepsis	  accounts	  for	  between	  6	  and	  15%	  of	  all	  intensive	  care	  unit	  (ICU)	  admissions,	  and	  is	  estimated	  to	  consume	  up	  to	  half	  of	  ICU	  resources	  [3].	  	  Many	  of	  these	  sicker	  patients	  will	  present	  through	  the	  emergency	  department	  (ED);	  severe	  sepsis	  is	  the	  suspected	  diagnosis	  in	  571,000	  ED	  visits	  annually	  [6].	  	  Thus,	  the	  majority	  of	  patients	  in	  severe	  sepsis	  will	  be	  hospitalized	  through	  the	  ED.	   	  	   Fortunately,	  in-­‐hospital	  mortality	  from	  sepsis	  may	  be	  decreasing.	  	  In	  a	  recent	  multicenter	   observational	   study	   involving	   over	   100,000	   ICU	   patients	   with	   severe	  sepsis,	   the	  mortality	   rate	  decreased	  between	  2000	  and	  2012,	   from	  35%	   to	  18.4%	  [7].	   	   This	   dramatic	   drop	   in	   mortality	   has	   been	   mirrored	   in	   other	   studies,	   both	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observationally	  after	  implementation	  of	  protocol-­‐based	  care	  [8,	  9]	  and	  in	  the	  control	  groups	  of	  recent	  randomized	  trials	  [10,	  11].	  	  It	  is	  unknown	  whether	  the	  decreasing	  mortality	   rates	   seen	   in	   these	   trials	   represent	   an	   improvement	   in	   sepsis	  interventions	   or	   an	   increased	   recognition	   of	   sepsis	   in	   infected	   patients.	  	  Nevertheless,	   given	   the	   increasing	   incidence	  of	   sepsis	  as	  discussed	  previously,	   the	  absolute	  number	  of	  deaths	  due	  to	  sepsis	  is	  likely	  still	  on	  the	  rise.	  	  By	  some	  estimates,	  severe	  sepsis	  accounts	  for	  around	  220,000	  deaths	  per	  year,	  making	  it	  the	  3rd	  most	  common	  cause	  of	  death	  in	  the	  US,	  after	  heart	  disease	  and	  malignancy	  [1].	  	   Although	   the	   trend	   towards	   improved	   immediate	   mortality	   is	   heartening,	  less	  is	  known	  about	  the	  long-­‐term	  prognosis	  of	  sepsis	  survivors.	  	  In	  a	  recent	  meta-­‐analysis,	  a	  discharge	  diagnosis	  of	  sepsis	  carried	  an	  increased	  risk	  of	  recurrent	  sepsis	  as	  well	  as	  death	  after	  hospital	  discharge,	  with	  a	  mortality	  rate	  between	  7	  and	  43%	  at	  one	  year	  [12].	  	  Sepsis	  survivors	  were	  more	  likely	  to	  be	  discharged	  to	  acute	  or	  long-­‐term	   care	   facilities	   than	   other	   discharged	   patients	   of	   similar	   illness	   severity;	  furthermore,	   they	  suffered	  a	  pronounced	  decrease	   in	  quality	  of	   life	  when	  matched	  against	   their	   own	   pre-­‐sepsis	   condition,	   as	   well	   as	   compared	   to	   other	   patients	  recovering	  from	  critical	  illness	  [13,	  14].	  	  	  
Pathophysiology	  	   	  
The	  inflammatory	  response	  and	  microvascular	  dysfunction	  A	   basic	   understanding	   of	   the	   pathophysiology	   of	   sepsis	   is	   germane	   to	   both	   its	  clinical	   consequences	   and	   management.	   	   The	   presence	   of	   infection,	   usually	   by	  bacterial	   or	   fungal	   organisms,	   triggers	   an	   initial	   immune	   response	   via	   pattern-­‐recognition	   receptors	   in	   the	  cells	  of	   the	   innate	   immune	  system.	   	  Occasionally,	   and	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for	   reasons	   not	   well	   understood,	   local	   infection	   will	   trigger	   a	   systemic	   response	  heralding	   the	   onset	   of	   sepsis.	   	   This	   host	   response	   involves	   both	   pro-­‐	   and	   anti-­‐inflammatory	   pathways,	   and	   imbalances	   in	   these	   pathways,	   both	   in	   time	   and	   in	  scale,	   can	   be	   damaging	   to	   the	   host.	   	   In	   general,	   the	   pro-­‐inflammatory	   pathways	  activate	  earlier	   in	  the	  course	  of	  sepsis	  and	  are	  involved	  in	  controlling	  and	  clearing	  the	   infectious	   organism;	   these	   pathways	   are	   mostly	   implicated	   in	   the	   collateral	  damage	   to	   host	   organs	   in	   severe	   sepsis	   and	   septic	   shock	   [15].	   	   The	   anti-­‐inflammatory	  pathways	  are	  generally	  associated	  with	  repairing	  tissue	  damage	  and	  may	  peak	  later	  in	  the	  course	  of	  sepsis.	  	  In	  a	  weakened	  host,	  dampening	  the	  immune	  response	  can	  increase	  the	  risk	  of	  secondary	  and	  opportunistic	  infections	  [15].	  	   Pro-­‐inflammatory	   processes	   conspire	   to	   orchestrate	   the	   dysfunctional	   and	  self-­‐perpetuating	   tissue	  damage	   that	  underlies	   severe	  sepsis.	   	  Activated	  via	   innate	  responses	   to	  pathogen	  motifs,	   leukocytes	   infiltrate	  both	   infected	  and	  non-­‐infected	  tissues,	  activating	  complement	  and	  releasing	  damaging	  substrates	  such	  as	  proteases	  and	   reactive	   oxygen	   species.	   	   When	   misdirected,	   these	   attacks	   cause	   damage	   to	  normally-­‐functioning	  host	  cells.	  	  The	  pro-­‐inflammatory	  milieu	  is	  also	  responsible	  for	  coagulation	  abnormalities	  via	  the	  intermediary	  protease-­‐activated	  receptors	  (PARs)	  [15].	  	  Increased	  tissue	  factor	  from	  damaged	  endothelial	  cells,	  the	  down-­‐regulation	  of	  normal	  anticoagulant	  mechanisms	  (protein	  C,	  S,	  and	  antithrombin),	  and	  depression	  of	   natural	   fibrinolysis	   all	   contribute	   to	   clot	   formation;	   the	   ultimate	   result	   is	  disseminated	  intravascular	  coagulation	  (DIC)	  [16].	  	  The	  downstream	  effect	  of	  these	  pathways,	   especially	   in	   the	   presence	   of	   hypoperfusion,	   is	   damage	   to	   collateral	  tissues	  and	  organ	  dysfunction.	   	   Furthermore,	  necrotic	   cell	  death	   releases	  damage-­‐
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associated	   molecular	   pattern	   (DAMP)	   molecules,	   leading	   to	   a	   vicious	   cycle	   of	  immune	  activation	  and	  tissue	  destruction	  [15].	  	   The	  key	  intermediary	  between	  the	  damage	  described	  above	  and	  global	  tissue	  underperfusion	   is	   the	   vascular	   endothelium;	  microvascular	  dysfunction	   lies	   at	   the	  basis	  of	  severe	  sepsis	  and	  septic	  shock.	   	  The	  microvascular	  circulation	   is	   the	  main	  controller	   of	   end-­‐organ	   perfusion	   [17].	   	   In	   severe	   sepsis,	   the	   diffuse	   endothelial	  damage,	   hypercoagulability,	   and	   loss	   of	   vascular	   barrier	   function	   impair	   oxygen	  delivery	   and	   cause	   third-­‐spacing	   of	   fluids	   into	   tissues.	   	   The	   resulting	   tissue	  hypoperfusion	  leads	  to	  abnormal	  systemic	  vasodilation	  and	  a	  decrease	  in	  systemic	  vascular	   resistance,	   likely	   via	   uninhibited	   release	   of	   vasoactive	  mediators	   such	   as	  nitric	   oxide	   and	   prostacyclin.	   	   When	   not	   corrected,	   these	   hypovolemic	   and	  distributive	  mechanisms	   contribute	   to	   hypoperfusion,	   organ	   dysfunction,	   and	   the	  shock	  state.	  	  
Organ-­‐specific	  dysfunction	  At	   the	   level	   of	   individual	   organs,	   direct	   tissue	   damage	   and	   hypoperfusion-­‐related	  anoxic	  injury	  is	  initially	  reversible;	  however,	  if	  not	  corrected	  these	  insults	  can	  lead	  to	  irreversible	  loss	  of	  function	  and	  ultimately	  to	  organ	  failure.	  	  The	  mechanisms	  and	  clinical	  manifestations	  of	   failure	   in	  each	  organ	  are	  distinct.	   	  Acute	  kidney	   injury	   is	  common,	  either	  as	  a	  consequence	  of	  decreased	  perfusion	  or	  direct	  vascular	   injury;	  tubular	  necrosis	  and	  resultant	  chronic	  kidney	  disease	  can	  occur	  if	  the	  insults	  are	  not	  adequately	  reversed	  [18].	   	  Similarly,	  hypoperfusion	  and	  damage	  to	  the	  blood-­‐brain	  barrier	  can	  cause	  acute	  central	  nervous	  system	  (CNS)	  disturbances,	  most	  commonly	  encephalopathy.	  	  Splanchnic	  hypoperfusion	  can	  lead	  to	  gut	  translocation	  of	  bacteria	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and	  bacterial	  toxins,	  the	  systemic	  effects	  of	  which	  are	  multiplied	  if	  hypoperfusion	  of	  the	  liver	  decreases	  first-­‐pass	  metabolism	  [19].	  	  	   Microvascular	   damage	   to	   the	   pulmonary	   circulation	   can	   impair	   barrier	  function	   of	   alveolar	   capillaries,	   leading	   to	   interstitial	   and	   alveolar	   edema.	   	   The	  clinical	   effect	   is	   ventilation/perfusion	   mismatching,	   causing	   hypoxemia:	   if	   severe	  enough,	  the	  acute	  respiratory	  distress	  syndrome	  (ARDS)	  develops,	  as	  evidenced	  by	  a	   PaO2/FiO2	   ratio	   of	   less	   than	   300	   [20].	   	   Sepsis-­‐induced	   ARDS	   seems	   to	   be	  much	  more	   common	   in	   chronic	   alcoholics	   [21].	   	   Sepsis-­‐induced	   cardiomyopathy	   is	  another	  well-­‐recognized	  clinical	   entity.	   	  The	  mechanism	   is	  not	  entirely	  elucidated,	  but	   certainly	   involves	  myocardial	   depression	  by	   inflammatory	   cytokines;	   in	   shock	  states,	   cardiac	  muscle	   hypoperfusion	   likely	   contributes	   [22].	   	   In	   one	   study	   of	   108	  severe	   sepsis	   and	   septic	   shock	   patients,	   64%	   had	   evidence	   of	   myocardial	  dysfunction,	   whether	   via	   left	   ventricular	   systolic,	   diastolic,	   or	   right	   ventricular	  failure	   [23].	   	   The	   development	   of	   cardiomyopathy	   also	   contributes	   to	   poor	   tissue	  oxygenation	  and	  has	  implications	  for	  treatment	  strategies.	  	  
Evidence	  of	  systemic	  hypoperfusion	  At	  the	  global	   level,	   impairment	  in	  microvascular	  circulation	  and	  hypotension	  leads	  to	   an	   imbalance	   between	   oxygen	   delivery	   and	   oxygen	   requirements:	   a	   critical	  juncture	  on	  the	  path	  to	  tissue	  hypoxia,	  irreversible	  tissue	  damage,	  organ	  failure,	  and	  death.	  	  The	  relationship	  between	  global	  oxygen	  consumption	  and	  its	  determinants	  is	  summarized	  in	  the	  following	  equation:	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  (Equation	  1)	   VO2	  =	  CO	  ×	  Hb	  ×	  1.34	  ×	  (SaO2	  –	  Sv02)	  	  	  	  	  	  (VO2:	  oxygen	  consumption,	  CO:	  cardiac	  output,	  Hb:	  hemoglobin	  concentration,	  	  	  	  	  	  	  	  	  	  SaO2:	  oxygen	  saturation	  of	  arterial	  blood,	  SvO2:	  oxygen	  saturation	  of	  mixed	  	  	  	  	  	  	  	  	  	  	  venous	  blood)	  	  	   When	  oxygen	  demand	  (DO2)	  outstrips	  supply,	  a	  DO2/VO2	  mismatch	  develops,	  and	   the	   body	   attempts	   to	   respond	   to	   global	   tissue	   hypoxia	   by	   optimizing	   certain	  variables	  in	  the	  equation	  above	  [24].	   	  Regulation	  of	  some	  of	  these	  variables	  occurs	  directly:	   in	   brief,	   cardiac	   output	   is	   regulated	   by	   autonomic	   nervous	   activity	   and	  catecholaminergic	   stimuli,	   SaO2	   by	   changes	   in	   ventilator	   drive,	   and	   hemoglobin	  levels	  (slowly)	  by	  EPO	  secretion	  and	  subsequent	  RBC	  production.	  	  In	  contrast,	  there	  does	   not	   appear	   to	   be	   any	   direct	   process	   by	  which	   the	   body	   regulates	   SvO2	   [24].	  	  Therefore,	  changes	  in	  SvO2	  are	  most	  truly	  representative	  of	  a	  growing	  gap	  between	  oxygen	  consumption	  and	  oxygen	  demand	  by	  tissues:	  the	  DO2/VO2	  mismatch.	  	  ScvO2,	  the	   saturation	   of	   venous	   blood	   at	   the	   level	   of	   the	   entrance	   to	   the	   right	   atrium,	   is	  considered	  a	  surrogate	   for	  SvO2;	   it	   is	  usually	  3-­‐5mmHg	  higher	   than	  SvO2	   [24].	   	  As	  will	  be	  discussed	  in	  a	  later	  section,	  ScvO2	  is	  often	  measured	  in	  clinical	  situations	  and	  utilized	  as	  a	  surrogate	  for	  the	  adequacy	  of	  oxygen	  delivery	  in	  severe	  sepsis.	  	  	   Another	   physiologic	   marker	   of	   tissue	   hypoxia	   is	   the	   serum	   lactate	   level.	  	  Under	  hypoxic	  conditions,	  lactate	  is	  a	  byproduct	  of	  cellular	  glycolysis	  to	  regenerate	  much-­‐needed	  reducing	  power	  (in	  the	  form	  of	  NAD+).	  	  Lactate	  excreted	  from	  the	  cell	  into	  the	  bloodstream	  can	  either	  be	  metabolized	  directly	  by	  certain	  tissues	  (such	  as	  the	  heart)	  or	  converted	  into	  glucose	  via	  gluconeogenesis	  in	  the	  Cori	  cycle,	  mostly	  in	  the	  liver	  but	  to	  a	  smaller	  extent	  in	  the	  kidneys	  [25].	  	  This	  production	  of	  lactate	  often	  parallels	   the	   increased	   production	   and	   release	   of	   protons	   by	  metabolically-­‐active,	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hypoxic	   cells	   (a	   result	   of	   a	   shift	   in	   the	   ratio	   of	  ATP	   to	  ADP/AMP)	   [25].	   	   Thus,	   the	  serum	   lactate	   has	   traditionally	   served	   as	   a	   marker	   for	   the	   presence	   of	   tissue	  hypoxia,	   whether	   at	   the	   local	   level	   (in	   acute	  mesenteric	   ischemia)	   or	   globally	   (in	  various	   forms	   of	   shock).	   	   Lactate	   production	   could	   also	   occur	   via	   anaerobic	  metabolism	   in	   the	   absence	   of	   hypoxia,	   as	   seen	   with	   mitochondrial	   dysfunction	  states.	  	  	  	   More	   recently,	   the	   accuracy	   of	   using	   lactate	   levels	   as	   an	   indicator	   of	  anaerobic	   states	   has	   been	   questioned,	   and	   alternative	   hypotheses	   have	   been	  proposed.	   	   Lactate	   may	   be	   a	   byproduct	   of	   stress-­‐induced	   muscle	   metabolism,	   a	  hypermetabolic	  response	  to	  the	  catecholaminergic	  surge	  commonly	  seen	  in	  severe	  sepsis.	  	  Alternatively,	  a	  decrease	  in	  lactate	  clearance	  by	  the	  liver	  or	  kidneys	  may	  be	  responsible	   for	   lactate	   elevation	   in	   a	   subset	   of	   septic	   patients	   [25].	   	   Some	   studies	  even	   suggest	   that	   elevated	   lactate	   may	   play	   a	   protective	   role	   in	   sepsis	   as	   an	  alternative	  metabolic	  fuel	  for	  the	  heart	  and	  brain	  [26].	  	  Although	  uncertainty	  exists	  regarding	  its	  true	  nature,	  the	  serum	  lactate	  level	  continues	  to	  be	  utilized	  in	  clinical	  situations	  as	  a	  surrogate	  for	  tissue	  hypoxia	  and	  as	  a	  prognostic	  indicator	  in	  sepsis.	  	  
Classification	  	   	  Given	  the	   incredible	  variability	  of	  physiologic	  derangements	   in	  sepsis,	  an	   inclusive	  and	   accurate	   classification	   system	   is	   essential	   for	   aiding	   clinical	   diagnosis	   and	  treatment	   decisions,	   as	   well	   as	   for	   informing	   study	   design.	   	   For	   many	   years,	   the	  medical	   field	   lacked	   definitive	   criteria	   for	   making	   the	   diagnosis	   of	   sepsis	   and	  documenting	  its	  severity.	  	  In	  1992,	  the	  American	  College	  of	  Chest	  Physicians	  (ACCP)	  and	  the	  Society	  for	  Critical	  Care	  Medicine	  (SCCM)	  jointly	  developed	  a	  classification	  
	  	  
9	  
system	  for	  sepsis	  in	  order	  to	  standardize	  diagnosis	  and	  to	  categorize	  cases	  along	  a	  spectrum	  of	  disease	  severity	  [27].	  	  	  	   The	  classification	  system	  included	  various	  definitions	  for	  sepsis	  syndromes.	  	  It	   first	  defined	  the	  systemic	  inflammatory	  response	  syndrome	  (SIRS),	  composed	  of	  four	  criteria:	   fever	   (>38°C)	  or	  hypothermia	   (<36°C),	   tachycardia	   (>90	  beats/min),	  tachypnea	   (>30	   breaths/min)	   or	   PaCO2	   <32	   mmHg,	   and	   an	   abnormal	   WBC	  (>12,000,	  <4,000,	  or	  >10%	  bands).	  	  The	  diagnosis	  of	  SIRS	  requires	  fulfilling	  at	  least	  2	  of	  the	  4	  above	  criteria	  [27],	  shown	  in	  Table	  1.	  	  	  Table	  1.	  	  Criteria	  for	  the	  Systemic	  Inflammatory	  Response	  Syndrome	  (SIRS)*	  (1) temperature	  >	  38°C	  or	  <	  36°C	  (2) heart	  rate	  >	  90	  beats	  per	  minute	  (3) respiratory	  rate	  >	  20	  breaths	  per	  minute	  or	  PaCO2	  <	  32mmHg	  (4) white	  blood	  cell	  count	  >	  12,000/mm3,	  <	  4,000/mm3,	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  or	  >	  10%	  immature	  (band)	  forms	  *	  Adapted	  from	  ACCP/SCCM	  Consensus	  Conference	  [27].	  	  	   Using	   the	   above	   criteria	   for	   the	   system	   inflammatory	   response,	   the	  consensus	   defined	   sepsis	   as	   the	   presence	   of	   SIRS	  with	   a	   documented	   or	   probable	  infectious	   source.	   	   Severe	   sepsis	   was	   defined	   as	   sepsis	   with	   organ	   dysfunction,	  hypoperfusion,	   or	   hypotension;	   sepsis-­‐induced	   hypotension	   is	   a	   subset	   of	   severe	  sepsis	   defined	   by	   a	   systolic	   blood	   pressure	   (SBP)	   less	   than	   90	   mmHg,	   a	   mean	  arterial	  pressure	   (MAP)	   less	   than	  65	  mmHg,	  or	  a	  decrease	   in	  SBP	  greater	   than	  40	  mmHg	   from	   baseline.	   	   The	  most	   severe	   form	   of	   sepsis	   is	   septic	   shock,	   defined	   as	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sepsis	  with	  persistent	  hypotension	  or	  hyperlactatemia	  (above	  4.0	  mmol/L)	  despite	  adequate	   fluid	   resuscitation.	   These	   definitions	   have	   been	   shown	   to	   correlate	  stepwise	  with	  mortality:	  in	  one	  large	  series,	  patients	  with	  SIRS,	  sepsis,	  severe	  sepsis	  and	   septic	   shock	   had	   hospital	   mortality	   rates	   of	   7%,	   16%,	   20%,	   and	   46%,	  respectively	  [28].	  	   	  	   The	   consensus	   document	   also	   categorized	   the	   multiple	   organ	   dysfunction	  syndrome	   (MODS),	   a	   severe	   and	   deadly	   consequence	   of	   sepsis	   related	   to	  hypoperfusion	  and	  endothelial	  damage.	  	  Multiple	  organ	  failure	  in	  response	  to	  acute	  insult	  had	  already	  been	  recognized	  for	  many	  years,	  but	  the	   focus	  of	   the	  consensus	  document	  on	  organ	  dysfunction,	  before	   the	  presence	  of	  overt	   failure,	  was	  original.	  	  The	   document	   defined	   MODS	   as	   “the	   presence	   of	   altered	   organ	   function	   in	   an	  acutely	   ill	   patient	   such	   that	   homeostasis	   cannot	   be	   maintained	   without	  intervention,”	   and	  subclassified	  MODS	   into	  primary	  and	  secondary	  etiologies	   [27].	  	  Primary	  MODS	   can	  be	   considered	   a	   direct	   reaction	   to	   the	   initial	   insult;	   secondary	  MODS	  is	  a	  consequence	  of	  the	  host	  response	  to	  the	  original	  injury.	   	  Either	  type	  can	  lead	   to	   progressive	   organ	   failure	   and	   death,	   sometimes	   far	   removed	   in	   time	   and	  severity	   from	   the	   initial	   presentation	   [27].	   	   Although	   no	   universally-­‐accepted	  criteria	  exist	  for	  the	  diagnosis	  of	  MODS,	  it	  logically	  requires	  the	  continued	  presence	  of	  multiple	  measures	  of	  organ	  dysfunction.	  
 In	   2001,	   the	   ACCP/SCCM	   revisited	   their	   consensus	   document	   and	   altered	  some	   of	   their	   previous	   definitions,	  most	   importantly	   on	   the	   concept	   of	   SIRS	   [29].	  	  Although	   characteristic	   of	   sepsis,	   the	   presence	   of	   SIRS	   is	   also	   common	   in	   other	  conditions,	  including	  trauma,	  pancreatitis,	  and	  burns.	  	  However,	  these	  criteria	  are	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Table	  2.	  	  Sepsis	  definitions,	  International	  Sepsis	  Definitions	  Conference.*	  Infection,	  documented	  or	  suspected,	  and	  some	  of	  the	  following:	  	  General	  variables	  	  	  	  	  	  	  	  	  Fever	  (core	  temperature	  >38.3°C)	  	  	  	  	  	  	  	  	  Hypothermia	  (core	  temperature	  <36°C)	  	  	  	  	  	  	  	  	  Heart	  rate	  >90	  min-­‐1	  or	  >2	  SD	  above	  the	  normal	  value	  for	  age	  	  	  	  	  	  	  	  	  Tachypnea	  	  	  	  	  	  	  	  	  Altered	  mental	  status	  	  	  	  	  	  	  	  Significant	  edema	  or	  positive	  fluid	  balance	  (>20	  mL/kg	  over	  24	  hrs)	  	  	  	  	  	  	  	  	  Hyperglycemia	  (plasma	  glucose	  >120	  mg/dL	  or	  7.7	  mmol/L)	  in	  the	  absence	  of	  diabetes	  	  Inflammatory	  variables	  	  	  	  	  	  	  	  	  Leukocytosis	  (WBC	  count	  >12,000	  μL-­‐1)	  	  	  	  	  	  	  	  	  Leukopenia	  (WBC	  count	  <4000	  μL-­‐1)	  	  	  	  	  	  	  	  	  Normal	  WBC	  count	  with	  >10%	  immature	  forms	  	  	  	  	  	  	  	  	  Plasma	  C-­‐reactive	  protein	  >2	  SD	  above	  the	  normal	  value	  	  	  	  	  	  	  	  	  Plasma	  procalcitonin	  >2	  SD	  above	  the	  normal	  value	  	  Hemodynamic	  variables	  	  	  	  	  	  	  	  	  Arterial	  hypotension	  (SBP	  <90	  mm	  Hg,	  MAP	  <70,	  or	  an	  SBP	  decrease	  >40	  mm	  Hg	  in	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  adults	  or	  <2	  SD	  below	  normal	  for	  age)	  	  	  	  	  	  	  	  	  	  SvO2	  >70%	  
	  	  	  	  	  	  	  	  	  	  	  Cardiac	  index	  >3.5	  L/min/M-­‐23	  	  Organ	  dysfunction	  variables	  	  	  	  	  	  	  	  	  Arterial	  hypoxemia	  (PaO2/FIO2	  <300)	  	  	  	  	  	  	  	  	  Acute	  oliguria	  (urine	  output	  <0.5	  mL/kg/hr	  or	  45	  mmol/L	  for	  at	  least	  2	  hours)	  	  	  	  	  	  	  	  	  Creatinine	  increase	  >0.5	  mg/dL	  	  	  	  	  	  	  	  	  Coagulation	  abnormalities	  (INR	  >1.5	  or	  aPTT	  >60	  secs)	  	  	  	  	  	  	  	  Ileus	  (absent	  bowel	  sounds)	  	  	  	  	  	  	  	  	  Thrombocytopenia	  (platelet	  count	  <100,000	  μL-­‐1)	  	  	  	  	  	  	  	  	  Hyperbilirubinemia	  (plasma	  total	  bilirubin	  >4	  mg/dL	  or	  70	  mmol/L)	  	  Tissue	  perfusion	  variables	  	  	  	  	  	  	  	  	  Hyperlactatemia	  (>1	  mmol/L)	  	  	  	  	  	  	  	  	  Decreased	  capillary	  refill	  or	  mottling	  	  	  *	  Adapted	  from	  2001	  SCCM/ESICM/ACCP/ATS/SIS	  International	  Sepsis	  Definitions	  Conference	  [29].	  WBC,	  white	  blood	  cell;	  SBP,	  systolic	  blood	  pressure;	  MAP,	  mean	  arterial	  blood	  pressure;	  SvO2,	  mixed	  venous	   oxygen	   saturation;	   INR,	   international	   normalized	   ratio;	   aPTT,	   activated	   partial	  thromboplastin	  time.	  	  	  not	   exclusive	   to	   these	   disease	   states	   but	   are	   in	   fact	   present	   in	  many	   hospitalized	  patients;	   in	  one	  recent	  study	  of	  over	  100,000	  ED	  encounters,	   the	  presence	  of	  SIRS	  correlated	  with	  infection	  in	  only	  26%	  of	  cases,	  whereas	  56%	  of	  patients	  with	  SIRS	  did	  not	  fit	  into	  disease	  states	  normally	  associated	  with	  these	  criteria	  [30].	  	  Given	  the	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increased	  scrutiny	  surrounding	  the	  tenuous	  ability	  of	  the	  SIRS	  criteria	  to	  delineate	  the	  host	  response	  to	  infection,	  the	  ACCP/SCCM	  redefined	  sepsis	  as	  the	  presence	  of	  documented	   or	   probable	   infection	   in	   association	   with	   clinical	   signs/symptoms	  suggestive	   of	   a	   broader	   inflammatory	   response	   [29];	   these	   consist	   of	   clinical	   and	  laboratory	  variables	  as	  displayed	  in	  Table	  2.	  	  This	  definition	  suspended	  the	  explicit	  need	  for	  2	  of	  4	  SIRS	  criteria	  to	  be	  met.	  	  However,	  despite	  their	  removal	  from	  current	  sepsis	   guidelines,	   SIRS	   criteria	   are	   still	   widely	   used	   as	   convenient	   objective	  measures	   of	   sepsis	   in	   observational	   trials,	   in	   accordance	   with	   the	   original	   1992	  consensus.	  	  
Indicators	  of	  sepsis	  severity	  	  Despite	   its	   utility,	   our	   current	   classification	   system	   for	   sepsis	   belies	   an	   incredibly	  diverse	   patient	   population;	  many	   factors	   influence	   the	   severity	   of	   the	   illness	   and	  alter	   the	   prognosis	   of	   the	   individual	   patient.	   	   Recognizing	   the	   incredible	  heterogeneity	   in	   sepsis	   and	   the	   many	   factors	   affecting	   outcomes,	   the	   2001	  International	   Sepsis	   Definitions	   Conference	   conceptualized	   a	   new	   system	   for	  categorizing	   sepsis	   [29].	   	   The	   PIRO	   system	   (which	   stands	   for	   Predisposition,	  Infection,	  Response	  and	  Organ	  dysfunction)	  is	  loosely	  designed	  around	  known	  and	  suspected	   prognostic	   factors,	   and	   offers	   a	   template	   by	   which	   clinicians	   can	  conceptualize	   the	   severity	   of	   an	   individual	   patient’s	   septic	   presentation.	   	   The	  following	   sections	  will	   discuss	   known	   risk	   factors	   in	   each	   component	   of	   the	  PIRO	  system.	  	  Therapeutic	  factors	  also	  influence	  outcomes	  in	  sepsis,	  as	  will	  be	  discussed	  in	  a	  later	  section.	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Predisposing	  characteristics	  of	  the	  host	  Well-­‐known	   risk	   factors	   for	   developing	   sepsis	   include	   age,	   certain	   demographic	  factors,	   and	   comorbidities.	   	   Elderly	   age	   is	   a	   strong	  predictor	   of	   developing	   sepsis,	  with	  a	  stepwise	  increase	  in	  risk:	  in	  a	  longitudinal	  survey	  of	  over	  30,000	  adults,	  the	  hazard	  ratios	  for	  developing	  sepsis	  in	  adults	  between	  the	  ages	  of	  55-­‐64,	  65-­‐74,	  and	  ≥75	  were	  1.44,	  2.29,	  and	  3.87	  respectively	  when	  compared	  to	  an	  age	  range	  of	  45-­‐54	  [31].	   	   In	   the	   same	   study,	   the	   frequency	   of	   sepsis	   episodes	   also	   correlated	  significantly	   with	   tobacco	   use,	   alcohol	   use,	   lower	   education,	   and	   lower	   income.	  	  Women	  who	  develop	  sepsis	  are	  generally	  older	  and	  less	  likely	  to	  have	  severe	  sepsis	  than	  their	  male	  counterparts,	  but	  are	  possibly	  at	  increased	  risk	  of	  death	  in	  the	  ICU	  [32,	  33].	   	  Chronic	  comorbid	  conditions	  which	  increase	  the	  likelihood	  of	  developing	  sepsis	   include	  a	  history	  of	   chronic	   lung	  disease,	  peripheral	  artery	  disease,	   chronic	  kidney	  disease,	  myocardial	   infarction	  and	  diabetes,	  among	  others;	   the	  presence	  of	  multiple	  comorbidities	  has	  an	  additive	  effect	  on	  the	  risk	  of	  developing	  sepsis	   [31].	  	  Lastly,	   there	   is	   likely	   a	   large	   genetic	   component	   involving	   innate	   and	   adaptive	  immunity	  that	  exacerbates	  or	  mitigates	  the	  risk	  of	  sepsis	  [34].	  	   Furthermore,	  the	  severity	  and	  prognosis	  of	  a	  sepsis	  episode	  is	  influenced	  by	  underlying	   comorbidities.	   	   Age	   above	   40	   years	   is	   a	   stepwise	   negative	   prognostic	  factor,	   and	   the	   effect	   of	   increasing	   age	   is	   most	   pronounced	   in	   the	   absence	   of	  comorbidities	   [3].	   	  Mortality	   from	  sepsis	  seems	   to	  be	   lowest	   in	  previously	  healthy	  young	   adults:	   in	   a	   large	   retrospective	   analysis,	   adults	   younger	   than	   45	   without	  comorbidities	  who	  developed	  severe	  sepsis	  had	  a	  mortality	  rate	  of	  less	  than	  5%	  [7].	  	  Immunocompromised	   states	   such	   as	   AIDS	   [35],	   solid	   or	   hematologic	   malignancy	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[36],	   neutropenia	   [36],	   chronic	   liver	   disease	   [3],	   chronic	   renal	   disease	   [3],	   and	  asplenia	   [37]	   worsen	   prognosis	   to	   varying	   degrees	   in	   severe	   sepsis.	   	   Alcohol	  dependence	   is	   independently	   associated	   with	   higher	   mortality	   in	   critically-­‐ill	  patients	  with	  severe	  sepsis	  and	  septic	  shock	  [38].	  	  	  
Characteristics	  of	  infection	  The	  prognosis	   in	   sepsis	   is	   also	  predicated	  on	   the	   characteristics	  of	   the	  underlying	  infection.	   	  The	   type	  of	  organism	  responsible	  may	   influence	  outcomes.	   	  The	   largest	  observational	   trial	  of	  sepsis	   to	  date	  showed	  that	  Gram-­‐positive	  organisms	  account	  for	  the	  majority	  (52.1%)	  of	  sepsis	  cases	  with	  a	  documented	  culture,	  as	  compared	  to	  gram-­‐negative	   organisms	   (37.6%),	   polymicrobial	   infections	   (4.7%),	   fungal	  infections	  (4.6%),	  and	  anaerobes	  (1.0%)	  [4].	  	  Other	  studies	  have	  shown	  that	  Gram-­‐negative	   sepsis	   cases	   may	   predominate	   in	   the	   ICU	   setting	   [39,	   40].	   	   The	   most	  common	   Gram-­‐positive	   organisms	   are	   Staphylococcus	   aureas	   and	   Streptococcus	  pneumonia,	  whereas	  Gram-­‐negative	  organisms	  are	  usually	  E.	  coli,	  Pseudomonas	  and	  Klebsiella	  subspecies	  [41].	  	  Although	  the	  presence	  of	  bacteremia	  positively	  predicts	  the	   development	   of	   SIRS	   [42],	   bacteremia	   itself	   does	   not	   appear	   to	   be	   associated	  with	  mortality	   in	   sepsis	   [43].	   	   Bloodstream	   infections	   carry	   a	   worse	   prognosis	   if	  they	  are	  caused	  by	  nosocomial	  pathogens,	  such	  as	  MRSA	  (OR	  2.7),	  fungal	  infections	  (OR	  2.32-­‐2.66)	  or	  pseudomonas	  (OR	  1.6)	  [44].	  	  However,	  only	  one	  third	  to	  one	  half	  of	   septic	  patients	  have	  positive	  blood	  cultures	   [45,	  46],	  and	  up	   to	  30%	  of	  patients	  have	   negative	   cultures	   from	   all	   sites	   [40].	   	   In	   some	   cases,	   blood	   cultures	  may	   be	  incorrectly	  negative	  due	  to	  previous	  use	  of	  antibiotics	  or	  the	  incorrect	  collection	  of	  blood	  cultures	  [47].	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   The	   source	   of	   infection	   in	   sepsis	   likewise	   influences	   severity.	   	   Respiratory	  infections	   are	   the	   most	   common	   source	   (35-­‐44%),	   followed	   by	   urinary	   (9-­‐37%),	  occult	  bacteremia	  (12-­‐17%),	  abdominal	  (8-­‐19%),	  wound/soft	  tissue	  (5-­‐7%),	  device-­‐related	   (2-­‐6%),	   and	   other	   sources	   (including	   endocarditis,	   CNS,	   bone	   and	   joint	  infections)	  [3,	  45,	  48].	  	  Sepsis	  develops	  commonly	  in	  the	  setting	  of	  pneumonia;	  in	  an	  observational	   study	   of	   1,339	   patients	   admitted	   with	   community-­‐acquired	  pneumonia	  (CAP),	  severe	  sepsis	  developed	  in	  48%	  [49].	  	   Sepsis	   from	   a	   genitourinary	   source	   (urosepsis)	   is	   generally	   considered	   to	  have	  a	  better	  prognosis	  than	  other	  causes	  of	  sepsis,	  especially	  pneumonia	  [3,	  50].	  	  In	  a	   study	   cohort	  of	   almost	  200,000	  patients	   in	   the	  United	  States,	  Angus	  et	   al.	   found	  that	  patients	  who	  developed	  severe	  sepsis	  from	  a	  lung	  infection	  had	  a	  mortality	  of	  32.9%,	  whereas	  the	  mortality	  of	  urosepsis	  was	  16.1%	  [3].	   	  In	  a	  more	  recent,	  large-­‐scale	   cohort	   from	   Australia,	   the	   mortality	   from	   urosepsis	   in	   2012	   was	   6.7%	  compared	  to	  17.0%	  in	  sepsis	  from	  a	  non-­‐urinary	  source	  [7].	  	  The	  range	  of	  prognosis	  in	  sepsis	  from	  abdominal	  sources	  seems	  to	  be	  wider;	  although	  one	  study	  showed	  a	  mortality	   rate	   of	   55%	   in	   septic	   patients	  with	   abdominal	   foci,	   larger	   studies	   quote	  mortality	   rates	  closer	   to	  urosepsis	   [3].	   	  This	  may	  be	  due	   to	  differences	   in	  severity	  between	  sources	  within	  the	  abdomen.	   	   In	  one	  study	  of	  around	  8,000	  patients	  with	  septic	   shock,	   mortality	   rates	   depended	   on	   the	   underlying	   diagnosis	   including	  ischemic	   bowel	   (77.9%),	   spontaneous	   bacterial	   peritonitis	   (76.4%),	   perforated	  viscus	   (55.6%),	   pancreatitis	   (50.0%),	   cholecystitis/cholangitis	   (38.3%),	   and	  enterocolitis/diverticulitis	   (28.0%)	   [51];	   these	   rates	   roughly	   reflect	   the	   clinical	  severity	  of	  the	  underlying	  disease	  process.	   	  In	  the	  same	  study,	  mortality	  from	  skin,	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soft-­‐tissue	  and	  bone	  infections	  was	  high	  (42.0-­‐52.5%).	   	  Furthermore,	  the	  presence	  of	  multiple	  sources	  of	  infection	  seems	  to	  portend	  a	  poor	  prognosis	  [52].	   	  However,	  distinctions	   in	   mortality	   between	   different	   infectious	   sources	   are	   not	   universally	  demonstrable	  [43].	  	  	  
Features	  of	  the	  host	  response	  Many	  clinicians	  are	  intuitively	  aware	  that	  a	  formidable	  host	  response	  to	  infection,	  as	  exhibited	   by	   abnormalities	   in	  multiple	   SIRS	   criteria,	   is	   clinically	   relevant	   and	   has	  prognostic	   information.	   	   In	   one	   study	   of	   the	   SIRS	   criteria,	   in-­‐hospital	   mortality	  increased	  steadily,	   from	  14%	  with	  2	  criteria,	  26%	  with	  3	  criteria,	  and	  36%	  with	  4	  SIRS	  criteria	  met	  [42].	  	  In	  keeping	  with	  this	  data,	  most	  of	  our	  current	  therapies	  seek	  to	   counteract	   the	   excessive	   host	   response	   to	   infection	   that	   occurs	   in	   sepsis.	  	  However,	   comparatively	   little	   is	   known	   about	   the	   specific	   pathways	   of	   host	  response	   that	   correlate	   with	   severity	   in	   sepsis.	   Biomarkers	   of	   immune	   activation	  may	  hold	  promise	  as	  risk	  stratifiers,	  and	  over	  150	  have	  been	  proposed.	   	  C-­‐reactive	  protein	   is	   the	   most	   widely	   available	   marker	   of	   the	   inflammatory	   response;	   it	   is	  released	  by	  hepatocytes	   after	   stimulation	   from	  cytokines	   including	   IL-­‐6	   as	  part	   of	  the	   acute	   phase	   response.	   	   However,	   given	   its	   frequent	   elevation	   in	   non-­‐septic	  conditions,	  its	  specificity	  is	  too	  poor	  to	  be	  of	  use	  as	  a	  prognostic	  indicator.	  	  	   Procalcitonin	   is	   one	   of	   the	   best	   markers,	   not	   only	   for	   its	   high	   negative	  predictive	  value	  in	  ruling	  out	  infection	  but	  also	  as	  a	  prognosticator	  of	  severity	  [53].	  	  Although	  not	  specifically	  performed	  in	  sepsis,	  one	  study	  of	  472	  critically-­‐ill	  patients	  demonstrated	  an	  increased	  risk	  of	  death	  with	  an	  initial	  elevated	  procalcitonin	  level	  or	  an	   increase	  over	  24	  hours	  [54].	   	  The	  ability	  of	  other	  biomarkers,	   including	   IL-­‐6	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and	   sTREM-­‐1,	   to	   risk-­‐stratify	   sepsis	   patients	   remains	   undefined.	   	   It	   is	   likely	   that,	  given	  the	  complexity	  of	  the	  host	  immune	  response,	  combinations	  of	  biomarkers	  will	  allow	  for	  better	  risk	  stratification	  than	  any	  single	  marker	  alone.	   	  However,	  there	  is	  as	  yet	  no	  evidence	  that	  incorporation	  of	  sepsis	  biomarkers,	  including	  procalcitonin,	  into	  sepsis	  alerts	  has	  improved	  outcomes.	  	   Impairment	   in	   certain	   host	   endocrine	   pathways	   may	   exacerbate	  hypoperfusion	   in	   sepsis	   by	   augmenting	   systemic	   vasodilatation.	   	   A	   relative	  deficiency	   of	   endogenous	   cortisol,	   called	   critical	   illness-­‐related	   corticosteroid	  insufficiency	  (CIRCI),	  is	  commonly	  seen	  in	  sepsis;	  this	  syndrome	  is	  likely	  an	  effect	  of	  inflammatory	  mediators	  on	  both	  suppression	  of	  the	  hypothalamic-­‐pituitary-­‐adrenal	  axis	   and	  peripheral	   tissue	   corticosteroid	   resistance	   [55].	   	  The	  prevalence	  of	  CIRCI	  may	  be	  as	  high	  as	  60%	  in	  patients	  with	  septic	  shock	  [56].	   	  A	  relative	  deficiency	   in	  vasopressin	  in	  septic	  shock	  patients	  may	  also	  contribute	  to	  hypotension	  [57].	  	  	  	  
Organ	  dysfunction	  As	  was	  discussed	  in	  the	  previous	  section,	  severe	  sepsis	  (which	  by	  definition	  involves	  sepsis-­‐induced	   organ	   dysfunction)	   carries	   a	   worse	   prognosis	   than	   the	   sepsis	  syndrome.	   	   However,	   the	   type	   of	   organ	   or	   organ	   system	   involved	   also	   seems	   to	  affect	  outcomes.	  	  In	  a	  retrospective	  analysis	  of	  over	  3,000	  patients	  presenting	  to	  an	  emergency	   department	   with	   sepsis,	   Shapiro	   et	   al.	   found	   higher	   odds	   ratios	   for	  mortality	  in	  patients	  with	  hematologic	  (OR	  4.5),	  cardiovascular	  (3.6),	  or	  respiratory	  (3.6)	  dysfunction	   [58].	   	   In	  particular,	   coagulation	  dysfunction	   is	   considered	  one	  of	  the	   worst	   organ	   dysfunctions	   in	   severe	   sepsis;	   the	   presence	   of	   DIC	   is	   an	  independent	  predictor	  of	   organ	   failure	   and	  mortality,	  with	   a	   rate	  of	  up	   to	  77%	   in	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Risk	  scoring	  systems	  Given	   the	   massive	   heterogeneity	   of	   the	   patient	   population	   in	   sepsis,	   and	   the	  presence	  of	  many	  known	  and	  presumed	  prognostic	   influences,	  much	  research	  has	  been	  focused	  on	  finding	  a	  more	  universal	  system	  of	  prognostication.	  	  One	  method	  is	  to	  create	  objective	  scores	  to	  signify	  increased	  risk	  of	  a	  poor	  outcome.	  	  Some	  scoring	  systems,	   such	   as	   the	   Pneumonia	   Severity	   Index	   (PSI)	   or	   CURB-­‐65	   for	   pneumonia,	  are	  limited	  to	  a	  single	  type	  of	  presentation	  and	  are	  not	  generalizable.	  	  The	  APACHE	  II	  score	  was	  originally	  formulated	  to	  be	  used	  72	  hours	  into	  admission	  for	  critically-­‐ill	  patients,	  and	  incorporates	  12	  physiologic	  variables	  [62].	  	  In	  a	  study	  of	  fewer	  than	  100	   critically-­‐ill	   patients	  presenting	   to	   the	  ED,	  Nguyen	   et	   al.	   found	   that	   the	   initial	  APACHE	  II	  predicted	  mortality	  at	  12	  hours,	  and	  that	  the	  largest	  changes	  in	  the	  score	  over	   hospitalization	   occurred	   in	   the	   first	   few	   hours	   within	   the	   emergency	  department	  [63].	   	  However,	  these	  data	  are	  not	  exclusive	  to	  septic	  patients,	  and	  the	  score	  is	  too	  cumbersome	  to	  be	  utilized	  clinically	  in	  the	  emergency	  department.	  	   Scores	  dedicated	  to	  assessing	  organ	  dysfunction	  in	  sepsis	  are	  widespread	  in	  the	   research	   literature.	   	   Two	   of	   the	   most	   prominent	   are	   the	   Multiple	   Organ	  Dysfunction	   Score	   (MODS)	   and	   the	   Sequential	   Organ	   Failure	   Assessment	   (SOFA).	  	  MODS	   was	   developed	   in	   1995,	   after	   an	   extensive	   search	   of	   the	   previous	   sepsis	  literature	  to	  identify	  the	  most	  optimal	  descriptors	  of	  organ	  failure	  [64].	  	  The	  MODS	  included	   six	   components	   of	   organ	   dysfunction:	   respiratory	   (PaO2/FiO2),	   renal	  (creatinine	   level),	   hepatic	   (bilirubin	   levels),	   hematologic	   (platelet	   count),	   CNS	  (Glasgow	  Coma	  Scale),	   and	   cardiovascular	   (pressure-­‐adjusted	  heart	   rate,	   a	  unique	  variable	  devised	  for	  the	  score).	  Each	  dysfunction	  was	  scored	  from	  0	  to	  4,	  for	  a	  total	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MODS	   score	   out	   of	   24	   points.	   	   In	   the	   validation	   cohort,	   the	   MODS	   score	   was	  predictive	  of	  ICU	  mortality	  in	  a	  graded	  fashion:	  mortality	  was	  25%	  with	  scores	  of	  9-­‐12,	   50%	  with	   scores	   of	   13-­‐16,	   75%	  with	   scores	   of	   17-­‐20,	   and	   100%	  with	   scores	  greater	  than	  20	  [64].	  	   The	   SOFA	   score	   is	   another	   method	   of	   characterizing	   organ	   dysfunction.	  	  Similarly	   to	   the	   MODS,	   the	   SOFA	   score	   incorporates	   assessments	   of	   respiratory	  (PaO2/FiO2),	   hepatic	   (bilirubin	   level),	   renal	   (creatinine	   level	   or	   urine	   output),	  neurologic	   (Glasgow	   Coma	   Score),	   cardiovascular	   (hypotension)	   and	   hematologic	  (platelet	  count)	  function.	  	  In	  the	  ICU	  setting,	  the	  initial,	  peak	  and	  mean	  SOFA	  scores	  all	  correlate	  well	  with	  mortality	  [65].	  	  In	  a	  population	  of	  248	  emergency	  department	  patients	  with	   severe	   sepsis	   and	   evidence	   of	   hypoperfusion,	   the	   initial	   SOFA	   score	  was	  found	  to	  be	  moderately	  effective	  at	  predicting	  in-­‐hospital	  mortality	  [66].	  	   However,	  risk	  in	  sepsis	  depends	  on	  more	  than	  merely	  the	  presence	  of	  organ	  dysfunction,	   as	   the	   PIRO	  model	   shows.	   	   Howell	   et	   al.	   developed	   a	   scoring	   system	  based	  on	  the	  full	  extent	  of	  risk	  variables	  involved	  in	  sepsis	  severity;	  their	  PIRO	  score	  incorporated	  predisposing	  traits	  (age,	  COPD,	  liver	  disease,	  malignancy,	  and	  nursing	  home	   residency),	   infection	   characteristics	   (pneumonia,	   cellulitis,	   or	   other),	   host	  response	   criteria	   (tachypnea,	   tachycardia,	   and	   bandemia)	   and	   various	   objective	  measures	   of	   organ	   dysfunction	   [67].	   	   In	   the	   derivation	   cohort	   as	   well	   as	   in	   two	  validation	  cohorts,	  the	  PIRO	  score	  had	  a	  high	  degree	  of	  accuracy	  in	  predicting	  sepsis	  mortality	  [67].	  	  Because	  it	  incorporates	  known	  risk	  factors	  from	  each	  component	  of	  the	   PIRO	   system,	   the	   PIRO	   score	   is	   intuitively	   attractive	   as	   a	   prognostic	   tool;	  however,	  its	  complexity	  may	  make	  it	  unwieldy	  in	  the	  emergency	  department.	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   Responding	  to	  the	  need	  for	  a	  PIRO-­‐based,	  prognostic	  tool	  for	  sepsis	  patients	  in	   the	   emergency	   setting,	   Shapiro	   et	   al.	   developed	   the	   Mortality	   in	   Emergency	  Department	   Sepsis	   (MEDS)	   score.	   	   As	   shown	   in	   Table	   3,	   the	   MEDS	   score	  incorporates	  nine	  clinical	  variables	  that	  are	  immediately	  available	  from	  the	  patient	  history,	   physical	   exam,	   and	   early	   laboratory	   results.	   	   In	   the	   validation	   set	   of	   the	  initial	  study,	  the	  MEDS	  score	  correlated	  impressively	  with	  in-­‐hospital	  mortality,	  in	  a	  graded	  fashion:	  1.1%	  with	  MEDS	  0-­‐4,	  4.4%	  with	  MEDS	  5-­‐7,	  9.3%	  with	  MEDS	  8-­‐12,	  16%	  with	  MEDS	  12-­‐15,	  and	  39%	  with	  MEDS	  >15	  [68].	   	  The	  score	  and	  its	  stepwise	  correlation	   with	   28-­‐day	   mortality	   has	   been	   externally	   validated	   by	   other	  investigators	  [69],	  it	  performs	  similarly	  to	  the	  more	  complex	  PIRO	  score,	  and	  it	  may	  outperform	  organ	  dysfunction	  scores	  (such	  as	  SOFA)	  originally	  formulated	  for	  	  
 
Table	  3.	  	  Mortality	  in	  Emergency	  Department	  Sepsis	  (MEDS)	  Score.	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  Points	  
	  	  	  	  	  Rapidly	  terminal	  co-­‐morbid	  illness*	  	  	  	  	  	  Age	  >	  65	  years	  	  	  	  	  	  	  Bands	  >	  5%	  	  	  	  	  	  Tachypnea	  or	  hypoxemia	  	  	  	  	  	  	  	  	  	  	  Septic	  shock	  	  	  	  	  	  Platelet	  count	  <	  150,000	  mm3	  	  	  	  	  	  Altered	  mental	  status	  	  	  	  	  	  Nursing	  home	  resident	  	  	  	  	  	  Lower	  respiratory	  infection	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  2	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	  Adapted	  from	  Shapiro	  et	  al.	  [68].	  *	  Terminal	   illness	   is	  defined	  as	  metastatic	  cancer	  or	  a	  disease	  condition	  with	  a	  >50%	  likelihood	  of	  predicted	  fatality	  within	  30	  days.	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hospitalized	  patients	  [70].  One	  potential	  problem	  with	  the	  MEDS	  score	  exists	  in	  the	  intermediate	   range	   (scores	   5-­‐15)	  where	  MEDS	  may	  underestimate	  mortality	   [71].	  	  Another	  criticism	  of	  MEDS	  is	  that	  it	  places	  a	  great	  deal	  of	  weight	  (6	  points)	  on	  the	  assessment	  of	  a	  terminal	  chronic	  condition,	  which	  is	  somewhat	  subjective	  and	  often	  outweighs	  other	  components	  of	  the	  score.	  	  
Serum	  lactate	  as	  prognostic	  measure	  The	   best	   prognostication	   tool	   would	   ideally	   be	   an	   objective	   measure,	   readily	  available	  and	  easily	   interpretable	  upon	  patient	  presentation.	   	  One	  such	  measure	   is	  the	   lactate	   level.	   	   As	   described	   in	   a	   previous	   section,	   the	   serum	   lactate	   level	  may	  represent	   tissue	   hypoperfusion,	   a	   hypermetabolic	   state	  with	   activation	   of	   skeletal	  muscle,	  mitochondrial	  dysfunction,	  decreased	  clearance	  by	  the	  liver	  or	  kidneys,	  or	  a	  combination	  of	  these	  mechanisms.	  	  An	  elevated	  lactate	  is	  also	  not	  specific	  for	  severe	  sepsis	  and	  occurs	  in	  many	  other	  disease	  states,	  such	  as	  in	  other	  forms	  of	  shock,	  liver	  failure,	  drugs	  and	   toxins	   (especially	  when	   interfering	  with	  mitochondrial	  activity),	  diabetic	  ketoacidosis,	  and	  regional	  forms	  of	   ischemia	  [25].	   	  However,	  regardless	  of	  etiology,	  the	  serum	  lactate	  has	  been	  used	  for	  decades	  as	  a	  marker	  of	  poor	  prognosis	  and	  mortality	   in	  sepsis	   [72,	  73].	   	   In	  2005,	  Shapiro	  et	  al.	   reported	  a	  study	  of	  1,278	  patients	   presenting	   to	   an	   emergency	   department	   with	   an	   infection-­‐related	  diagnosis;	   28-­‐day	   mortality	   rates	   for	   normal	   (<2.5	   mmol/L),	   intermediate	   (2.5-­‐4	  mmol/L)	   and	   high	   (>4	   mmol/L)	   lactate	   levels	   were	   4.9%,	   9.0%	   and	   28.4%	  respectively.	   	  Furthermore,	   the	  specificity	  of	  a	  high	   lactate	   for	  death	  within	  3	  days	  was	  91%,	  although	  the	  sensitivity	  was	  poor	  [74].	  	  
	  	  
23	  
	   Many	  other	  studies	  have	  supported	  these	  findings	  [75-­‐77].	   	   In	  one	  series	  of	  over	  800	  patients	  presenting	  to	  the	  emergency	  department,	  both	  intermediate	  (2-­‐4	  mmol/L)	   and	   high	   (>4	   mmol/L)	   lactate	   levels	   correlated	   with	   28-­‐day	   mortality;	  these	   associations	  persisted	   in	  both	   shock	   and	  non-­‐shock	  groups	   after	   controlling	  for	  the	  severity	  of	  other	  organ	  dysfunction	  [75].	   	  Howell	  et	  al.	   found	  that	  in	  severe	  sepsis,	  an	  initial	  lactate	  level	  greater	  than	  2.5	  mmol/L	  was	  associated	  with	  an	  odds	  ratio	  for	  hospital	  mortality	  of	  7.1	  compared	  to	  a	  lactate	  less	  than	  2.5	  mmol/L	  [78].	  	  After	   admission,	   sustained	   elevations	   in	   lactate	   is	   a	   poor	   prognostic	   sign:	   time-­‐weighted	  lactate	  levels	  >2	  mmol/L,	  also	  known	  as	  the	  “lac-­‐time”	  [79],	  is	  associated	  with	  an	  in-­‐hospital	  mortality	  OR	  of	  4.8	  [76].	   	  Even	  lactate	  levels	  within	  the	  normal	  range	   (defined	   in	   one	   study	   as	   <2.3	  mmol/L)	   are	   predictive	   of	   organ	   dysfunction	  and	  mortality	  in	  septic	  shock	  [77].	  	   Given	   its	   very	   clear	   prognostic	   value,	   some	   clinicians	   have	   considered	  entirely	   replacing	   the	  more	  difficult	   and	   invasive	  measurements	   of	   hypoperfusion	  (such	   as	   ScvO2)	   with	   serial	   lactate	   measurements.	   	   One	   possible	   goal	   is	   lactate	  clearance,	   defined	   as	   a	   decrease	   in	   the	   serum	   lactate	   level	   during	   sepsis	  resuscitation.	   	   Nguyen	   et	   al.	   calculated	   6-­‐hour	   lactate	   clearance	   in	   111	   septic	  patients	   presenting	   to	   an	   emergency	   department	   and	   found	   that	   a	   low	   lactate	  clearance	   (<10%	  decrease	   or	   any	   increase	   from	   initial	   lactate	   level)	   had	   a	   67.6%	  accuracy	  of	  predicting	   in-­‐hospital	  mortality	  [80].	   	  The	  specificity	  of	   this	  cutoff	  was	  84%,	   although	   the	   sensitivity	  was	   very	   low.	   	   Furthermore,	   the	   authors	   estimated	  that	   the	   risk	   of	   death	   decreased	   by	   around	  11%	   for	   each	   10%	   increase	   in	   lactate	  clearance	  at	  6	  hours.	  	  Arnold	  et	  al.	  published	  a	  similar	  trial	  showing	  that	  lactate	  non-­‐
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clearance	   was	   associated	   with	   a	   mortality	   rate	   of	   60%	   vs.	   19%	   with	   clearance.	  	  Interestingly,	   in	   this	   trial,	   79%	   of	   patients	  with	   lactate	   non-­‐clearance	   had	  met	   an	  ScvO2	  goal	  of	  ≥70%	  [81].	  	  These	  data	  have	  spurred	  the	  use	  of	  lactate	  clearance	  as	  a	  goal	  for	  directing	  sepsis	  resuscitation	  in	  the	  proximal	  phases	  of	  care.	  	  In	  one	  trial	  to	  test	   the	   role	   of	   lactate	   compared	   to	   ScvO2	   in	   goal-­‐directed	   resuscitation	   of	   early	  sepsis,	   Jones	   et	   al.	   found	   that	   lactate	   clearance	   was	   non-­‐inferior	   to	   ScvO2	  optimization	  in	  predicting	  hospital	  mortality	  [82].	  	  
Management	  	  The	  proper	  management	  of	  sepsis	  relies	  on	  early	  identification	  of	  patients,	  prompt	  treatment	   with	   antibiotics	   and	   infectious	   source	   control,	   and	   appropriate	  hemodynamic	   resuscitation	   governed	   by	   perfusion	   assessments.	   	   These	   priorities	  are	  detailed	   in	  the	  Surviving	  Sepsis	  Campaign	  (SSC),	  originally	   formulated	   in	  2004	  and	  most	  recently	  updated	  in	  2012	  [83-­‐85].	  	  
Early	  identification	  The	  management	   of	   sepsis	   relies	   first	   and	   foremost	   on	   the	   recognizing	   the	   initial	  clinical	  signs	  and	  physiologic	  derangements	  that	  occur	  in	  patients	  with	  early	  sepsis.	  	  Similar	  to	  the	  concept	  of	  the	  “golden	  hour”	  in	  other	  life-­‐threatening	  conditions	  such	  as	  trauma,	  myocardial	  infarction	  and	  stroke,	  early	  recognition	  allows	  sepsis-­‐specific	  therapies	  to	  be	  quickly	  implemented	  and	  may	  decrease	  the	  likelihood	  of	  progressing	  to	  a	  more	  severe	  septic	  state.	   	  The	  key	  ingredients	  for	  early	  identification	  of	  sepsis	  include	   a	   high	   clinical	   suspicion	   for	   infection,	   the	   identification	   of	   a	   physiologic	  response	   indicative	   to	   systemic	   inflammation,	   and	   subsequent	   screening	   for	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associated	   hypoperfusion	   or	   organ	   dysfunction.	   However,	   the	   often-­‐cryptic	  presentation	  of	  early	  sepsis	  requires	  a	  much	  higher	  degree	  of	  clinical	  suspicion	  and	  a	  more	  thorough	  screening	  assessment	  than	  may	  be	  necessary	  in	  other	  conditions.	  	   One	  screening	  method	   involves	  assessment	  of	   the	  “10	  vital	  signs”	  of	  sepsis:	  changes	   in	   the	   five	   traditional	   vital	   signs	   (hypothermia,	   tachycardia,	  tachypnea/bradypnea,	  hypotension,	  and	  new	  onset	  of	  pain)	  and	   five	  other	  criteria	  assessing	   perfusion:	   oxygen	   saturation	   <90%,	   a	   decreased	   level	   of	   consciousness,	  capillary	  refill	  >3	  seconds,	  urinary	  output	  <30ml/hr	  over	  5	  hours,	  and	  a	  base	  deficit	  or	  low	  ScvO2.	  	  Nine	  of	  these	  vital	  signs	  can	  usually	  be	  assessed	  or	  estimated	  within	  minutes;	  the	  last	  requires	  an	  arterial	  or	  central	  blood	  gas	  measurement.	  	  Especially	  important	   is	   the	   presence	   of	   hypotension;	   even	   when	   non-­‐sustained,	   low	   blood	  pressure	  is	  a	  sensitive	  risk	  marker	  for	  poor	  outcomes	  and	  should	  not	  be	  dismissed	  [86].	  	   Sepsis	  alert	  systems	  are	  becoming	   increasingly	  common	  in	  both	  emergency	  departments	  and	  on	  hospital	  wards.	   	  A	  high	  clinical	   suspicion	   for	  early	  sepsis	  and	  effective	   screening	  measures	   is	   important	   for	   detecting	   patients	   in	   time	   for	   early,	  outcome-­‐modifying	  treatments	  [87].	   	  Screening	  tools	   in	  the	  ED	  setting,	  such	  as	  the	  MEWS	  (modified	  early	  warning	  system),	  can	  improve	  sepsis	  identification	  and	  have	  prognostic	   utility	   for	   making	   triage	   decisions	   [88].	   	   Emergency	   medical	   services	  (EMS)	   involvement	   also	   appears	   to	   improve	   care	   in	   sepsis;	   patients	   with	   severe	  sepsis	  or	  septic	  shock	  who	  present	  via	  EMS	  transport	  or	  receive	  care	  by	  EMS	  prior	  to	   arrival	   tend	   to	   have	   better	   in-­‐hospital	   outcomes,	   although	   no	  mortality	   benefit	  has	  been	  shown	  [89].	  	  One	  concern	  with	  sepsis	  alert	  systems	  is	  their	  accuracy;	  as	  a	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screening	  mechanism,	  a	  high	  sensitivity	  is	  desirable,	  but	  this	  often	  translates	  into	  a	  low	   specificity	   and	   many	   false	   positive	   alerts.	   	   For	   example,	   in	   a	   recent	   study	  implementing	  a	  severe	  sepsis	  alert	  and	  rapid	  response	  team	  system,	  50%	  of	  sepsis	  alerts	   were	   triggered	   on	   non-­‐septic	   patients,	   and	   90%	   of	   the	   remaining	   alerts	  involved	  patients	  already	  diagnosed	  with	  sepsis	  [90].	  	  This	  study	  found	  an	  increase	  in	   ICU	  admissions	  but	  no	  change	   in	  mortality	  after	   implementation.	   	  Still,	   it	   seems	  that	   current	   sepsis	   alert	   systems	   will	   tolerate	   a	   high	   false	   positive	   rate	   of	   alerts	  (more	  than	  50%)	  in	  order	  to	  avoid	  missing	  potential	  sepsis	  cases.	  	   Early	  recognition	  and	  screening	  is	  necessary	  but	  not	  sufficient	  for	  improving	  care	  in	  sepsis;	  there	  must	  also	  be	  a	  dedicated	  pathway	  for	  receiving	  essential	  early	  treatment.	   	   To	   this	   end,	   many	   institutions	   have	   built	   systems-­‐based	   approaches	  triggered	   by	   early	   recognition,	   including	   a	   rapid	   response	   system	   (RRS)	   or	  dedicated	  medical	  emergency	  teams	  (METs)	  to	  respond	  to	  potential	  sepsis	  patients	  upon	  identification.	   	  In	  one	  of	  the	  largest	  trials	  of	  a	  sepsis	  alert	  system,	  Sebat	  et	  al.	  compared	   septic	   shock	   morbidity	   and	   mortality	   both	   before	   and	   after	   the	  implementation	   of	   several	   interventions	   (increased	   sepsis	   education,	   automatic	  electronic	  alerts,	  and	  a	  medical	  emergency	  team).	  	  They	  found	  that	  times	  to	  effective	  interventions	  and	  mortality	  decreased	  substantially	  over	   the	  5	  years	  of	   follow-­‐up;	  the	  sepsis-­‐specific	  mortality	  also	  dropped	  from	  50%	  to	  10%	  [91].	  	  This	  study	  is	  rare	  in	   the	   literature	   for	  having	  such	  a	  dramatic	  effect,	  possibly	  due	  to	   its	  emphasis	  on	  multiple	  interventions	  and	  long	  follow-­‐up.	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Early	  antibiotics	  Early	   antimicrobial	   therapy	   is	   essential	   in	   sepsis;	   delaying	   the	   treatment	   of	   the	  inciting	  infection	  increases	  the	  risk	  of	  organ	  dysfunction,	  shock	  and	  death.	  	  Kumar	  et	  al.	  described	  a	  series	  of	  2,154	  septic	  patients	  who	  received	  antibiotic	  therapy	  after	  the	   onset	   of	   hypotension,	   and	   found	   that	   mortality	   increased	   by	   7.6%	   for	   each	  hour’s	  delay	  in	  receiving	  antibiotics.	  	  In	  their	  cohort,	  the	  time	  to	  antibiotics	  was	  the	  strongest	  predictor	  of	  risk:	  stronger	  even	  than	  measures	  of	  disease	  severity	  such	  as	  the	   APACHE	   II	   score	   [92].	   	   The	   importance	   of	   early	   antibiotics	   on	   improving	  outcomes	  has	  been	  established	  in	  community-­‐acquired,	  hospital-­‐acquired,	  and	  ICU-­‐acquired	   sepsis	   [43].	   	   Furthermore,	   empiric	   antibiotic	   therapy	   should	   have	   broad	  coverage,	   dictated	   by	   the	   characteristics	   of	   the	   host	   (such	   as	   neutropenia	   or	   risk	  factors	  for	  drug-­‐resistant	  pathogens),	  likely	  source	  of	  infection,	  and	  local	  resistance	  patterns;	   inadequate	   initial	  antibiotic	  coverage	   is	  associated	  with	  a	  2-­‐fold	   increase	  in	  hospital	  mortality	  [93].	  	  Blood	  cultures	  should	  ideally	  be	  drawn	  before	  initiation	  of	   antibiotic	   coverage,	   although	   not	   if	   this	   will	   inappropriately	   delay	   antibiotic	  administration.	   	  The	  SSC	  guidelines	  recommend	  daily	   reassessment	  of	   the	  empiric	  antibiotic	   regimen	   and	   de-­‐escalation	   as	   tolerable,	   in	   order	   to	   minimize	   adverse	  effects	  and	  the	  emergence	  of	  resistance	  [83].	  	  
Source	  identification	  and	  control	  In	   septic	  patients,	   it	   is	   important	   to	   adequately	   assess	   for	   any	   continuing	   focus	  of	  infection.	   	   This	   assessment	   will	   obviously	   be	   tailored	   to	   the	   individual’s	   clinical	  presentation;	   sources	   to	   consider	   include	   pneumonia,	   urinary	   tract	  infection/pyelonephritis,	   intra-­‐abdominal	   sources,	   skin	   and	   soft	   tissue	   infections,	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septic	   arthritis,	   osteomyelitis,	   meningitis,	   endocarditis,	   and	   abscesses	   from	   any	  location,	  among	  others.	   	  The	  diagnostic	  workup	  must	  include	  imaging	  to	  assess	  for	  infectious	  foci,	  and	  directed	  cultures	  (blood,	  CSF,	  sputum,	  urine,	  wound)	  should	  be	  performed	   in	   order	   to	   properly	   identify	   the	   causative	   organism	   and	   permit	   de-­‐escalation	   of	   antibiotic	   coverage.	   	   Certain	   sources	   require	   specific	   management,	  including	  drainage	  of	  an	  abscess,	  removal	  of	  potentially	  infected	  devices/lines,	  and	  debridement	  of	  necrotic	  tissue;	  if	  source	  control	  requires	  a	  procedure,	  it	  should	  be	  performed	   within	   the	   shortest	   amount	   of	   time	   as	   long	   as	   the	   patient	   is	   stable	  (preferably	  within	  12	  hours	  of	  presentation).	   	  For	  the	  most	  part,	  the	  least	  invasive	  method	  of	   source	  control	   is	  preferable	   in	   the	   septic	  patient,	   such	  as	  percutaneous	  rather	  than	  surgical	  abscess	  drainage	  [83].	  	   	  
Fluid	  resuscitation	  Fluid	   therapy	   remains	   the	   focus	   of	   early	   resuscitation	   in	   sepsis.	   	   Septic	   patients	  often	   become	   hypovolemic,	   resulting	   from	   decreased	   intake,	   increased	   insensible	  fluid	  losses	  (fever,	  elevated	  respiratory	  rate),	  and	  third-­‐spacing	  of	  fluids	  into	  tissue	  as	  a	  result	  of	  vascular	  endothelial	  dysfunction.	  	  Furthermore,	  septic	  shock	  is	  a	  form	  of	  distributive	  hypotension,	  which	  may	  respond	  to	  fluid	  therapy	  in	  its	  early	  stages.	  	  The	   SSC	   guidelines	   recommend	   an	   initial	   fluid	   challenge	   of	   at	   least	   30ml/kg;	  crystalloids	  are	   considered	   the	   first	   line	   fluid,	   although	   colloids	   including	  albumin	  can	  be	  considered	  as	  part	  of	  this	  initial	  fluid	  bolus	  [83].	  	  In	  the	  SAFE	  trial,	  Finfer	  et	  al.	  found	  no	  difference	  in	  mortality	  between	  albumin	  and	  crystalloids	  when	  used	  as	  the	   primary	   resuscitation	   fluid	   [94].	   	   In	   ALBIOS,	   a	   more	   recent	   trial	   of	   albumin	  supplementing	   crystolloid	   resuscitation	   vs.	   crystalloid	   alone,	   there	   was	   no	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difference	  between	  the	  two	  strategies	  in	  terms	  of	  mortality	  or	  any	  of	  the	  secondary	  outcomes	  [95].	  	  The	  SSC	  guidelines	  state	  that	  albumin	  can	  be	  considered	  in	  patients	  who	  are	  likely	  to	  receive	  a	  large	  amount	  of	  crystalloids,	  in	  order	  to	  minimize	  the	  risk	  of	  fluid	  overload.	  	  Other	  colloids	  such	  as	  hydroxyethylstarch	  (HES)	  are	  discouraged	  due	  to	  an	  increase	  in	  mortality	  and	  need	  for	  renal	  replacement	  therapy	  [83].	  	   Adequate	   volume	   resuscitation	   is	   a	   cornerstone	   of	   management	   in	   early	  sepsis.	  	  However,	  an	  inappropriate	  amount	  of	  fluid	  resuscitation	  can	  be	  detrimental,	  causing	   fluid	   overload	   leading	   to	   pulmonary	   edema	   and	   rarely	   to	   abdominal	  compartment	   syndrome.	   	   Over-­‐resuscitation	   with	   normal	   saline	   has	   also	   been	  associated	   with	   hyperchloremic	   metabolic	   acidosis,	   an	   increased	   risk	   of	   acute	  kidney	  injury,	  and	  a	  worsening	  of	  underlying	  lung	  injury	  in	  the	  setting	  of	  ARDS	  [96,	  97].	   	   The	   SSC	   recommends	   continuing	   fluid	   resuscitation	   as	   long	   as	   there	   is	  continued	   improvement	   in	   hemodynamic	   variables,	   whether	   static	   (heart	   rate,	  blood	   pressure)	   or	   dynamic	   (pulse	   pressure	   variation,	   stroke	   volume	   variation)	  [83].	   	   Pulse	   pressure	   variation	   is	   heralded	   as	   an	   accurate	   measure	   of	   fluid	  responsiveness;	  however,	  its	  assessment	  is	  only	  relevant	  in	  intubated	  patients	  who	  are	  not	  taking	  spontaneous	  breaths	  [98].	  	  In	  the	  spontaneously-­‐breathing	  patient,	  a	  simple	  passive	   leg	  raise	  may	  mimic	  the	  effect	  of	  an	  additional	   fluid	  bolus	  and	  thus	  predict	  the	  patient’s	  responsiveness	  to	  further	  fluid.	  	  Bedside	  ultrasonography	  of	  the	  inferior	   vena	   cava	   also	   allows	   ultrasound-­‐proficient	   clinicians	   to	   assess	   fluid	  responsiveness.	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Inotropes	  In	   patients	   with	   measured	   or	   perceived	   low	   cardiac	   output	   or	   in	   patients	   who	  remain	  hypotensive	  despite	  adequate	  fluid	  resuscitation	  and	  vasopressor	  use,	  other	  agents	   should	   be	   considered.	   	   An	   inotrope	   is	   usually	   recommended	   in	   order	   to	  augment	  cardiac	  output	  in	  patients	  with	  underlying	  cardiac	  dysfunction,	  or	  if	  there	  are	  signs	  to	  suggest	  sepsis-­‐induced	  cardiomyopathy	  such	  as	  an	  elevated	  troponin	  or	  ultrasonographic	   signs	   of	   ventricular	   dysfunction	   [83].	   	   Inotrope	   therapy	   should	  also	  be	  considered	  empirically	  if	  the	  goal	  ScvO2	  is	  not	  reached	  despite	  adequate	  fluid	  resuscitation	  and	  vasopressor	  use.	  	  Dobutamine	  is	  the	  first-­‐line	  choice	  for	  inotropic	  therapy	   in	   septic	   shock.	   	   Little	   data	   is	   available	   to	   assess	   the	   individual	   effect	   of	  additional	  therapy	  on	  outcomes;	  however,	  the	  goal	  of	  supplementing	  cardiac	  output	  to	  supranormal	  levels	  is	  no	  longer	  considered	  desirable	  in	  sepsis	  [105].	  	  
Corticosteroids	  In	   the	   absence	   of	   a	   history	   of	   adrenal	   insufficiency,	   the	   administration	   of	  corticosteroids	  in	  septic	  shock	  is	  contentious.	  	  A	  proportion	  of	  sepsis	  patients	  suffer	  from	   critical	   illness-­‐related	   corticosteroid	   insufficiency	   (CIRCI),	   a	   form	   of	  inadequate	   stress	   response	   likely	   related	   to	   cytokine-­‐mediated	   endocrine	  dysfunction	  that	  may	  cause	  vasopressor-­‐refractory	  shock.	   	  Since	  CIRCI	   is	  a	   type	  of	  relative	   rather	   than	   absolute	   adrenal	   insufficiency,	   random	   cortisol	   levels	   are	   not	  diagnostic,	  and	  therefore	  ACTH	  stimulation	  test	  is	  preferable	  [55].	  	  In	  a	  randomized	  trial	   of	   vasopressor-­‐unresponsive	   septic	   shock,	   Annane	   et	   al.	   showed	   that	  corticosteroids	  improved	  mortality	  in	  ACTH	  non-­‐responders	  (53%	  mortality	  in	  the	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corticosteroid	  group	  vs.	  63%	  in	  the	  control)	  [106].	  	  In	  the	  larger	  CORTICUS	  trial,	  all	  patients	   with	   septic	   shock	   were	   included;	   mortality	   was	   not	   affected	   by	  corticosteroid	   therapy,	   even	   in	   patients	   with	   a	   negative	   response	   to	   ACTH	  stimulation	  [107].	   	  However,	   in	  patients	  whose	  shock	  was	  reversed,	  corticosteroid	  therapy	   hastened	   that	   reversal.	   	   In	   clinical	   practice,	   an	   ACTH	   stimulation	   test	   is	  usually	  unfeasible	  and	  rarely	  warranted	  in	  the	  presence	  of	  septic	  shock,	  and	  so	  it	  is	  difficult	  to	  make	  a	  definitive	  diagnosis	  of	  CIRCI.	   	  The	  SSC	  guidelines	  suggest	  that	   if	  hemodynamic	   stability	   is	   not	   achievable	   with	   adequate	   fluid	   resuscitation	   and	  vasopressor	  therapy,	  intravenous	  hydrocortisone	  (at	  200mg/day)	  can	  be	  given	  as	  a	  continuous	  infusion	  [83].	  	  
Mechanical	  ventilation	  Patients	   with	   severe	   sepsis	   and	   septic	   shock	   often	   require	   intubation	   and	  mechanical	  ventilation.	  	  The	  oxygen	  demand	  involved	  in	  the	  work	  of	  breathing	  may	  be	   increased	   up	   to	   40%	   of	   total	   demand	   in	   septic	   patients	   compared	   to	   5%	   at	  baseline,	  due	  to	  interstitial/alveolar	  edema	  [87];	  furthermore,	  total	  oxygen	  demand	  may	  be	   increased	   in	   the	  septic	  state	  as	  a	   result	  of	   fever,	   tachycardia,	  and	  acidosis.	  	  Mechanical	  ventilation	  can	  radically	  decrease	  the	  extra	  work	  of	  breathing	  and	  also	  improve	  central	  oxygenation	   if	  necessary.	   	   In	  patients	  with	  severe	  sepsis	  or	  septic	  shock	  who	  require	  intubation,	  a	  lung-­‐protective	  strategy	  of	  mechanical	  ventilation	  is	  recommended	   even	   in	   the	   absence	   of	   ARDS.	   	   Lung	   protective	   ventilation	  incorporates	   low	   tidal	   volumes	   (6ml/kg	   of	   ideal	   body	   weight),	   low	   plateau	  pressures	   (<30cm	   H20)	   and	   the	   application	   of	   positive	   end-­‐expiratory	   pressure	  (PEEP)	  to	  avoid	  alveolar	  collapse;	  in	  the	  ARDSnet	  trial,	  a	  lung-­‐protective	  ventilation	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strategy	  was	   associated	  with	   an	  absolute	   reduction	   in	  mortality	  of	  8.8%	   [108].	   	   If	  ARDS	  develops,	   further	  treatment	  should	  involve	  minimizing	  fluid	  therapy,	  a	  short	  course	   of	   neuromuscular	   blockade,	   continuing	   lung	   protective	   ventilation,	   and	  considering	  prone	  positioning	  for	  patients	  with	  severe	  ARDS	  [83].	  	   	  
Additional	  therapies	  Other	   supportive	   treatments	   for	   sepsis	   are	   described	   in	   the	   Surviving	   Sepsis	  Guidelines;	  a	  specific	  few	  will	  be	  discussed	  here.	   	  Red	  blood	  cell	  transfusions	  were	  originally	  considered	  at	  a	  hemoglobin	  threshold	  of	  10	  g/dL	  [109];	  however,	  multiple	  trials	   in	   different	   patient	   populations,	   including	   one	   in	   septic	   shock	   patients	  specifically,	   have	   shown	   that	   a	   restrictive	   approach	   (>7	   g/dL)	   is	   non-­‐inferior	   to	   a	  liberal	  one	  (>9	  g/dL)	  in	  terms	  of	  survival	  [110].	  	  Likewise,	  fresh	  frozen	  plasma	  and	  platelets	   should	   be	   transfused	   according	   to	   standard	   indications	   for	   all	   patients,	  including	   bleeding	   or	   planned	   procedures.	   	   Bicarbonate	   therapy	   is	   not	  recommended	  to	  improve	  lactic	  acidosis	  or	  the	  efficacy	  of	  vasopressors,	  unless	  the	  patient’s	  arterial	  pH	  is	  below	  7.15	  [83].	  	  If	  renal	  replacement	  therapy	  is	  required	  in	  patients	   with	   septic	   shock,	   continuous	   therapies	   are	   preferred	   over	   intermittent	  hemodialysis	  in	  order	  to	  preserve	  hemodynamic	  stability.	  	  Glucose	  control	  in	  septic	  patients	   is	   similar	   to	   other	   critically-­‐ill	   patients;	   insulin	   infusion	   protocols	   are	  recommended	  to	  target	  a	  glucose	   level	  of	  <180	  mg/dL,	  based	  on	  the	  results	  of	   the	  NICE-­‐SUGAR	  trial	  [111].	  	  	   Lastly,	  a	  host	  of	  specific	  therapies	  targeting	  both	  inflammatory	  pathways	  and	  coagulation	  pathways	  have	  shown	  no	  benefit	  in	  sepsis	  trials,	  leading	  to	  sepsis	  being	  described	  as	  a	   “pharmaceutical	   graveyard.”	   	  The	  most	  hopeful	   agent,	   recombinant	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activated	   protein	   C,	  was	   initially	   found	   to	   improve	  mortality	   in	   severe	   sepsis	   and	  septic	  shock;	  however,	  after	  another	  trial	  showed	  no	  benefit	  to	  its	  administration	  in	  this	  population,	  it	  was	  withdrawn	  from	  the	  market	  [83].	  	  More	  research	  is	  urgently	  needed	   to	   understand	   which	   patients	   may	   benefit	   from	   targeted	  immunomodulatory	  agents.	  	  	  
Early	  goal-­‐directed	  therapy	  In	  2001,	  Rivers	  et	  al.	  instituted	  the	  first	  protocolized	  care	  algorithm	  for	  septic	  shock	  patients	   in	   the	  emergency	  department	  setting	   [109].	  Their	   trial	  protocol	  called	   for	  optimization	  of	  certain	  hemodynamic	  variables	  (seen	  in	  Figure	  1),	  including	  central	  venous	   pressure	   (CVP	   8-­‐12mmHg),	  mean	   arterial	   pressure	   (MAP	   >65mmHg)	   and	  central	  venous	  oxygenation	  saturation	  (ScvO2	  >70%).	  	  Fluid	  boluses	  of	  500mL	  were	  given	   to	   improve	   CVP,	   and	   vasopressors	  were	   utilized	   to	   control	  MAP.	   	   If	   both	   of	  these	   variables	  were	   optimized	   and	   ScvO2	   remained	   below	   goal,	   dobutamine	   and	  red	  cell	  transfusions	  (to	  target	  of	  hematocrit	  >30%)	  were	  given	  to	  optimize	  oxygen	  delivery.	  	   Early	  goal-­‐directed	   therapy	   (EGDT)	  demonstrated	  a	  dramatic	   improvement	  in	   the	   hospital	   mortality	   rate	   compared	   to	   the	   control	   group:	   30.5%	   vs.	   46.5%	  respectively;	   these	   differences	   were	   maintained	   in	   the	   28-­‐	   and	   60-­‐day	   mortality	  rates	   as	  well	   [109].	   	   Since	   its	   publication,	   numerous	   groups	  have	   replicated	   these	  findings	  in	  observational	  studies	  of	  sepsis	  care,	  pre-­‐	  and	  post-­‐EGDT-­‐implementation	  [112,	  113].	  	  A	  meta-­‐analysis	  of	  nine	  trials	  by	  Jones	  et	  al.	  showed	  that	  on	  average,	  the	  mortality	   rate	   fell	   by	   20.3%	   after	   implementation	   of	   an	   EGDT-­‐based	   protocol	   for	  severe	  sepsis	  and	  septic	   shock	  patients	   [114].	   	  Another	  by	  Wira	  et	  al.	   included	  25	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trials	  and	  found	  a	  similar	   improvement	   in	  mortality	  with	   implementation	  of	  EGDT	  protocols,	  from	  41.6%	  to	  25.8%	  [8].	  	   Despite	  the	  strong	  foundation	  of	  observational	  data	  favoring	  EGDT,	  two	  large	  randomized	   control	   trials	   have	   tempered	   enthusiasm	   for	   early-­‐goal	   directed	  therapy.	  	  In	  the	  ProCESS	  trial,	  a	  total	  of	  1,342	  patients	  patients	  presenting	  to	  the	  ED	  
	  




in	   septic	   shock	  were	   assigned	   to	   one	   of	   three	   groups:	   EGDT	   protocol-­‐based	   care,	  standard	  therapy	  protocol-­‐based	  care,	  and	  usual	  care.	  	  EGDT-­‐based	  care	  showed	  no	  advantage	   in	   60-­‐day	   mortality	   (21.0%)	   over	   either	   standard	   protocol-­‐based	   care	  (18.2%)	   or	   the	   “usual	   care”	   group	   (18.9%)	   [10].	   	   There	   were	   also	   no	   significant	  differences	   in	   any	   of	   the	   secondary	   outcomes,	   including	   90-­‐day	  mortality,	   1-­‐year	  mortality,	  or	  need	  for	  organ	  support.	  	  Recently,	  another	  randomized	  control	  trial	  of	  EGDT	  has	  corroborated	  the	  ProCESS	  results;	  in	  the	  ARISE	  trial,	  the	  EGDT	  care	  group	  had	  the	  same	  90-­‐day	  mortality	  (18.2%)	  as	  the	  “usual	  care”	  group	  (18.6%)	  [11].	  	   Importantly,	   the	   “usual	   care”	   groups	   of	   both	   trials	   had	   almost	   universal	  antibiotic	   coverage	   by	   6	   hours,	   appropriate	   fluid	   management,	   and	   rates	   of	  vasopressor	  use	  and	  central	   line	  placement	  greatly	  exceeding	  those	  of	   the	  original	  EGDT	   trial;	   the	   rates	   of	   vasopressor	   requirement	   in	   the	  ProCESS	   and	  ARISE	   trials	  were	   50.3%	   and	   62.2%,	   respectively,	   compared	   to	   44.1%	   in	   Rivers	   et	   al.	  	  Expeditious	   delivery	   of	   life-­‐saving	   interventions	   likely	   contributed	   to	   the	  comparatively	   low	  mortality	   rate	   of	   the	   “usual	   care”	   groups	   in	   both	   ProCESS	   and	  ARISE.	   	   Still,	   both	   trials	   showed	  no	  benefit	   of	   EGDT	  over	  modern	   “usual	   care”	   for	  septic	   shock.	   	   Although	   another	   large	   randomized	   trial	   of	   EGDT	   will	   soon	   be	  published	   (ProMISe),	   it	   is	   unlikely	   to	   alter	   the	   conclusion	   that	   EGDT	  may	   not	   be	  effective	  in	  its	  current	  form	  for	  all	  patients	  in	  septic	  shock.	  	  
Protocolized	  care	  and	  sepsis	  bundles	  After	   septic	   patients	   have	   been	   correctly	   identified,	   protocolized	   management	  ensures	  that	  they	  receive	  prompt	  and	  effective	  treatments	  based	  on	  their	  severity.	  For	  severe	  sepsis	  and	  septic	   shock,	   the	  Surviving	  Sepsis	  Campaign	  has	   formulated	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sepsis	   care	   bundles,	   and	   these	  have	  been	  distributed	  widely	   in	   both	   the	   inpatient	  and	   emergency	   department	   settings.	   	   The	   SSC	   sepsis	   bundles	   are	   separated	   into	  components	  to	  be	  completed	  at	  3-­‐hour	  and	  6-­‐hour	  deadlines	  (Table	  4)	  [83].	  The	  3-­‐hour	   bundle	   includes	   obtaining	   blood	   cultures	   prior	   to	   antibiotic	   use,	   drawing	   a	  lactate	   level,	   administering	   broad-­‐spectrum	   antibiotics,	   and	   administering	   an	  appropriate	  fluid	  challenge	  if	  the	  patient	  is	  hypotensive	  or	  hyperlactatemic.	  The	  6-­‐hour	  bundle	   consists	   of	   applying	  vasopressors	   for	   a	  MAP	  <65mmHg,	   remeasuring	  lactate	   if	   the	   initial	   lactate	   was	   elevated,	   and	   employing	   invasive	   hemodynamic	  monitoring	  (targeting	  goals	  for	  ScvO2	  and	  CVP)	  if	  hypotension	  or	  hyperlactatemia	  is	  refractory	  to	  adequate	  volume	  resuscitation;	  these	  bundles	  are	  modeled	  after	  the	  	  	  
 Table	  4.	  	  Surviving	  Sepsis	  Campaign	  Bundles.*	  	  To	  be	  completed	  within	  3	  hours:	  1) Measure	  lactate	  level	  2) Obtain	  blood	  cultures	  prior	  to	  administration	  of	  antibiotics	  3) Administer	  broad-­‐spectrum	  antibiotics	  4) Administer	  30mL/kg	  crystalloid	  for	  hypotension	  or	  lactate	  ≥	  4	  mmol/L	  	  	  To	  be	  completed	  within	  6	  hours:	  5) Apply	   vasopressors	   (for	   hypotension	   that	   does	   not	   respond	   to	   initial	   fluid	  resuscitation)	  to	  maintain	  a	  mean	  arterial	  pressure	  (MAP)	  ≥	  65	  mm	  Hg	  6) In	   the	   event	   of	   persistent	   arterial	   hypotension	   despite	   volume	   resuscitation	  (septic	  shock)	  or	  initial	  lactate	  ≥	  4	  mmol/L	  (36	  mg/dL):	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  -­‐	  	  Measure	  central	  venous	  pressure	  (CVP)Δ	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  -­‐	  	  Measure	  central	  venous	  oxygen	  saturation	  (ScvO2)Δ	  7) Remeasure	  lactate	  if	  initial	  lactate	  was	  elevated*	  	  Δ	  Targets	   for	   quantitative	   resuscitation	   included	   in	   the	   guidelines	   are	   CVP	   of	   ≥	   8	  mmHg,	  ScvO2	  of	  ≥	  70%,	  and	  normalization	  of	  lactate.	  *Adapted	   from	   Surviving	   Sepsis	   Campaign,	   International	   Guidelines	   for	  Management	  of	  Severe	  Sepsis	  and	  Septic	  Shock,	  2012.	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original	  EGDT	  trial	  [109,	  115].	  	  As	  mentioned	  previously,	  lactate	  clearance	  has	  been	  put	   forward	   as	   a	   possible	   replacement	   of	   the	  more	   invasive	   ScvO2	   targeting,	   and	  clearly	  is	  reasonable	  as	  a	  goal	  in	  patients	  without	  central	  access.	  	   Observational	  data	  of	  bundled	  sepsis	  care	  has	  been	  favorable.	  	  To	  determine	  the	  relationship	  between	  bundle	  compliance	  and	  outcomes,	  Levy	  et	  al.	  analyzed	  data	  from	  29,470	  patients	  in	  the	  Surviving	  Sepsis	  Campaign	  database	  [116].	  	  There	  was	  a	  significant	   mortality	   difference	   between	   those	   sites	   with	   high	   bundle	   compliance	  (29.0%)	  and	  those	  with	  low	  compliance	  (38.6%);	  this	  translated	  into	  a	  25%	  relative	  risk	   reduction	   with	   high	   bundle	   compliance.	   	   Although	   this	   observational	   data	  favors	  protocolized	  care,	   the	  results	  of	  randomized	  control	   trials	  have	  not	  been	  as	  encouraging.	   	   For	   example,	   the	   ProCESS	   trial	   failed	   to	   show	   any	   survival	   benefit	  between	  protocolized	  and	  usual	  care	  [10].	   	  This	   lack	  of	  benefit	  was	  surprising,	  but	  likely	  a	  result	  of	  the	  high	  level	  of	  “usual	  care”	  providers’	  awareness	  and	  competence	  in	   treating	   sepsis	   according	   to	   evidence-­‐based	   guidelines,	   a	   major	   goal	   of	   the	  Surviving	  Sepsis	  Campaign.	  	  
Alternative	  classification	  systems	  
	  Given	  the	  wide	  range	  of	  mortality	  seen	  in	  sepsis	  studies,	  the	  poor	  clinical	  utility	  of	  complex	   scoring	   systems,	   and	   the	   recent	  negative	   results	  of	   large	   controlled	   trials	  using	   goal-­‐directed	   resuscitation,	   it	   is	   clear	   that	   we	   need	   a	   new	   approach	   to	  classifying	  severity	   in	  sepsis.	   	  The	  current	  system	  seems	   inadequate	   to	   the	   task	  of	  indicating	  sepsis	  severity,	  prognosticating	  outcomes,	  and	  directing	  evidence-­‐based	  management,	   especially	   in	   the	   proximal	   phases	   of	   care.	   	   A	   better	   classification	  schema	   could	   improve	   decisions	   on	   disposition	   as	   well	   as	   triage	   important	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therapeutic	  maneuvers,	  such	  as	  central	  line	  placement,	  to	  the	  patients	  most	  likely	  to	  benefit.	   	   Furthermore,	   investigating	   subcategories	   of	   the	   traditional	   diagnoses	   of	  severe	   sepsis	   and	   septic	   shock	   could	   help	   us	   to	   identify	   patient	   populations	  who	  may	  benefit	  from	  early	  goal-­‐directed	  interventions	  in	  future	  trials.	  	  
Cryptic	  shock	  Cryptic	   shock,	   also	   known	   as	   cryptic	   septic	   shock,	   is	   defined	   as	   normotension	   or	  fluid-­‐responsive	  hypotension	  with	  high	   serum	   lactate	   levels	   (>4.0	  mmol/L)	   and	   is	  widely	   accepted	   as	   having	   a	   prognosis	   similar	   to	   overt	   septic	   shock.	   	   As	   was	  discussed	   in	  detail	   in	  a	  previous	  section,	  an	  elevated	   lactate	   is	  a	  strong	  prognostic	  factor	  for	  both	  the	  development	  of	  organ	  dysfunction	  and	  early	  mortality,	  especially	  in	   the	   high	   range	   above	   4	   mmol/L,	   and	   this	   correlation	   exists	   independently	   of	  refractory	  hypotension	  [75].	   	  In	  a	  post-­‐hoc	  analysis	  of	  cryptic	  shock	  patients	  in	  the	  original	  EGDT	  trial,	  the	  mortality	  rate	  of	  cryptic	  shock	  patients	  in	  the	  control	  group	  was	   an	   astonishing	   60.9%,	   compared	   to	   20%	   in	   the	   treated	   group	   [117].	   	   Other	  studies	   have	   shown	   that	  mortality	   in	   cryptic	   shock	   is	   substantially	   higher	   than	   in	  other	  groups	  of	  severe	  sepsis,	  and	  approaches	  the	  mortality	  rate	  seen	  in	  overt	  septic	  shock	  [75,	  76,	  118].	  	   Because	   of	   the	   high	   mortality	   in	   this	   patient	   population	   with	   occult	  hypoperfusion,	   the	   Surviving	   Sepsis	   Campaign	   guidelines	   recommend	   that	   these	  patients	   receive	   protocolized,	   quantitative	   resuscitation	   similar	   to	   patients	   with	  overt	   septic	   shock,	   with	   a	   goal	   of	   normalizing	   lactate.	   	   However,	   in	   practice,	   it	   is	  unlikely	   that	   cryptic	   shock	   patients	   receive	   the	   same	   level	   of	   clinical	   attention	   by	  emergency	  providers,	  and	  therefore	  appropriate	  resuscitation	  may	  be	  inadequate	  or	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delayed	   [119].	   	   Some	   patients	   in	   cryptic	   shock	   will	   ultimately	   progress	   to	   overt	  shock;	  in	  one	  study,	  the	  mortality	  rate	  of	  these	  cryptic-­‐to-­‐overt	  shock	  patients	  was	  indistinguishable	  from	  patients	  presenting	  with	  overt	  shock	  [120].	   	  Lastly,	   there	   is	  considerable	   evidence	   that	  patients	  with	  even	   slightly	   elevated	   lactate	   levels	  have	  an	   increased	   risk	   of	   death	   over	   other	   patients	   with	   severe	   sepsis	   [77,	   121];	   one	  group	  has	  termed	  this	  patient	  subgroup	  “pre-­‐shock”	  [122].	  	  Some	  evidence	  suggests	  that	   in-­‐hospital	  mortality	   rates	   are	  higher	   for	   cryptic-­‐to-­‐overt	   shock	  patients	   than	  for	  patients	  presenting	  to	  the	  ED	  in	  septic	  shock	  [123],	  suggesting	  that	  developing	  prediction	  tools	  for	  decompensation	  in	  cryptic	  shock	  is	  an	  imperative	  for	  improving	  the	  proximal	  phases	  of	  care.	  	  	  
Vasoplegic	  shock	  and	  tissue-­‐dysoxic	  shock	  The	   serum	   lactate	   level	  may	   also	   risk-­‐stratify	   patients	  with	   septic	   shock;	  multiple	  studies	  have	  shown	  that	  initial	  lactate	  predicts	  mortality	  in	  shock	  patients	  [75,	  124-­‐126].	  	  Some	  investigators	  have	  created	  new	  terms	  for	  subsets	  of	  septic	  shock	  based	  on	   lactate	   levels:	   “tissue-­‐dysoxic”	   shock	   for	   patients	   with	   elevated	   lactate,	   and	  “vasoplegic”	  shock	  for	  patients	  with	  normal	  or	  mildly	  elevated	  lactate.	  	  In	  one	  study,	  Sterling	   et	   al.	   used	   a	   lactate	   cutoff	   of	   2	   mmol/L	   to	   divide	   247	   ED	   septic	   shock	  patients	  into	  vasoplegic	  and	  dysoxic	  categories;	  mortality	  was	  9%	  in	  the	  vasoplegic	  group	   and	   26%	   in	   the	   dysoxic	   group	   [126].	   	   Similar	   numbers	  were	   published	   by	  Hernandez	   et	   al.	   in	   their	   prospective	   study	   of	   “persistent	   sepsis-­‐induced	  hypotension	   without	   hyperlactatemia”	   (defined	   as	   hypotension	   requiring	  vasopressor	  use	  and	  a	  lactate	  <2.5);	  mortality	  rates	  were	  7.9%	  and	  20%	  for	  lactates	  <2.5	  and	  >2.5,	  respectively	  [127].	   	  The	  distinction	  between	  dysoxic	  and	  vasoplegic	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shock	  may	   in	   fact	  have	  a	  physiologic	  basis;	  Hernandez	  et	  al.	   found	   that	  vasoplegic	  shock	   patients	   seem	   to	   have	   better	   microcirculatory	   function	   (as	   evidenced	   by	  percentage	   of	   perfused	   vessels	   and	   microcirculatory	   flow	   on	   sublingual	  videomicroscopy).	   	   Patients	   without	   hyperlactatemia	   also	   had	   lower	   rates	   of	  mechanical	  ventilation	  and	  lower	  disease	  severity	  scores.	  [127].	  	   One	  large	  retrospective	  study	  has	  attempted	  to	  utilize	  this	  diversity	  in	  sepsis	  presentations	  to	  create	  a	  new	  prognostic	  schema	  for	  severe	  sepsis	  and	  septic	  shock	  [128].	  	  Of	  1,948	  patients	  analyzed,	  52%	  were	  diagnosed	  with	  severe	  sepsis,	  8%	  with	  cryptic	  shock,	  28%	  with	  vasoplegic	  shock,	  and	  12%	  with	  dysoxic	  shock.	   	  Mortality	  was	  highest	  among	  the	  dysoxic	  shock	  patients	  at	  60.3%,	  and	  lowest	  among	  patients	  with	  severe	  sepsis	  at	  16.8%.	  	  The	  mortality	  rates	  for	  patients	  with	  vasoplegic	  shock	  and	   cryptic	   shock	   were	   48.1%	   and	   35.2%,	   although	   the	   difference	   was	   not	  statistically	  significant.	  	  The	  study	  also	  showed	  that	  mortality	  rates	  begin	  to	  rise	  as	  the	   lactate	   increases	   above	   2	   mmol/L,	   consistent	   with	   findings	   of	   other	   groups.	  	  However,	   the	   investigators	   lacked	   the	   ability	   to	   compare	   these	   lactate	   values	   to	  more	  standard	  hemodynamic	  variables	  of	  hypoperfusion,	  such	  as	  ScvO2.	  	  
Other	  subsets	  of	  septic	  shock	  Beyond	  initial	  lactate	  levels,	  there	  are	  likely	  other	  early	  predictors	  of	  risk	  in	  severe	  sepsis	   and	   septic	   shock.	   	   One	   such	   predictor	   is	   vasopressor	   dependence.	  	  Vasopressor	  use	  is	  commonly	  used	  as	  a	  surrogate	  for	  septic	  shock,	  since	  guidelines	  recommend	  vasopressor	  use	   for	  persistent	  hypotension	  (MAP	  <65	  mmHg)	  despite	  adequate	   volume	   resuscitation.	   	   In	   practice,	   however,	   some	   patients	   with	   septic	  shock	   may	   only	   require	   a	   short	   course	   of	   vasopressors,	   whereas	   others	   require	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prolonged	   use	   with	   increasing	   doses	   and	   additional	   agents.	   	   It	   is	   known	   that	  prolonged	  vasopressor	  use	  beyond	  3	  days	   in	   the	   ICU	   is	   associated	  with	   increased	  mortality	   [129];	   less	   is	   known	   about	   shorter	   vasopressor	   requirements,	   such	   as	  within	   the	   hours	   of	   the	   emergency	   department	   stay.	   	   However,	   it	   is	   intuitive	   that	  patients	   requiring	  prolonged	   vasopressor	   support	  will	   have	  worse	   outcomes	   than	  those	  who	  are	  quickly	  weaned.	  	  	   Another	  similar	  question	  revolves	  around	  the	  risk	  associated	  with	  increasing	  doses	   or	   added	   vasopressor	   agents.	   	   Severe	   septic	   shock	   has	   been	   previously	  defined	   as	   septic	   shock	   requiring	   high-­‐dose	   vasopressor	   therapy	   (such	   as	  norepinephrine	   above	  15μg/min	   [99]);	   however,	   based	  on	   the	   SSC	  guidelines,	   if	   a	  patient	   continues	   to	   be	   hypotensive	   despite	   low-­‐dose	   therapy	   with	   one	   agent,	  additional	   vasopressors	   are	   often	   added	   rather	   than	   increasing	   the	   dose	   of	   the	  initial	  agent	  [83].	  	  Although	  it	  has	  been	  shown	  that	  an	  ICU	  requirement	  for	  multiple	  vasopressors	   predicts	   a	   very	   poor	   outcome	   [130],	   little	   is	   known	   about	   multiple	  vasopressor	  requirements	  in	  the	  ED	  setting.	  	  Lastly,	  it	  is	  unknown	  if	  septic	  patients	  who	   initially	  present	   to	   the	  emergency	  department	  with	  very	   low	  blood	  pressures	  (which	  we	  define	  as	  presenting	  “in	  hemodynamic	  extremis”)	  are	  at	  higher	  risk	  than	  those	  who	   develop	   hypotension	   after	   presentation.	   	   In	   a	   series	   of	   patients	   in	   the	  emergency	  department	  with	  undifferentiated	  hypotension,	  the	  lowest	  systolic	  blood	  pressure	   (SBP)	   correlated	   inversely	   with	   in-­‐hospital	   mortality;	   however,	   the	  patients	  were	  not	  stratified	  by	  initial	  SBP,	  and	  the	  cause	  of	  the	  hypotension	  was	  not	  specified	  [131].	  	  Further	  characterization	  of	  septic	  patients	  presenting	  “in	  extremis”	  is	  warranted.	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Hypothesis	  and	  Aims	  of	  Research	  	  
Hypothesis	  In	  a	  novel	  5-­‐group	  classification	  system	  for	  severe	  sepsis	  and	  septic	  shock,	  we	  hypothesize	  that	  high	  initial	  serum	  lactate	  levels	  and	  Emergency	  Department	  vasopressor	  dependence	  will	  be	  independently	  predictive	  of	  increased	  28-­‐day	  in-­‐hospital	  mortality.	  	  





Study	  setting	  and	  design	  The	   setting	  of	   our	   study	   is	   a	   dual-­‐site	   emergency	  department	   of	   a	  major	   teaching	  hospital,	  which	  sees	  greater	  than	  120,000	  patient	  visits	  per	  year;	  the	  two	  sites	  were	  the	   adult	   section	   of	   the	   Yale-­‐New	   Haven	   Hospital	   ED	   and	   the	   Shoreline	   Medical	  Center	   ED	   in	   Guilford,	   CT.	   	   This	   retrospective	   study	   was	   performed	   on	   a	  prospectively-­‐identified	   population	   of	   patients	   in	   the	   Yale	   Emergency	   Medicine	  Sepsis	   Registry	   with	   severe	   sepsis	   or	   septic	   shock	   presenting	   to	   both	   emergency	  departments.	   	  Our	  registry	  and	  the	  study	  were	  reviewed	  and	  approved	  by	  the	  Yale	  Human	  Investigation	  Committee	  (HIC),	  which	  oversees	  research	  on	  patient	  medical	  records	   at	   Yale-­‐New	  Haven	  Hospital.	   	   The	   registry	  was	   formulated	   by	  Dr.	   Charles	  Wira,	  III,	  and	  three	  previous	  medical	  students	  have	  performed	  investigations	  using	  this	   registry	   for	   their	   medical	   theses.	   	   This	   author	   was	   added	   to	   the	   list	   of	   HIC-­‐certified	   investigators	   in	   2013,	   and	   the	   independent	   research	  here	  presented	  was	  approved	  by	  the	  Emergency	  Medicine	  Research	  Committee	  in	  the	  same	  year.	  	  	  
Study	  population	  and	  inclusion/exclusion	  criteria	  Between	   July	   1st,	   2005	   and	   September	   5,	   2009,	   patients	   presenting	   to	   both	  emergency	   departments	   were	   screened,	   and	   521	   patients	   with	   severe	   sepsis	   or	  septic	   shock	  were	   included	   in	   the	   registry.	   	   Screening	  was	  performed	  by	  Dr.	  Wira	  according	   to	   clinical	   suspicion	   of	   sepsis;	   screened	   patients	  who	  met	   the	   inclusion	  and	  lacked	  exclusion	  criteria	  were	  entered	  into	  the	  registry.	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   Inclusion	  criteria	   for	   this	  study	  are	  shown	  in	  Table	  5.	   	  All	   included	  patients	  were	  18	  years	  of	  age	  or	  older,	  met	  2	  or	  more	  criteria	  for	  the	  Systemic	  Inflammatory	  Response	  Syndrome	  (SIRS),	  had	  a	  presumed	  or	  documented	  source	  of	  infection,	  and	  had	   at	   least	   one	   organ	   dysfunction	   newly-­‐diagnosed	   during	   their	   stay	   in	   the	  Emergency	   Department.	   	   Exclusion	   criteria	   included	   an	   age	   less	   than	   18,	   lack	   of	  criteria	   for	  meeting	  the	  diagnosis	  of	  severe	  sepsis	  or	  septic	  shock	  (as	  described	   in	  Table	  5),	  a	  discharge	  directly	  from	  the	  emergency	  department,	  or	  documentation	  of	  a	   pre-­‐existing	   advance	   directive	   for	   implementing	   comfort	   care	   only.	   	   End-­‐organ	  dysfunction	  was	  defined	  as	  in	  section	  C	  of	  Table	  5.	  	  Patients	  were	  required	  to	  have	  at	  	  Table	  5:	  	  Inclusion	  criteria.*	  1. At	  least	  18	  years	  of	  age	  2. Meets	  criteria	  for	  severe	  sepsis	  as	  follows:	  a. Two	   or	   more	   criteria	   for	   the	   Systemic	   Inflammatory	   Response	   Syndrome	   (SIRS),	  including:	  
• Body	  temperature	  >	  100.4°F	  or	  <	  96.8°F	  
• Heart	  rate	  >	  90	  min-­‐1	  
• Respiratory	  rate	  >	  20	  min-­‐1	  or	  PaCO2	  <	  32	  mmHg	  
• White	  blood	  cell	  count	  >	  12,000	  μL-­‐1,	  <4,000	  μL-­‐1,	  or	  >10%	  immature	  (band)	  forms	  b. Documented	  suspicion	  of	  a	  source	  of	  infection,	  including	  any	  one	  of	  the	  following:	  
• White	  blood	  cell	  count	  >	  12,000	  μL-­‐1,	  <4,000	  μL-­‐1,	  or	  >10%	  immature	  (band)	  forms	  
• Body	  temperature	  >	  100.4°F	  or	  <	  96.8°F	  
• Antibiotics	  administered	  in	  the	  Emergency	  Department	  
• Documentation	  of	  presumed	  source	  of	  infection	  in	  the	  Emergency	  Department	  c. At	   least	   one	   newly	   diagnosed	   organ	   dysfunction	   in	   the	   Emergency	   Department,	  including:	  
• Transient	  systolic	  BP	  <	  90mmHg	  that	  responds	  to	  fluid	  resuscitation	  
• Lactate	  level	  >	  2	  mmol/L	  
• Unexplained	  acidosis	  (pH	  <	  7.35)	  or	  serum	  bicarbonate	  <	  21	  
• Altered	  mental	  status	  (change	  from	  baseline)	  
• Platelets	  <	  150,000	  μL-­‐1	  without	  a	  history	  of	  thrombocytopenia	  
• Elevation	  of	  bilirubin	  above	  normal	  or	  either	  direct	  or	  indirect	  bilirubin	  >	  baseline	  
• High	  coagulation	  factors	  (any	  elevation	  in	  absence	  of	  heparin	  or	  warfarin	  use)	  
• Acute	  renal	  failure	  (Cr	  >	  0.5	  from	  baseline,	  or	  abnormal	  if	  no	  baseline	  available)	  
• Hypoxemia	  (oxygen	  saturation	  less	  than	  90%	  or	  change	  in	  oxygen	  requirement)	  
• Troponin	  elevation	  above	  baseline	  *Adapted	  from	  the	  2001	  Sepsis	  Definitions	  Conference	  [29].	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least	  one	  of	  the	  following	  new	  organ	  dysfunctions	  in	  the	  ED:	  transient	  hypotension,	  hyperlactatemia,	   unexplained	   acidemia,	   new	   neurologic	   dysfunction,	  thrombocytopenia,	   hyperbilirubinemia,	   coagulation	   abnormalities,	   acute	   kidney	  injury,	  hypoxemia,	  or	  an	  elevated	  troponin	  measurement.	  	  
Data	  extraction	  After	  screening,	  subsequent	  data	  extraction	  from	  medical	  charts	  was	  performed	  by	  medical	  students	  and	  residents,	  under	  the	  supervision	  of	  the	  faculty	  supervisor	  Dr.	  Wira;	   comparison	  of	  a	   subset	  of	  over	  500	  data	  points	  extracted	   in	  parallel	  by	   two	  previous	   investigators	   showed	   >95%	   concurrence,	   demonstrating	   the	   accuracy	   of	  the	  chart	  extraction	  process.	  The	  entire	  medical	  chart,	  from	  emergency	  department	  presentation	   to	   hospital	   discharge,	   was	   reviewed	   during	   extraction;	   electronic	  medical	  records	  included	  “ChartView,”	  “Lynx	  Medical	  Systems,”	  and	  “Sunrise	  Clinical	  Manager.”	  	   Customized	   data	   collection	   forms	   and	   a	   glossary	   of	   terms	   were	   used	   to	  record	   pre-­‐defined	   data	   points,	   as	   detailed	   below;	   the	   data	   collection	   form	   is	  included	   in	   the	  Appendix.	  Patients	  were	  assigned	  a	  study	   identifier	  (ID)	  at	   time	  of	  data	  extraction,	  and	  the	  collection	  forms	  with	  included	  patient-­‐identifying	  data	  were	  secured	   in	   a	   locked	   file	   cabinet	   in	   the	  Department	   of	   Emergency	  Medicine	   during	  and	  after	  the	  extraction	  process.	   	  The	  collected,	  hard-­‐copy	  data	  was	  transcribed	  by	  Dr.	  Wira	  to	  a	  password-­‐protected,	  customized	  Microsoft	  Excel	  database	  (Redmond,	  WA,	   USA),	   accessible	   only	   by	   Dr.	   Wira.	   	   De-­‐identification	   occurred	   through	   the	  creation	  of	   a	   copy	  Excel	   database	   incorporating	   only	   study	   ID	   and	   lacking	  patient	  identifiers	  such	  as	  name,	  medical	  record	  number	  and	  admission	  date.	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   The	  data	  points	  extracted	   from	   the	  chart	  were	  pre-­‐determined	  by	  Dr.	  Wira	  and	   other	   investigators,	   and	   included	   demographics,	   vital	   signs	   and	   other	   clinical	  data	   from	   the	   ED,	   laboratory	   data,	   and	   specifics	   of	   the	   clinical	   course	   during	  hospitalization.	   	   The	   collected	   demographic	   data	   included	   patient	   age,	   gender,	  previous	  medical	  history,	  and	  residence	  in	  an	  extended	  care	  facility.	   	  In	  general,	  all	  vital	   signs	   were	   collected	   for	   the	   entirety	   of	   the	   ED	   stay;	   in	   patients	   requiring	  vasopressor	  therapy	  in	  the	  ED,	  the	  heart	  rate	  and	  systolic/diastolic	  blood	  pressures	  were	  recorded	  only	  until	   the	   initiation	  of	  vasopressors.	   	  Extracted	   laboratory	  data	  included	   initial	   serum	   electrolytes,	   blood	   urea	   nitrogen	   (BUN),	   creatinine,	   cardiac	  troponins,	  direct	  and	  indirect	  bilirubin	  levels,	  international	  normalized	  ration	  (INR),	  prothrombin	   time	   (PT),	   partial	   prothrombin	   time	   (PTT),	   white	   blood	   cell	   count,	  percentage	   bands,	   hematocrit,	   platelet	   count,	   and	   final	   microbial	   culture	   results	  from	  blood,	   urine,	   and	   other	   sources.	   	   Arterial	   blood	   gas	   results	  were	   recorded	   if	  drawn.	  	  Initial	  and	  peak	  lactate	  levels	  during	  the	  ED	  stay	  were	  recorded,	  as	  well	  as	  the	  first	  repeated	  lactate	  level	  after	  admission.	  	   Other	  clinical	  data	  recorded	  from	  the	  ED	  stay	  included	  arrival	  and	  departure	  times,	  length	  of	  stay,	  type	  of	  cultures	  drawn,	  presence	  and	  time	  to	  administration	  of	  various	   therapies	   (antibiotics,	   fluid	   repletion,	   central	   line	  placement),	   and	   specific	  measurements	   of	   CVP	   and	   ScvO2	   if	   available.	   	   Every	   patient	   was	   assessed	   for	  whether	   early	   goal-­‐directed	   therapy	   was	   implemented;	   documentation	   of	   EGDT	  required	  the	  presence	  of	  a	  central	  line	  placed	  during	  the	  ED	  stay	  as	  well	  as	  CVP	  and	  SCVO2	   measurements	   continued	   throughout	   the	   first	   24	   hours	   of	   hospital	   stay.	  Specifically,	   the	  presence	  of	  vasopressor	  therapy,	   time	  to	   initiation	  of	  vasopressor,	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and	   types	   of	   vasopressor	   agents	   (norepinephrine,	   dopamine,	   vasopressin,	  epinephrine	  and/or	  phenylephrine)	  were	  recorded	  for	  the	  ED	  stay.	  	  Other	  therapies,	  such	   as	   dobutamine,	   corticosteroids,	   and	   intubation	   in	   the	   ED,	   were	   recorded	   if	  implemented.	   	  APACHE	  II	  and	  MEDS	  scores	  were	  calculated	  from	  the	  relevant	  data	  obtained	  in	  the	  ED.	  	  Finally,	  specifics	  of	  the	  hospital	  stay	  included	  admission	  location	  (ICU,	   step-­‐down	   unit,	   or	   floor),	   use	   of	   mechanical	   ventilation,	   vasopressor	   use	  within	  72	  hours	  of	  presentation,	  and	  vasopressor	  use	  after	  72	  hours.	  	  
	  
Study	  protocol	  and	  classification	  system	  As	   described	   previously,	   all	   subjects	   included	   in	   the	   study	  met	   criteria	   for	   severe	  sepsis	   or	   septic	   shock,	   shown	   in	   Table	   5	   in	   accordance	   with	   the	   original	   1992	  ACCP/SCCM	   definitions	   [27].	   The	   subgroup	   of	   septic	   shock	   subjects	   were	  subsequently	  defined	  by	  the	  presence	  of	  severe	  sepsis	  and	  a	  systolic	  blood	  pressure	  less	   than	   90mmHg	   that	   was	   unresponsive	   to	   adequate	   fluid	   resuscitation,	   in	  accordance	  with	  both	  1992	  and	  2001	  ACCP/SCCM	  guidelines.	  	  [27,	  29]	  	   In	  the	  primary	  analysis,	  initial	  lactate	  levels	  and	  vasopressor	  requirements	  in	  the	   ED	   were	   used	   to	   categorize	   subjects;	   these	   definitions	   are	   listed	   in	   Table	   6.	  	  Subjects	  who	  did	  not	  have	  a	  serum	  lactate	  level	  drawn	  in	  the	  ED	  were	  excluded	  from	  this	  analysis.	   	  Those	  subjects	  who	  received	  vasopressors	   in	   the	  ED	  were	  classified	  into	   two	   groups:	   dysoxic	   shock	   (initial	   lactate	   >4.0mmol/L)	   or	   vasoplegic	   shock	  (initial	   lactate	  ≤4.0	  mmol/L).	  Subjects	  who	  did	  not	   receive	  vasopressors	   in	   the	  ED	  were	  classified	  into	  three	  groups:	  cryptic	  shock	  major	  (initial	  lactate	  >4.0	  mmol/L),	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Table	  6.	  	  Definitions	  of	  classification	  system.	  	  	  	  	  	  	  	  	  	  	  	  Group	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Definition	  	  	  	  	  Dysoxic	  shock*	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Vasopressor	  use	  in	  ED	  +	  initial	  lactate	  >	  4	  mmol/L	  	  	  	  	  Vasoplegic	  shock*	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Vasopressor	  use	  in	  ED	  +	  initial	  lactate	  ≤	  4	  mmol/L	  	  	  	  	  Cryptic	  shock	  major†	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  No	  vasopressor	  use	  in	  ED	  +	  initial	  lactate	  >	  4	  mmol/L	  	  	  	  	  Cryptic	  shock	  minor	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  No	  vasopressor	  use	  in	  ED	  +	  initial	  lactate	  between	  2-­‐4	  mmol/L	  	  	  	  	  Severe	  sepsis	  without	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  No	  vasopressor	  use	  in	  ED	  +	  initial	  lactate	  ≤	  2	  mmol/L	  	  	  	  	  lactate	  elevation	  	  	  	  	  Severe	  shock	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Multiple	  vasopressors	  in	  the	  ED	  	  	  	  	  Hemodynamic	  extremis	  	  	  	  	  	  	  	  	  	  	  	  	  Initial	  systolic	  blood	  pressure	  <	  70	  mmHg	  *	  Variously	  defined	  in	  the	  literature	  [125-­‐128].	  †	  	  Originally	  defined	  as	  “cryptic	  shock”	  by	  Donnino	  et	  al.	  [117].	  	  	  cryptic	   shock	   minor	   (initial	   lactate	   ≥2.0	   and	   <4.0	   mmol/L)	   and	   severe	   sepsis	  without	   lactate	   elevation	   (initial	   lactate	   ≤2.0).	   Other	   analyses	   involved	   separate	  subgroups	   of	   the	   registry;	   severe	   shock	  was	  defined	  by	   the	  use	   of	  more	   than	  one	  vasopressor	  agent	   in	   the	  ED,	  and	  hemodynamic	  extremis	  was	  defined	  by	  an	   initial	  blood	  pressure	  <70mmHg	  at	  presentation.	  	  
Statistical	  analysis	  The	   primary	   outcome	   for	   our	   study	   was	   28-­‐day	   mortality.	   	   Secondary	   outcomes	  included	   ED	   LOS,	   severity	   of	   illness	   variables	   (such	   as	   rates	   of	   individual	   and	  cumulative	   organ	   dysfunction,	   MEDS	   and	   APACHE	   II	   scores,	   intubation	   rates,	  vasopressor	  use	  within	  72	  hours),	  and	  treatment	  or	  intervention	  variables	  (such	  as	  time	   to	   antibiotics,	   mean	   crystalloid	   volume,	   documented	   source	   control,	   and	  components	   and	   documentation	   of	   EGDT).	   	   Categorical	   data,	   such	   as	   28-­‐day	  mortality,	   were	   reported	   as	   a	   percentage,	   and	   these	   percentages	   were	   compared	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Characteristics	  of	  included	  patients	  In	  total,	  521	  subjects	  in	  severe	  sepsis	  or	  septic	  shock	  were	  included	  in	  the	  registry.	  	  Of	  these,	  75	  subjects	  were	  excluded	  from	  the	  classification	  system	  because	  no	  initial	  serum	  lactates	  were	  drawn	  in	  the	  ED;	  the	  remainder	  (446,	  or	  85.6%	  of	  all	  registry	  subjects)	   was	   included	   in	   the	   primary	   analysis.	   	   These	   subjects	   were	   then	  categorized	   by	   initial	   lactates	   and	   vasopressor	   use	   in	   the	   ED,	   as	   described	   by	   the	  study	  protocol	  in	  Figure	  2;	  the	  definitions	  for	  each	  group	  are	  documented	  in	  Table	  6.	  	   The	  mean	   age	   of	   all	   446	   included	   subjects	  was	   63.7	   ±	   17.5	   years,	   and	   the	  gender	   distribution	  was	   nearly	   equal	  with	   53%	   of	   subjects	   being	  men.	   	   65.7%	   of	  subjects	   presented	   with	   severe	   sepsis,	   whereas	   34.3%	   were	   in	   septic	   shock.	   	   A	  detailed	  account	  of	  the	  various	  frequencies	  of	  comorbid	  conditions	  is	  found	  in	  Table	  7.	   	   The	   most	   common	   comorbidities	   included	   hypertension	   (54.7%),	   diabetes	  (33.2%),	   congestive	   heart	   failure	   (23.5%)	   and	   coronary	   artery	   disease	   (24.2%).	  	  Additionally,	  many	  subjects	  had	  risk	  factors	  for	  an	  immunosuppressed	  state:	  27.8%	  with	  a	  history	  of	  cancer	  (of	  whom	  a	  third	  had	  received	  chemotherapy),	  6.1%	  with	  a	  diagnosis	  of	  HIV	   infection	  or	  AIDS,	  8.7%	  with	   liver	  disease,	   11.7%	  with	   end-­‐stage	  renal	  disease,	  and	  8.7%	  with	  immunosuppression	  not	  otherwise	  specified.	  	  Almost	  a	  third	  of	  subjects	  resided	  in	  an	  extended	  care	  facility.	  	   On	   presentation	   to	   the	   ED,	   all	   subjects	   met	   at	   least	   2	   SIRS	   criteria	   by	  definition,	  and	  the	  mean	  number	  of	  positive	  SIRS	  criteria	  was	  2.89	  ±	  0.76.	  	  The	  most	  common	  source	  of	  infection	  was	  pulmonary	  in	  29.8%	  of	  subjects;	  the	  other	  common	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  Figure	  2.	  	  	  Flow	  diagram	  of	  classification	  system.	  *	  Subjects	  without	  initial	  lactate	  level	  measured	  constituted	  14.4%	  of	  the	  total	  registry.	  	  sources	   included	   genitourinary	   (16.1%),	   abdominal	   (11.2%),	   and	   skin	   and	   soft	  tissue	  infections	  (6.3%).	  The	  primary	  infectious	  source	  was	  unknown	  in	  28.8%	  of	  all	  subjects.	   	  Given	  the	  definitions	  of	  inclusion,	  the	  presence	  of	  organ	  dysfunction	  was	  universal.	   	   Hyperlactatemia	   (defined	   as	   a	   serum	   level	   ≥2	  mmol/L)	   was	   common,	  occurring	   in	   54.3%	   of	   subjects.	   	   Unexplained	   acidosis	   (44.6%),	   transient	  hypotension	   (38.6%),	   acute	   kidney	   injury	   (41.7%),	   hyperbilirubinemia	   (36.5%),	  hypoxemia	  (31.6%),	  and	  altered	  mental	  status	  from	  baseline	  (32.3%)	  were	  among	  the	  most	  common	  types	  of	  organ	  dysfunction.	  	  Almost	  a	  quarter	  of	  patients	  (24.4%)	  had	  elevations	  in	  their	  troponin	  levels.	  	  A	  minority	  of	  patients	  had	  a	  coagulopathy	  or	  thrombocytopenia	  (15%	  each).	  	  Finally,	  the	  mean	  MEDS	  score	  for	  all	  included	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Table	  7.	  	  Subject	  characteristics	  (n	  =	  446).	  Male	  gender	   110	  (53.1%)	  Mean	  age	  ±	  SD	  (years)	   	  	  63.7	  ±	  17.5	  Diagnosis	   	  	   Severe	  sepsis	   367	  (65.7%)	  	   Septic	  shock	   	  	  71	  (34.3%)	  Diagnostic	  criteria	   	  	   Mean	  number	  of	  SIRS	  criteria	  ±	  SD∆	   	  	  2.89	  ±	  0.76	  	   Documented	  source	  of	  infection	   	  	   	   Genito-­‐urinary	   	  	  72	  (16.1%)	  	   	   Intra-­‐abdominal	   	  	  50	  (11.2%)	  	   	   Pneumonia	   133	  (29.8%)	  	   	   Soft	  Tissue	   	  	  28	  (6.3%)	  	   	   Other†	   	  	  35	  (7.8%)	  	   Mean	  number	  of	  organ	  dysfunctions	  ±	  SD	   	  	  3.3	  ±	  1.9	  	   	   Transient	  hypotension	   170	  (38.1%)	  	   	   Hyperlactatemia	   242	  (54.3%)	  	   	   Unexplained	  acidosis	   199	  (44.6%)	  	   	   Altered	  mental	  status	   144	  (32.3%)	  	   	   Thrombocytopenia	   	  	  67	  (15.0%)	  	   	   Hyperbilirubinemia	   163	  (36.5%)	  	   	   Coagulopathy	  (without	  prior	  anticoagulation)	   	  	  67	  (15.0%)	  	   	   Acute	  kidney	  injury	   186	  (41.7%)	  	   	   Hypoxemia	   141	  (31.6%)	  	   	   Troponin	  elevation	   109	  (24.4%)	  Past	  medical	  history	   	  	   Alcohol	  abuse	   	  	  45	  (10.1%)	  	   Asthma	   	  	  29	  (6.5%)	  	   Cancer	   	  	  83	  (18.6%)	  	   Cancer	  with	  chemotherapy	   	  	  41	  (9.2%)	  	   Congestive	  heart	  failure	   105	  (23.5%)	  	   Coronary	  artery	  disease	   108	  (24.2%)	  	   Chronic	  altered	  mental	  status	   	  	  58	  (13.0%)	  	   Chronic	  obstructive	  pulmonary	  disease	   	  	  83	  (18.6%)	  	   CVA	  /	  TIA	   	  	  70	  (15.7%)	  	   Diabetes	   148	  (33.2%)	  	   End	  stage	  renal	  disease	   	  	  52	  (11.7%)	  	   HIV	  or	  HIV/AIDS	   	  	  27	  (6.1%)	  	   Hypertension	   244	  (54.7%)	  	   Immunosuppression	   	  	  39	  (8.7%)	  	   Liver	  disease	   	  	  39	  (8.7%)	  Residing	  in	  extended	  care	  facility	  (ECF)	   142	  (31.8%)	  Mean	  MEDS	  score	  ±	  SD	   	  	  11.3	  ±	  4.7	  Mean	  APACHE	  II	  score	  ±	  SD	   	  	  18.7	  ±	  7.2	  SD	   =	   standard	   deviation,	   CVA	   =	   cerebrovascular	   accident,	   TIA	   =	   transient	   ischemic	   attack,	   HIV	   =	   human	  immunodeficiency	  virus,	  AIDS	  =	  acquired	   immune	  deficiency	  syndrome,	  MEDS	  =	  Mortality	   in	  Emergency	  Department	  Sepsis.	  
†	  e.g.,	  central	  nervous	  system	  infection	  or	  line	  infection,	  ∆	  includes	  hyperlactatemia.	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subjects	  was	  11.3	  ±	  4.7,	  and	  the	  mean	  APACHE	  II	  score	  was	  18.7	  ±	  7.2.	  	   The	   treatments	   and	   interventions	   received	  by	   included	   subjects,	   as	  well	   as	  hospital	  outcomes,	  are	  summarized	  in	  Table	  8.	  	  Overall,	  92.6%	  of	  subjects	  received	  antimicrobial	  therapy	  during	  their	  ED	  stay;	  the	  most	  common	  antimicrobial	  agents	  included	  piperacillin/tazobactam,	   vancomycin,	   ceftriaxone,	   and	   ciprofloxacin.	   	  The	  mean	  time	  to	  antibiotics	  was	  2	  hours	  and	  34	  minutes,	  with	  a	  standard	  deviation	  of	  2	  hours	   and	   12	   minutes.	   	   Cultures	   were	   drawn	   in	   almost	   all	   patients,	   with	   blood	  cultures	  the	  most	  frequent	  (95.5%);	  only	  52.9%	  of	  patients	  had	  a	  positive	  result	  on	  any	   culture.	   	   The	   frequency	   of	   hospital	   vasopressor	   use	   within	   72	   hours	   of	  admission	  was	  27.6%,	  and	  only	  2.2%	  were	  started	  on	  vasopressors	  more	   than	  72	  hours	   after	   admission.	   	   The	   most	   frequently	   used	   vasopressor	   agent	   was	  norepinephrine	   (used	   in	   95.3%	   of	   vasopressor-­‐dependent	   subjects),	   followed	   by	  vasopressin	   (31.6%),	  dopamine	   (29.3%),	  phenylephrine	   (18.1%),	  and	  epinephrine	  (6.8%).	   	  49.6%	  (n=66)	  hospital	  vasopressor-­‐dependent	  subjects	  were	  treated	  with	  multiple	   vasopressor	   agents.	   	   Corticosteroids	   were	   given	   in	   29.1%	   of	   cases,	  dobutamine	   was	   used	   in	   5.2%,	   and	   31.2%	   of	   patients	   required	   mechanical	  ventilation	  at	  some	  point	   in	   their	  hospital	  course.	   	  Source	  control	  was	  achieved	   in	  18.6%	  of	  subjects.	  	  Finally,	  the	  overall	  28-­‐day	  mortality	  for	  all	  included	  subjects	  was	  13.9%;	  subjects	  presenting	  in	  severe	  sepsis	  had	  a	  mortality	  rate	  of	  10.6%,	  whereas	  those	  presenting	  in	  in	  septic	  shock	  had	  a	  mortality	  rate	  of	  29.1%.	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Table	  8.	  	  Interventions,	  treatments	  and	  outcomes	  (n	  =	  446).	  Mean	  length	  of	  ED	  stay	  ±	  SD	  (hours)	   6.80	  ±	  4.15	  Mean	  intravenous	  fluid	  amount	  ±	  SD	  (L)	   2.88	  ±	  2.16	  Antimicrobial	  Treatment	   	  	   Received	   413	  (92.6%)	  	   Mean	  time	  ±	  SD	  (hours)	   2.57	  ±	  2.20	  	   Type	  of	  Antimicrobial†	   	  	   	   	  Acyclovir	   	  	  	  	  6	  (1.3%)	  	   	  	  	   	  Ampicillin	   	  	  	  	  7	  (1.6%)	  	   	   	  Ceftazadime	   	  	  21	  (4.7%)	  	   	   	  Ceftriaxone	   	  	  94	  (21.1%)	  	   	   	  Ciprofloxacin	   	  	  92	  (20.6%)	  	   	   	  Doxycycline	   	  	  73	  (16.4%)	  	   	   	  Metronidazole	   	  	  42	  (9.4%)	  	   	   	  Gentamicin	   	  	  	  	  16	  (3.6%)	  	   	   	  Ampicillin/Sulbactam	   	  	  	  	  24	  (5.4%)	  	   	   	  Vancomycin	   245	  (54.9%)	  	   	   	  Piperacillin/Tazobactam	   226	  (50.7%)	  	   	   	  Other§	   	  	  	  	  29	  (6.5%)	  Cultures	   	  	   Blood	  culture	  drawn	   426	  (95.5%)	  	   Urine	  culture	  drawn	   308	  (69.1%)	  	   Other	  culture	  drawn‡	   147	  (33.0%)	  	   Any	  culture	  positive∆	   236	  (52.9%)	  Hospital	  vasopressors	   	  	   Less	  than	  72	  hours	  after	  admission	   123	  (27.6%)	  	   Greater	  than	  72	  hours	  after	  admission	   	  	  10	  (2.2%)	  Hospital	  use	  of	  dobutamine	  	   	  	  23	  (5.2%)	  Hospital	  use	  of	  corticosteroids	   130	  (29.1%)	  Source	  controlψ	   	  	  83	  (18.6%)	  Hospital	  use	  of	  mechanical	  ventilation	   139	  (31.2%)	  28-­‐day	  mortality	   	  	  62	  (13.9%)	  
SD	  =	  standard	  deviation.	  †	  N	  =	  413	  (total	  subjects	  receiving	  antimicrobials).	  §	  amoxicillin,	  clindamycin,	  meropenem,	  moxifloxacin,	  trimethoprim-­‐sulfamethoxazole.	  ‡	  e.g.,	  sputum,	  wound,	  or	  cerebrospinal	  fluid	  cultures.	  ∆	  N	  =	  435	  (total	  subjects	  with	  at	  least	  1	  culture	  drawn).	  
ψ	  abscess	  drained,	  line	  pulled,	  endoscopic	  or	  operative	  management.	  	  
	  
Frequencies	  of	  presentation	  and	  baseline	  characteristics	  Included	  patients	  of	   the	  registry	  were	  stratified	  by	   initial	   serum	   lactate	   levels	  and	  vasopressor	   requirement,	   and	   then	   assigned	   to	   one	   of	   five	   groups,	   described	   in	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Table	  6.	  	  16.6%	  (n=74)	  of	  the	  whole	  registry	  required	  vasopressors	  in	  the	  ED;	  4.9%	  (n=22)	   were	   in	   dysoxic	   shock,	   whereas	   11.7%	   (n=52)	   were	   in	   vasoplegic	   shock.	  	  	  83.4%	   (n=372)	   subjects	   did	   not	   require	   vasopressors	   in	   the	   ED:	   54	   (12.1%)	  presented	   in	   cryptic	   shock	   major,	   138	   (30.9%)	   in	   cryptic	   shock	   minor,	   and	   180	  (40.4%)	  in	  severe	  sepsis	  without	  an	  elevated	  lactate	  level.	  	  	   Table	   9	   lists	   the	   baseline	   characteristics	   of	   each	   group.	   	   The	   mean	   age	   of	  subjects	   was	   between	   60-­‐65	   years	   for	   all	   groups:	   dysoxic	   shock	   (60.9±16.8),	  vasoplegic	  shock	  (64.9	  ±15.4),	  cryptic	  shock	  major	  (63.0±17.1),	  cryptic	  shock	  minor	  (64.4±17.9),	  and	  severe	  sepsis	  without	  lactate	  elevation	  (63.4±18.2).	   	  Although	  the	  gender	   distribution	   of	   the	   registry	  was	   slightly	  weighted	   towards	  men	   (53.1%	   of	  total	   subjects),	   there	   was	   variability	   in	   the	   percentage	   of	   male	   subjects	   between	  groups:	  54.5%	  in	  dysoxic	  shock,	  42.3%	  in	  vasoplegic	  shock,	  61.1%	  in	  cryptic	  shock	  minor,	   60.1%	   in	   cryptic	   shock	  minor,	   and	   42.2%	   in	   severe	   sepsis	  without	   lactate	  elevation.	  	  Subjects	  in	  cryptic	  shock	  major	  and	  cryptic	  shock	  minor	  were	  statistically	  more	  likely	  to	  be	  male	  than	  subjects	  in	  severe	  sepsis	  without	  hyperlactatemia	  (p	  =	  0.019	  and	  0.002,	  respectively).	  	  	  	   There	   were	   no	   major	   variations	   between	   the	   groups	   in	   terms	   of	   the	  frequencies	  of	  various	  comorbidities	  known	  to	  affect	  sepsis	  severity:	  alcohol	  abuse,	  cancer,	  and	  HIV/AIDS	  or	  other	  immunosuppressed	  states	  (including	  end-­‐stage	  renal	  disease	   and	   diabetes).	   	   The	   frequency	   of	   liver	   disease	   in	   the	   dysoxic	   shock	   group	  was	  22.7%,	  whereas	  the	  range	  for	  the	  other	  groups	  was	  7.2-­‐9.6%;	  liver	  disease	  was	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Table 9.  Baseline patient characteristics by sub-group. 
Variable	   Dysoxic	  shock	  (n	  =	  22)	   Vasoplegic	  shock	  (n	  =	  52)	   Cryptic	  shock	  major	  (n	  =	  54)	   Cryptic	  shock	  minor	  (n	  =	  138)	  
Severe	  sepsis	  w/o	  lactate	  elev.	  (n	  =	  180)	  
Age	  (years)	   60.9	  ±	  16.8	   64.9	  ±	  15.4	   63.0	  ±	  17.1	   64.4	  ±	  17.9	   63.4	  ±	  18.2	  
Male	  gender	   12	  (54.5%)	   22	  (42.3%)	   33	  (61.1%)	   83	  (60.1%)	   76	  (42.2%)	  
Past	  Medical	  History	   	   	   	  	   Alcohol	  abuse	   4	  (18.2%)	   5	  (9.6%)	   9	  (16.7%)	   14	  (10.1%)	   13	  (7.2%)	  	   Asthma	   0	  (0%)	   4	  (7.7%)	   2	  (3.7%)	   5	  (3.6%)	   18	  (10.0%)	  	   Cancer	  	   5	  (22.7%)	   6	  (11.5%)	   9	  (16.7%)	   27	  (20.0%)	   36	  (20.0%)	  	   Cancer	  with	  chemotherapy	   3	  (13.6%)	   7	  (13.5%)	   4	  (7.4%)	   11	  (8.0%)	   16	  (8.9%)	  	   Congestive	  heart	  failure	   4	  (18.2%)	   18	  (34.6%)	   9	  (16.7%)	   27	  (20.0%)	   47	  (26.1%)	  	   Coronary	  artery	  disease	   0	  (0%)*	   14	  (26.9%)	   11	  (20.4%)	   40	  (29.0%)	   43	  (23.9%)	  	   Chronic	  altered	  mental	  status	   2	  (9.1%)	   6	  (11.5%)	   6	  (11.1%)	   23	  (16.7%)	   21	  (11.7%)	  	   COPD	   2	  (9.1%)	   13	  (25.0%)	   2	  (3.7%)	   22	  (16.0%)	   44	  (24.4%)	  	   CVA/TIA	   4	  (18.2%)	   7	  (13.5%)	   7	  (13.0%)	   23	  (16.7%)	   29	  (16.1%)	  	   Diabetes	   6	  (27.3%)	   21	  (40.4%)	   22	  (40.7%)	   50	  (36.2%)	   49	  (27.2%)	  	   End-­‐stage	  renal	  disease	   1	  (4.5%)	   10	  (19.2%)	   7	  (13.0%)	   15	  (10.9%)	   19	  (10.6%)	  	   HIV	  or	  HIV/AIDS	   2	  (9.1%)	   6	  (11.5%)	   1	  (2.0%)	   9	  (6.5%)	   9	  (5.0%)	  	   Hypertension	   6	  (27.3%)	   33	  (63.5%)	   27	  (50.0%)	   82	  (59.4%)	   96	  (53.3%)	  	   Immunosuppression	   2	  (9.1%)	   4	  (7.7%)	   3	  (5.6%)	   10	  (7.2%)	   20	  (11.1%)	  	   Liver	  disease	   5	  (22.7%)	   5	  (9.6%)	   5	  (9.3%)	   10	  (7.2%)	   14	  (7.8%)	  
Residing	  in	  ECF	   4	  (18.2%)	   16	  (30.8%)	   14	  (26.0%)	   45	  (32.6%)	   63	  (35.0%)	  
Documented	  source	  of	  infection	   	   	   	   	   	  	   Genito-­‐urinary	   2	  (9.1%)	   6	  (11.5%)	   9	  (16.7%)	   25	  (18.1%)	   30	  (16.7%)	  	   Intra-­‐abdominal	   4	  (18.2%)	   8	  (15.4%)	   12	  (22.2%)	   15	  (10.9%)	   11	  (6.1%)	  	   Pneumonia	   4	  (18.2%)	   13	  (25%)	   7	  (13.0%)	   43	  (31.2%)	   66	  (36.7%)	  	   Soft	  tissue	   0	  (0%)	   4	  (7.7%)	   1	  (2.0%)	   12	  (8.7%)	   11	  (6.1%)	  	   Other†	   1	  (4.5%)	   7	  (13.5%)	   4	  (7.4%)	   11	  (8.0%)	   12	  (6.7%)	  	   Unknown	   11	  (50.0%)	   14	  (27.0%)	   21	  (38.9%)	   32	  (23.2%)	   50	  (27.8%)	  SD	  =	  standard	  deviation,	  COPD	  =	  chronic	  obstructive	  pulmonary	  disease,	  CVA	  =	  cerebrovascular	  accident,	  TIA	  =	  transient	  ischemic	  attack,	  HIV	  =	  human	  immunodeficiency	  virus,	  AIDS	  =	  acquired	  immune	  deficiency	  syndrome,	  ECF	  =	  extended	  care	  facility,	  †	  e.g.,	  line	  infection	  or	  central	  nervous	  system	  infection.	  *	  p	  <	  0.05	  compared	  to	  values	  from	  all	  other	  groups.	  	  	  more	  common	  in	  dysoxic	  shock	  subjects	  than	  in	  subjects	  with	  cryptic	  shock	  minor	  (7.2%,	  p	  =	  0.037)	  and	  with	  severe	  sepsis	  without	  lactate	  elevation	  (7.8%,	  p	  =	  0.04).	  	  In	   general,	   the	   frequencies	   of	   other	   comorbidities	   listed	   in	   Table	   9	   were	   similar	  between	  the	  groups,	  with	  the	  exceptions	  of	  coronary	  artery	  disease	  in	  dysoxic	  shock	  subjects	  (0.0%)	  and	  COPD	  in	  cryptic	  shock	  major	  (3.7%).	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   A	   genito-­‐urinary	   source	   of	   infection	   was	   found	   in	   9.1%	   of	   dysoxic	   shock,	  11.5%	   in	   vasoplegic	   shock,	   16.7%	   in	   cryptic	   shock	  major,	   18.1%	   in	   cryptic	   shock	  minor,	  and	  16.7%	  in	  severe	  sepsis	  subjects	  without	   lactate	  elevation.	   	  The	  rates	  of	  pneumonia	  as	  a	  source	  were	  18.2%,	  25.0%,	  13.0%,	  31.2%,	  and	  36.7%	  respectively.	  	  Abdominal	   sources	   were	   found	   in	   18.2%,	   15.4%,	   22.2%,	   10.9%,	   and	   6.1%	   of	  subjects,	   respectively.	   	   Soft	   tissue	   sources	   were	   rare	   (0-­‐8.7%).	   	   The	   frequency	   of	  unknown	   sources	   of	   infection	  was	   50.0%	   for	   dysoxic	   shock,	   27.0%	   for	   vasoplegic	  shock,	  38.9%	  for	  cryptic	  shock	  major,	  23.2%	  for	  cryptic	  shock	  minor,	  and	  27.8%	  for	  severe	  sepsis	  without	  lactate	  elevation.	  	  
Clinical	  features	  Table	   10	   lists	   the	   clinical	   characteristics	   of	   subjects	   in	   each	   of	   the	   5	   classification	  groups.	   	  The	  mean	  number	  of	  positive	  SIRS	  criteria	  was	  similar	  for	  all	  groups,	  and	  the	   frequencies	   of	   various	   components	   of	   the	   SIRS	   criteria	   stayed	   roughly	   equal.	  	  Fever	  on	  presentation	  was	  seen	  in	  42.6%	  of	  cryptic	  shock	  major	  subjects,	  compared	  to	  53.8-­‐72.7%	  for	  all	  other	  groups	  (all	  p	  <	  0.04).	  	  Tachycardia	  was	  the	  most	  common	  positive	   SIRS	   criterion	   in	   all	   groups.	   	   Subjects	   requiring	   vasopressors	   presented	  with	   lower	   initial	   systolic,	   diastolic	   and	  mean	   arterial	   blood	   pressures	   than	   those	  not	   requiring	   vasopressors	   (all	   p	   <	   0.05).	   	   The	  mean	   shock	   index	   (SI)	   of	   dysoxic	  shock	   subjects	   was	   1.4±0.41	   beats/min×mmHg,	   higher	   than	   other	   groups	   (all	   p	  <0.0001).	  	  There	  was	  no	  difference	  in	  mean	  SI	  between	  vasoplegic	  shock	  and	  cryptic	  shock	  major	  groups	  (1.09±0.35	  vs.	  1.12±0.38	  beats/min×mmHg,	  p	  =	  0.39),	  an	  effect	  of	  a	  higher	  initial	  heart	  rate	  in	  cryptic	  shock	  major	  subjects	  compared	  to	  vasoplegic	  shock	  subjects	  (112.9±20.0	  vs.	  97.0±21.1	  beats/min,	  p	  =	  0.0001);	  these	  mean	  shock	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indices	   were	   statistically	   different	   from	   those	   of	   cryptic	   shock	   minor	   and	   severe	  sepsis	  subjects	  (0.91±0.28	  and	  0.90±0.27	  respectively,	  all	  p	  <	  0.001).	  	   There	   were	   differences	   in	   in	   both	   frequency	   and	   intensity	   of	   organ	  dysfunction	   across	   the	   classification	   system.	   	   The	   mean	   number	   of	   organ	  dysfunctions	   was	   4.64±2.40	   in	   dysoxic	   shock,	   3.53±1.87	   in	   vasoplegic	   shock,	  3.09±1.95	  in	  cryptic	  shock	  major,	  2.46±1.77	  in	  cryptic	  shock	  minor,	  and	  2.49±1.27	  in	   severe	   sepsis	   without	   lactate	   elevation.	   	   Due	   to	   the	   use	   of	   serum	   lactate	   as	   a	  discriminating	  variable	  between	  groups,	  hyperlactatemia	  was	  excluded	  as	  a	  type	  of	  organ	  dysfunction	   from	   these	   calculations.	   	  These	  differences	  were	  all	   statistically	  different	  when	  compared	  pairwise	  (all	  p	  <	  0.05),	  with	  the	  exception	  of	  the	  following	  direct	  comparisons:	  cryptic	  shock	  major	  to	  vasoplegic	  shock	  (p	  =	  0.24)	  and	  cryptic	  shock	  minor	   to	  severe	  sepsis	  without	   lactate	  elevation	  (p	  =	  0.86).	   	  A	  similar	   trend	  persisted	  on	  comparison	  of	  individual	  types	  of	  organ	  dysfunction,	  especially	  among	  the	   most	   common	   such	   as	   altered	   mental	   status	   (AMS)	   and	   acute	   kidney	   injury	  (AKI).	   	   The	  dysoxic	   shock	   group	  had	   the	  highest	   proportion	  of	   subjects	  with	  AMS	  (72.3%)	  compared	  to	  all	  other	  groups,	  including	  vasoplegic	  shock	  subjects	  (40.4%,	  p	  =	  0.021).	  	  AKI	  was	  common,	  occurring	  in	  81.8%	  of	  dysoxic	  shock	  subjects,	  48.1%	  of	  vasoplegic	  shock	  subjects,	  and	  59.3%	  of	  cryptic	  shock	  major	  subjects.	  	  These	  rates	  of	  AKI	  were	  higher	  than	  those	  seen	  in	  cryptic	  shock	  minor	  and	  severe	  shock	  without	  lactate	  elevation	  (41.3%,	  all	  p	  <	  0.036	  and	  30.0%,	  all	  p	  <	  0.0002,	  respectively).	  	  The	  prevalence	   of	   acidosis,	   thrombocytopenia	   and	   coagulation	   abnormalities	   also	  followed	  a	  similar	  trend.	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Table 10.  Clinical characteristics by sub-group. 
Variable	   Dysoxic	  shock	  (n	  =	  22)	   Vasoplegic	  shock	  (n	  =	  52)	   Cryptic	  shock	  major	  (n	  =	  54)	   Cryptic	  shock	  minor	  (n	  =	  138)	  
Severe	  sepsis	  w/o	  lactate	  elev.	  (n	  =	  180)	  
SIRS	  criteria	   	  	   Number	  of	  positive	  SIRS	  criteria	   3.00	  ±	  0.87	   2.88	  ±	  0.78	   2.89	  ±	  0.74	   2.93	  ±	  0.78	   2.86	  ±	  0.73	  	   Fever	   16	  (72.7%)	   28	  (53.8%)	   23	  (42.6%)	   85	  (61.6%)	   98	  (54.4%)	  	   Tachycardia	   19	  (86.4%)	   45	  (86.5%)	   47	  (87.0%)	   122	  (88.4%)	   146	  (81.1%)	  	   Tachypnea	   15	  (68.2%)	   43	  (82.7%)	   43	  (79.6%)	   107	  (77.5%)	   146	  (81.1%)	  	   Abnormal	  WBC	  count	   16	  (72.7%)	   34	  (65.4%)	   43	  (79.6%)	   90	  (65.2%)	   121	  (67.2%)	  
Initial	  vital	  signs	   	  	   Systolic	  blood	  pressure	  (SBP)	   88.2	  ±	  24.7	   93.5	  ±	  22.2	   108.5	  ±	  29.4	   122.2	  ±	  29.0	   119.5	  ±	  27.3	  	   Diastolic	  blood	  pressure	  (DBP)	   47.3	  ±	  17.4	   53.8	  ±	  18.6	   65.4	  ±	  22.0	   69.6	  ±	  18.1	   65.8	  ±	  17.2	  	   Mean	  arterial	  pressure	  (MAP)	   60.9	  ±	  17.6	   67.1	  ±	  18.0	   79.8	  ±	  23.2	   87.2	  ±	  20.2	   83.7	  ±	  18.8	  	   Heart	  rate	  (HR)	   119.1	  ±	  40.5	   97.0	  ±	  21.1	   112.9	  ±	  20.0	   105.6	  ±	  20.8	   103.1	  ±	  23.4	  	   Shock	  Index	  (HR/SBP)	   1.40	  ±	  0.41*	   1.09	  ±	  0.35	   1.12	  ±	  0.38	   0.91	  ±	  0.28	   0.90	  ±	  0.27	  
Glasgow	  Coma	  Scale	  scoreψ	   11.68	  ±	  4.52	   13.13	  ±	  3.46	   13.60	  ±	  2.75	   13.95	  ±	  2.45	   14.05	  ±	  2.13	  
Number	  of	  organ	  dysfunctions	  ϕ	   4.64	  ±	  2.40*	   3.53	  ±	  1.87	   3.09	  ±	  1.95	   2.46	  ±	  1.77	   2.49	  ±	  1.27	  
Type	  of	  organ	  dysfunction	   	  	   Transient	  hypotension	   13	  (59.1%)	   28	  (53.8%)	   20	  (37.0%)	   41	  (29.7%)	   68	  (37.8%)	  	   Hyperlactatemia	   22	  (100%)	   28	  (53.8%)	   54	  (100%)	   138	  (100%)	   0	  (0%)	  	   Acidosis	   15	  (68.2%)	   27	  (51.9%)	   27	  (50.0%)	   52	  (37.7%)	   78	  (43.3%)	  	   Altered	  mental	  status	   16	  (72.3%)*	   21	  (40.4%)	   16	  (29.6%)	   38	  (27.5%)	   53	  (29.4%)	  	   Thrombocytopenia	   7	  (31.8%)	   13	  (25.0%)	   8	  (14.8%)	   17	  (12.3%)	   22	  (12.2%)	  	   Hyperbilirubinemia	   13	  (59.1%)	   24	  (46.2%)	   21	  (38.9%)	   50	  (36.2%)	   55	  (30.6%)	  	   Coagulopathy	   8	  (36.4%)	   10	  (19.2%)	   13	  (24.1%)	   19	  (13.8%)	   17	  (9.4%)	  	   Acute	  kidney	  injury	   18	  (81.8%)	   25	  (48.1%)	   32	  (59.3%)	   57	  (41.3%)	   54	  (30.0%)*	  	   Hypoxemia	   8	  (36.4%)	   21	  (40.4%)	   9	  (16.7%)	   37	  (26.8%)	   66	  (36.7%)	  	   Troponin	  elevation	   5	  (22.7%)	   16	  (30.8%)	   22	  (40.7%)	   32	  (23.2%)	   34	  (18.9%)	  
MEDS	  score	   14.05	  ±	  5.18	   13.48	  ±	  4.65	   10.48	  ±	  4.21	   10.75	  ±	  4.55	   10.89	  ±	  4.58	  
APACHE	  II	  score	   26.95	  ±	  7.23*	   21.71	  ±	  6.54	   20.85	  ±	  6.89	   16.89	  ±	  7.00	   17.57	  ±	  6.45	  
Initial	  laboratory	  values	   	  	   WBC	  (1000	  per	  mm3)	  	   10.96	  ±	  8.83	   14.84	  ±	  11.51	   16.78	  ±	  12.58	   16.23	  ±	  18.86	   13.53	  ±	  7.39†	  	   Platelets	  (1000	  per	  mm3)	  †	   189.9	  ±	  123.8	   225.1	  ±	  131.9	   288.1	  ±	  151.7	   259.6	  ±	  120.4	   276.7	  ±	  149.0†	  	   Serum	  creatinine	  (mg/dL)	   2.77	  ±	  1.61	   2.88	  ±	  2.37	   2.50	  ±	  1.96	   2.22	  ±	  2.19	   1.95	  ±	  1.65‡	  	   Serum	  INR∆	   2.18	  ±	  2.46	   1.76	  ±	  1.32	   2.17	  ±	  3.71	   1.58	  ±	  2.15	   1.51	  ±	  1.35	  	   Arterial	  blood	  gas	  pH§	   7.17	  ±	  0.20*	   7.30	  ±	  0.13	   7.34	  ±	  0.18	   7.40	  ±	  0.08	   7.34	  ±	  0.11	  	   Serum	  lactate	  (mmol/L)	   7.82	  ±	  3.98*	   2.08	  ±	  0.83*	   5.99	  ±	  2.31*	   2.79	  ±	  0.53*	   1.22	  ±	  0.40*	  SD	  =	  standard	  deviation,	  SIRS	  =	  systemic	  inflammatory	  response	  syndrome,	  WBC	  =	  white	  blood	  cell,	  INR	  =	  international	  normalized	  ratio.	  *	  p	  <	  0.05	  compared	  to	  values	  from	  all	  other	  groups.	  
ψ	  N	  =	  22,	  52,	  54,	  135,	  175	  resp.	  †	  N	  =	  178.	  ‡	  	  N	  =	  179.	  ∆	  N	  =	  22,	  49,	  52,	  133,	  171	  resp.	  §	  N	  =	  14,	  25,	  21,	  52,	  65	  resp.	  ϕ	  excludes	  hyperlactatemia,	  as	  serum	  lactate	  levels	  determined	  group	  placement.	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   Considering	  laboratory	  tests,	  the	  mean	  arterial	  pH	  was	  lower	  in	  the	  dysoxic	  shock	  group	  (7.17±0.20)	  compared	  to	  all	  others	  (7.30-­‐7.40,	  all	  p	  <	  0.02;	  see	  sample	  sizes	  within	  legend	  of	  Table	  10).	  	  Mean	  platelet	  levels	  were	  low	  in	  the	  dysoxic	  shock	  group	  (189.9±123.8)	  in	  comparison	  to	  the	  three	  groups	  not	  on	  vasopressors	  (all	  p	  <	  0.02).	   	  All	   groups	  had	  an	  elevated	  mean	   initial	   serum	  creatinine.	   	  The	   initial	  WBC	  counts	  and	  serum	  INR	  did	  not	  differ	  substantially	  between	  the	  groups.	  	  Finally,	  the	  mean	   serum	   lactates	   were	   7.82±3.98	   for	   dysoxic	   shock,	   2.08±0.83	   for	   vasoplegic	  shock,	   5.99±2.31	   for	   cryptic	   shock	  major,	   2.79±0.53	   for	   cryptic	   shock	  minor,	   and	  1.22±0.40	  for	  severe	  sepsis	  without	  lactate	  elevation.	  	   Mean	  MEDS	  and	  APACHE	  II	  scores	  varied	  across	  the	  groups.	  	  The	  mean	  MEDS	  scores	   were	   14.05±5.18	   for	   dysoxic	   shock,	   13.48±4.65	   for	   vasoplegic	   shock,	  10.48±4.21	   for	   cryptic	   shock	   major,	   10.75±4.55	   for	   cryptic	   shock	   minor,	   and	  10.89±4.58	  for	  severe	  sepsis	  without	  lactate	  elevation.	  	  The	  mean	  APACHE	  II	  scores	  were	  26.95±7.23	  for	  dysoxic	  shock,	  21.71±6.54	  for	  vasoplegic	  shock,	  20.85±6.89	  for	  cryptic	  shock	  major,	  16.89±7.00	  for	  cryptic	  shock	  minor,	  and	  17.57±6.45	  for	  severe	  sepsis	  without	  lactate	  elevation.	  	  	  
Treatments	  The	   frequencies	   of	   various	   treatments	   and	   interventions	   received	   by	   each	   group	  during	  the	  course	  of	   their	  ED	  stay	  are	  displayed	   in	  Table	  11.	   	  Blood	  cultures	  were	  drawn	  greater	  than	  90%	  of	  the	  time	  in	  all	  groups.	  	  Antibiotics	  were	  given	  in	  81.8%	  of	   cases	   of	   dysoxic	   shock,	   compared	   to	   98.1%	   in	   vasoplegic	   shock	   subjects	   (p	   =	  0.252);	  all	  other	  groups	  had	  a	  rate	  above	  90%.	  	  The	  mean	  time	  elapsed	  from	  ED	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Table 11.  Emergency Department treatment characteristics by sub-group. 
Variable	   Dysoxic	  shock	  (n	  =	  22)	   Vasoplegic	  shock	  (n	  =	  52)	   Cryptic	  shock	  major	  (n	  =	  54)	   Cryptic	  shock	  minor	  (n	  =	  138)	  
Severe	  sepsis	  w/o	  lactate	  elev.	  (n	  =	  180)	  Blood	  cultures	  drawn	   20	  (91.0%)	   51	  (98.1%)	   49	  (90.7%)	   131	  (95.0%)	   172	  (95.6%)	  Antibiotics	  given	   18	  (81.8%)	   51	  (98.1%)	   49	  (90.7%)	   126	  (91.3%)	   166	  (92.2%)	  Time	  to	  antibiotics	  (hours)ψ§	   1.67	  ±	  1.05	   2.43	  ±	  1.86	   2.34	  ±	  1.49	   2.51	  ±	  1.55	   3.10	  ±	  3.19	  Total	  fluid	  volume	  received	  (L)	   5.45	  ±	  3.73	   4.31	  ±	  2.40	   3.00	  ±	  1.64	   2.64	  ±	  1.84	   2.31	  ±	  1.78	  Central	  line	  placed	   20	  (91.0%)	   49	  (94.2%)	   15	  (27.8%)	   27	  (19.6%)	   39	  (21.7%)	  	   CVP	  measured	   10	  (45.5%)	   31	  (59.6%)	   8	  (14.8%)	   17	  (12.3%)	   24	  (13.3%)	  	   Initial	  CVP	  (cmH20)	   8.0	  ±	  5.9	   11.4	  ±	  5.9	   6.9	  ±	  2.9	   9.9	  ±	  4.5	   7.0	  ±	  4.9	  	   ScvO2	  measured	   11	  (50.0%)	   29	  (55.8%)	   13	  (24.1%)	   19	  (13.8%)	   27	  (15.0%)	  	   Initial	  ScvO2	  (%)	   74.6	  ±	  14.2	   69.8	  ±	  13.5	   67.1	  ±	  16.2	   70.5	  ±	  10.8	   67.2	  ±	  12.1	  EGDT	  documented	   5	  (22.7%)	   20	  (38.4%)	   7	  (13.0%)	   14	  (10.1%)	   23	  (12.8%)	  Vasopressors	  received	   22	  (100%)	   52	  (100%)	   n/a	   n/a	   n/a	  Number	  of	  vasopressor	  agents	   2.3	  ±	  1.2	   1.8	  ±	  0.9	   n/a	   n/a	   n/a	  Corticosteroids	  receivedψ	   11	  (50.0%)	   29	  (55.8%)	   11	  (20.4%)	   25	  (18.1%)	   54	  (30.0%)	  Dobutamine	  receivedψ	   4	  (18.2%)	   7	  (13.5%)	   5	  (9.3%)	   4	  (2.9%)	   3	  (1.7%)	  Source	  control	  obtainedψ	   2	  (9.1%)	   10	  (19.2%)	   10	  (18.5%)	   30	  (21.7%)	   31	  (17.2%)	  Intubated	   12	  (54.5%)	   17	  (32.7%)	   8	  (14.8%)	   17	  (12.3%)	   18	  (10.0%)	  ED	  length	  of	  stay	  (hours)	   6.62	  ±	  5.27	   6.79	  ±	  4.23	   5.96	  ±	  3.42	   6.93	  ±	  3.86	   6.98	  ±	  4.38	  
ψ	  Includes	  hospital	  stay.	  ∆	  abscess	  drained,	  line	  pulled,	  endoscopic	  or	  operative	  management.	  §	  N	  =	  18,	  51,	  49,	  126,	  167	  resp.	  	  presentation	  to	  receiving	  antibiotic	  therapy	  was	  shortest	  in	  the	  dysoxic	  shock	  group	  and	  longest	  in	  the	  subjects	  in	  severe	  sepsis	  without	  lactate	  elevation	  (1.67±1.05	  vs.	  3.10±3.19	  hours,	  p	  =	  0.0384);	   the	  other	  groups	   fell	  between	  2-­‐3	  hours.	   	  The	  mean	  crystalloid	  volume	  received	  in	  the	  ED	  by	  both	  the	  dysoxic	  shock	  group	  (5.45±3.73	  L)	  and	   vasoplegic	   shock	   group	   (4.31±2.40	   L)	   was	   larger	   than	   the	   groups	   not	   on	  vasopressors	  (all	  p	  <	  0.002).	   	  The	  cryptic	  shock	  major	  group	  also	  received	  a	  larger	  crystalloid	   volume	   than	   subjects	   in	   severe	   sepsis	   without	   lactate	   elevation	  (3.00±1.64	  L	  vs.	  2.31±1.78	  L,	  p	  =	  0.0117).	   	  The	  proportion	  of	   subjects	  whose	  care	  involved	  infectious	  source	  control	  (including	  drainage	  of	  abscesses,	  pulling	  infected	  lines,	  or	  obtaining	  endoscopic	  or	  operative	  control	  of	  infectious	  sources)	  was	  below	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25%	  in	  all	  subject	  groups	  without	  differences	  between	  groups.	  	  The	  mean	  length	  of	  stay	   in	   the	  ED	  was	   5.96-­‐6.98	   hours	   for	   all	   groups,	   and	  no	   differences	  were	   found	  between	  the	  mean	  lengths	  of	  stay.	  	   Central	   venous	   catheters	  were	  placed	   in	  many	  patients	   in	  order	   to	  provide	  therapies	   (fluids,	  vasopressors)	  as	  well	  as	  monitor	   the	  hemodynamic	  status	  of	   the	  subjects.	   	   Almost	   all	   of	   the	   subjects	   presenting	   in	   vasopressor-­‐dependent	   shock	  (91%	   of	   dysoxic	   shock	   subjects	   and	   94.2%	   of	   vasoplegic	   shock	   subjects)	   had	   a	  central	   line	   placed	   in	   the	   ED:	  more	   frequently	   than	   the	   subjects	   in	   cryptic	   shock	  major,	   cryptic	   shock	   minor	   and	   severe	   sepsis	   without	   lactate	   elevation	   (27.8%,	  19.6%,	   and	   21.7%	   respectively,	   all	   p	   <	   0.0001).	   	   The	   5	   patients	   in	   vasopressor-­‐dependent	  shock	  who	  did	  not	  have	  a	  central	  line	  placed	  received	  vasopressors	  via	  a	  peripheral	  line.	  	  	  	   Using	   the	   mention	   of	   early	   goal-­‐directed	   therapy	   (EGDT)	   in	   charted	  documentation	  as	  evidence	  of	   the	   intention	   to	   follow	  an	  EGDT-­‐based	  protocol,	  we	  found	  that	  among	  the	  groups	  on	  vasopressors,	  22.7%	  of	  dysoxic	  shock	  subjects	  and	  38.4%	  of	  vasoplegic	  shock	  groups	  had	  EGDT	  documentation.	   	  When	  combined,	  the	  rate	   of	   EGDT	   documentation	   was	   higher	   in	   the	   vasopressor-­‐dependent	   shock	  subjects	  compared	  to	  the	  cryptic	  shock	  major	  group	  (33.8%	  vs.	  13.0%,	  p	  =	  0.0076).	  	  Of	   those	  subjects	  who	  had	  central	  venous	  catheters	   in	   the	  ED,	  more	   than	  half	  had	  both	  CVP	  and	   ScvO2	  measured	   at	   least	   once.	   	  However,	   there	  were	  no	  differences	  between	   groups	   in	   terms	   of	   whether	   CVP	   or	   ScvO2	   was	  measured,	   as	   well	   as	   no	  differences	  between	  the	  mean	  initial	  CVP	  or	  ScvO2	  values.	  	  The	  dysoxic	  shock	  group	  had	  a	  mean	  initial	  ScvO2	  of	  74.6±14.2	  (n	  =	  11),	  and	  the	  vasoplegic	  shock	  group	  had	  a	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mean	  of	  69.8±13.5	  (n	  =	  29,	  p	  =	  0.33);	  however,	   the	  proportion	  of	  patients	   initially	  below	   the	   ScvO2	   goal	   of	   70%	   in	   each	   group	   (45.4%	   and	   54.8%,	   respectively,	   p	   =	  0.73)	  was	   roughly	   equal.	   	   Subjects	   in	   the	   cryptic	   shock	  major	   group	  whose	   Scv02	  was	  measured	  were	  very	  likely	  to	  be	  below	  goal	  ScvO2	  (69.2%,	  n	  =	  13)	  and	  averaged	  a	  low	  initial	  ScvO2	  mean	  (mean	  saturation	  of	  67.1%).	  	  	   By	   definition,	   100%	   of	   the	   dysoxic	   and	   vasoplegic	   shock	   groups	   received	  vasopressor	   therapy	   in	   the	  ED,	  whereas	   none	   of	   the	   other	   subjects	   did.	   	   16	   of	   22	  (73%)	   subjects	   in	   the	   dysoxic	   shock	   group	   and	   26	   of	   52	   (50%)	   of	   the	   vasoplegic	  group	  were	   on	  multiple	   vasopressor	   agents	   during	   their	   hospital	   stay	   (p	   =	   0.08).	  	  The	   mean	   number	   of	   vasopressor	   agents	   used	   in	   the	   dysoxic	   shock	   group	   was	  2.3±1.2,	   compared	   to	   1.8±0.9	   in	   the	   vasoplegic	   group	   (p	   =	   0.052).	   Rates	   of	  intubation	  in	  the	  ED	  were	  higher	  in	  the	  dysoxic	  shock	  (54.5%)	  and	  vasoplegic	  shock	  (32.7%)	  groups	  than	   in	  the	  groups	  not	  on	  vasopressors	  (all	  p	  <	  0.04),	  all	  of	  which	  had	  an	  intubation	  rate	  less	  than	  15%.	  	  	  	  	   Corticosteroids	  were	   commonly	   administered	   in	   both	  dysoxic	   shock	   (50%)	  and	   vasoplegic	   shock	   (55.8%)	   and	   were	   more	   likely	   to	   be	   administered	   to	   these	  subjects	  compared	  to	  those	  not	  requiring	  vasopressors	  (p	  <	  0.0001);	  a	  minority	  of	  subjects	  not	  requiring	  vasopressors	  still	   received	  corticosteroids	  (18.1-­‐30%).	   	  The	  prevalence	   of	   dobutamine	   administration	   in	   both	   the	   dysoxic	   shock	   (18.2%)	   and	  vasoplegic	   shock	   groups	   (13.5%)	  was	  higher	   than	   in	   the	   cryptic	   shock	  minor	   and	  severe	   sepsis	   without	   lactate	   elevation	   groups	   (p	   <	   0.003),	   but	   not	   statistically	  different	  from	  its	  prevalence	  in	  the	  treatment	  of	  cryptic	  shock	  major	  (9.3%).	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Hospital	  outcomes	  The	   clinical	   outcomes	   of	   the	   classification	   groups	   are	   displayed	   in	   Table	   12.	   	   All	  subjects	   were	   admitted	   to	   the	   hospital,	   as	   this	   was	   an	   inclusion	   criterion	   for	   the	  registry.	  	  The	  majority	  of	  subjects	  in	  all	  groups	  were	  admitted	  to	  acute	  or	  subacute	  care	  units	  (ICU,	  step-­‐down	  unit,	  or	  operating	  room)	  from	  the	  ED.	  	  All	  dysoxic	  shock	  and	  vasoplegic	  shock	  subjects	  were	  admitted	  to	  an	  ICU,	  although	  two	  dysoxic	  shock	  subjects	  died	  before	  transfer	  to	  the	  ICU;	  83.3%	  of	  cryptic	  shock	  major	  subjects	  were	  admitted	   to	   the	   ICU.	   	   In	   contrast,	   only	  47.1%	  of	   cryptic	   shock	  minor	   subjects	   and	  45.6%	  of	  severe	  sepsis	  subjects	  without	  lactate	  elevation	  were	  admitted	  to	  an	  ICU.	  	  Compared	  to	  the	  group	  in	  severe	  sepsis	  without	  lactate	  elevation,	  the	  odds	  ratios	  	  	  
Table 12.  Mortality and hospital outcomes by sub-group. 
Variable	   Dysoxic	  shock	  (n	  =	  22)	   Vasoplegic	  shock	  (n	  =	  52)	   Cryptic	  shock	  major	  (n	  =	  54)	   Cryptic	  shock	  minor	  (n	  =	  138)	  
Severe	  sepsis	  w/o	  lactate	  elev.	  (n	  =	  180)	  
Hospitalization	  outcomes	   	  	   Disposition	  from	  ED	   	  	   	   ICU	   20	  (90.9%)∆	   52	  (100%)	   45	  (83.3%)	   65	  (47.1%)	   82	  (45.6%)	  	   	   Step-­‐down	  unit	   0	  (0%)	   0	  (0%)	   2	  (3.7%)	   9	  (6.5%)	   8	  (4.4%)	  	   	   Floor	   0	  (0%)	   0	  (0%)	   6	  (11.1%)	   59	  (42.8%)	   87	  (48.3%)	  	   	   OR	   0	  (0%)	   0	  (0%)	   1	  (1.9%)	   5	  (3.6%)	   3	  (1.7%)	  	   On	  mechanical	  ventilation	   14	  (63.6%)	   27	  (51.9%)	   22	  (40.7%)	   36	  (26.1%)	   40	  (22.2%)	  	   Vasopressor	  use	   22	  (100%)	   52	  (100%)	   16	  (29.6%)	   24	  (17.4%)	   19	  (10.6%)	  	   	   Early	  (within	  72	  hours)	   22	  (100%)	   52	  (100%)	   16	  (29.6%)*	   17	  (12.3%)	   16	  (8.9%)	  	   	   Delayed	  (after	  72	  hours)	   0	  (0%)	   0	  (0%)	   0	  (0%)	   7	  (5.1%)	   3	  (1.7%)	  
Mortality	   	  	   28-­‐day	  mortality	   11	  (50.0%)*	   11	  (21.1%)	   10	  (18.5%)	   17	  (12.3%)	   13	  (7.2%)	  
∆2	  patients	  died	  before	  transfer	  to	  ICU.	  *	  p	  <	  0.05	  compared	  to	  values	  from	  all	  other	  groups.	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for	  admission	  to	  an	  acute	  or	  subacute	  care	  unit	  was	  42.1	  (2.5-­‐704.8,	  p	  <	  0.0001)	  for	  the	   dysoxic	   shock	   group,	   98.3	   (6.0-­‐1616.3,	   p	   <	   0.0001)	   for	   the	   vasoplegic	   shock	  group,	  and	  7.5	  (3.0-­‐18.4	  p	  <	  0.0001)	  for	  the	  cryptic	  shock	  major	  group.	  	  The	  rate	  of	  admission	   to	   acute/subacute	   care	  did	  not	  differ	  between	   cryptic	   shock	  minor	  and	  severe	  sepsis	  without	  lactate	  elevation.	  	   The	   use	   of	   mechanical	   ventilation	   during	   the	   hospital	   course	   was	   very	  common	  among	  all	  groups,	  and	  followed	  a	  stepwise	  trend:	  63.6%	  in	  dysoxic	  shock,	  51.9%	   in	   vasoplegic	   shock,	   40.7%	   in	   cryptic	   shock	  major,	   26.1%	   in	   cryptic	   shock	  minor,	   and	   22.2%	   severe	   sepsis	   without	   lactate	   elevation.	   	   Compared	   to	   severe	  sepsis	  without	  lactate	  elevation,	  the	  odds	  ratios	  for	  requiring	  mechanical	  ventilation	  were	   6.1	   (2.4-­‐15.6,	   p	   =	   0.0001)	   for	   dysoxic	   shock,	   3.8	   (2.0-­‐7.2,	   p	   <	   0.0001)	   for	  vasoplegic	  shock,	  2.4	  (1.3-­‐4.6,	  p	  =	  0.0087)	  for	  cryptic	  shock	  major,	  and	  1.2	  (0.7-­‐2.1,	  p	  =	  0.43)	  for	  cryptic	  shock	  minor.	   	  All	  subjects	  in	  the	  dysoxic	  and	  vasoplegic	  shock	  group	   continued	   on	   vasopressors	   at	   least	   during	   the	   proximal	   phase	   of	   their	  admission	   to	   the	   hospital.	   	   Additionally,	   29.6%	   of	   cryptic	   shock	   major	   subjects	  required	   vasopressor	   therapy	   during	   the	   first	   72	   hours	   of	   their	   hospitalization,	  compared	  to	  12.3%	  in	  cryptic	  shock	  minor	  (OR	  3.0	  (1.4-­‐6.5),	  p	  =	  0.0095)	  and	  8.9%	  in	  severe	  sepsis	  without	  lactate	  elevation	  (OR	  4.3	  (2.0-­‐9.4),	  p	  =	  0.0008).	  	  Of	  the	  133	  subjects	  on	  vasopressor	  therapy	  during	  their	  hospital	  stay,	  10	  (7.5%)	  were	  started	  on	   vasopressors	   more	   than	   72	   hours	   after	   admission,	   and	   these	   subjects	   were	  exclusively	  found	  in	  the	  categories	  of	  cryptic	  shock	  minor	  and	  severe	  sepsis	  without	  lactate	  elevation.	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  Figure	  3.	  	  Mortality	  rate	  at	  28	  days.	  	  	  	  	  	  Error	  bars	  represent	  95%	  confidence	  intervals.	  	  	  	   In	  the	  univariate	  analysis,	  the	  28-­‐day	  in-­‐hospital	  mortality	  rates	  decreased	  in	  a	   stepwise	   fashion:	   50.0%	   in	   dysoxic	   shock,	   21.1%	   in	   vasoplegic	   shock,	   18.5%	   in	  cryptic	   shock	   major,	   12.3%	   in	   cryptic	   shock	   minor,	   and	   7.2%	   in	   severe	   sepsis	  without	  lactate	  elevation.	   	  28-­‐day	  mortality	  was	  predicted	  by	  both	  ED	  vasopressor	  use	  (OR	  3.5	  (1.9-­‐6.4),	  p	  <	  0.0001)	  and	  an	  initial	  lactate	  greater	  than	  4	  mmol/L	  (OR	  3.1	  (1.7-­‐5.6),	  p	  =	  0.0003).	   	  On	  comparing	  groups	  pairwise,	  mortality	  in	  the	  dysoxic	  shock	  group	  was	  higher	  compared	  to	  groups	  in	  vasoplegic	  shock	  (OR	  3.7,	  1.3-­‐10.9,	  p	  =	  0.0243),	   cryptic	  shock	  major	   (OR	  4.4,	  1.5-­‐13.0,	  p	  =	  0.0098),	   cryptic	  shock	  minor	  (OR	  7.1,	  2.7-­‐18.9,	  p	  =	  0.0001),	  and	  severe	  sepsis	  without	  lactate	  elevation	  (12.9,	  4.7-­‐























35.2,	  p	  <	  0.0001).	  	  The	  mortality	  rates	  in	  vasoplegic	  shock	  and	  cryptic	  shock	  major	  subjects	  were	  higher	  than	  those	  in	  severe	  sepsis	  without	  lactate	  elevation,	  with	  odds	  ratios	   of	   3.5	   (1.4-­‐8.3,	   p	   =	   0.0078)	   and	   2.9	   (1.2-­‐7.1,	   p	   =	   0.0201)	   respectively.	  	  However,	  despite	  a	  downward	  trend	  in	  mortality	  rates,	  no	  conclusive	  differences	  in	  these	   rates	   were	   found	   between	   vasoplegic	   shock	   and	   cryptic	   shock	   major	   (p	   =	  0.81),	   between	   cryptic	   shock	  major	   and	  minor	   (p	   =	   0.3551),	   and	   between	   cryptic	  shock	  minor	  and	  severe	  sepsis	  without	  lactate	  elevation	  (p	  =	  0.1746).	  	  	   Multivariate	   analysis	  was	   performed	  using	   a	   logistic	   regression	  model	   that	  controlled	  for	  known	  clinical	  correlates	  of	  increased	  sepsis	  severity.	  	  The	  dependent	  variable	  was	  28-­‐day	  mortality,	   the	  primary	  outcome	  of	   this	   study.	   	  Results	  of	   this	  analysis	   are	   shown	   in	   Table	   13.	   	   Compared	   against	   the	   group	   in	   severe	   sepsis	  without	   lactate	   elevation,	   the	   odds	   ratios	   (ORs)	   for	   death	   before	   28	   days	   were	  15.055	  (4.997	   -­‐	  45.354,	  p	  =	  <	  0.0001)	   for	  dysoxic	  shock,	  3.606	  (1.435	   -­‐	  9.063,	  p	  =	  0.0064)	   for	   vasoplegic	   shock,	   3.771	   (1.458	   –	   9.756,	   p	   =	   0.0062)	   for	   cryptic	   shock	  major,	   and	   1.929	   (0.875	   -­‐	   4.255,	   p	   =	   0.1035)	   for	   cryptic	   shock	   minor.	   	   When	  compared	  directly	  against	  the	  vasoplegic	  shock	  group,	  the	  dysoxic	  shock	  group	  had	  a	  28-­‐day	  mortality	  OR	  of	  4.175	  (1.291	  –	  13.508,	  p	  =	  0.0002).	  	  Two	  covariates	  were	  predictive	   of	   increased	   risk	   of	   death	   before	   28	   days:	   every	   additional	   year	   of	   age	  demonstrated	  an	  increased	  OR	  of	  1.021	  (1.001	  –	  1.041,	  p	  =	  0.0394),	  and	  a	  previous	  diagnosis	   of	   cancer	   carried	   an	  OR	   of	   2.467	   (1.316	   –	   4.627,	   p	   =	   0.0049).	   	   A	   single	  covariate,	   genitourinary	   source	   of	   infection,	   was	   predictive	   of	   decreased	   risk	   of	  death	  before	  28	  days	  (OR	  0.329,	  0.117-­‐0.921,	  p	  =	  0.0343).	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Table 13.  Multivariate analysis of 28-day mortality. 	   Odds	  Ratio	  (OR)	   OR	  Confidence	  Intervals	   	  p	  value	  
Comparison	  of	  groups	  	   Dysoxic	  shock	   15.055*	   4.997	  -­‐	  45.354	   <	  0.0001	  	   Vasoplegic	  shock	   3.606*	   1.435	  -­‐	  9.063	   0.0064	  	   Cryptic	  shock	  major	   3.771*	   1.458	  –	  9.756	   0.0062	  	   Cryptic	  shock	  minor	   1.929	   0.875	  -­‐	  4.255	   0.1035	  
Parameters	  	   Female	  gender	   0.996	   0.544	  -­‐	  1.824	   0.9896	  	   Age	   1.021*	   1.001	  -­‐	  1.041	   0.0394	  	   Source	  of	  infection	  	   	   Pneumonia	   0.981	   0.493	  -­‐	  1.952	   0.9558	  	   	   Genitourinary	   0.329*	   0.117	  -­‐	  0.921	   0.0343	  	   	   Abdominal	   0.503	   0.182	  -­‐	  1.39	   0.1855	  	   	   Skin/soft	  tissue	   0.559	   0.12	  -­‐	  2.6	   0.4585	  	   Comorbid	  conditions	  	   	   Liver	  disease	   1.187	   0.417	  –	  3.381	   0.7483	  	   	   End-­‐stage	  renal	  disease	   1.009	   0.374	  –	  2.726	   0.9854	  	   	   Alcohol	  abuse	   0.579	   0.175	  –	  1.916	   0.3709	  	   	   Diabetes	  mellitus	   0.878	   0.458	  –	  1.684	   0.696	  	   	   HIV/AIDS	   2.923	   0.888	  –	  9.2622	   0.0776	  	   	   Cancer	   2.467*	   1.316	  –	  4.627	   0.0049	  	   	   Immunocompromised	  (NOS)	   0.971	   0.308	  –	  3.06	   0.9602	  	  Reference	  group:	  “Severe	  sepsis	  without	  lactate	  elevation.”	  *	  Significant	  at	  p	  <	  0.05.	  NOS	  =	  Not	  otherwise	  specified.	  	  
	  
Outcomes	  for	  exploratory	  groups	  In	  addition	  to	  the	  primary	  analyses	  described	  above,	  we	  undertook	  an	  exploratory	  analysis	   of	   other	   sepsis	   groups	  who	  we	   believed	  were	   likely	   to	   be	   at	   high	   risk	   of	  poor	   outcomes.	   	   The	   first	   group	   was	   those	   subjects	   requiring	   more	   than	   one	  vasopressor	   agent	   within	   the	   ED,	   which	   we	   categorized	   as	   “severe	   shock;”	   this	  included	  42	  subjects	   from	  both	   the	  dysoxic	  and	  vasoplegic	  shock	  groups.	   	  The	  28-­‐day	  mortality	  of	  the	  severe	  shock	  group	  was	  33.3%,	  compared	  to	  25.0%	  in	  subjects	  who	  required	  a	  single	  vasopressor	  agent	  (p	  =	  0.61).	  	  The	  severe	  shock	  subjects	  had	  a	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  To	  our	   knowledge,	   this	   is	   the	   first	   study	   to	   evaluate	   a	  novel	   classification	   scheme	  across	   the	   entire	   spectrum	   of	   severe	   sepsis	   and	   septic	   shock.	   	   To	   this	   end,	   we	  utilized	   two	   simple	   and	   readily-­‐available	   measures,	   initial	   lactate	   level	   on	   ED	  presentation	   and	   ED	   vasopressor	   utilization,	   to	   risk-­‐stratify	   patients	   at	   the	  hyperacute	  phase	  of	  care.	   	  Our	  aims	  were	   to	  describe	   the	   incidence	  and	  outcomes	  for	   the	   these	   classification	   groups,	   as	   well	   as	   other	   novel	   exploratory	   subgroups,	  with	   the	   intent	   of	   improving	   the	   ability	   of	   proximal	   phase	   providers	   to	   identify	  illness	  severity	  and	  risk-­‐stratify	  patients.	  	  	   In	   our	   primary	   analysis,	   we	   found	   that	   28-­‐day	   mortality	   differed	  substantially	   between	   groups;	   the	   differences	   persisted	   after	   adjusting	   for	   known	  covariates	   of	   sepsis	   severity,	   driven	   by	   strong	   independent	   yet	   additive	   risks	  associated	  with	  both	  elevated	  initial	   lactates	  and	  ED-­‐based	  vasopressor	  utilization.	  	  Related	   and	   significant	   differences	   in	   other	   outcome	   measures	   between	   these	  groups,	   such	   as	   measures	   of	   critical	   care	   utilization,	   corroborated	   the	   primary	  outcome.	   	   Where	   our	   results	   overlap	   with	   previous	   studies,	   our	   data	   generally	  support	   current	   understanding	   of	   the	   heterogeneity	   of	   outcomes	   within	   the	  traditional	  sepsis	  classification	  system.	  	  	   Our	  proposed	  classification	  system	  offers	  benefits	  to	  the	  emergency	  provider	  in	  that	  it	  utilizes	  simple	  metrics,	  generally	  available	  within	  the	  first	  two	  hours	  after	  presentation,	  to	  prognosticate	  in-­‐hospital	  mortality	  in	  patients	  with	  severe	  sepsis	  or	  septic	  shock.	  	  Our	  system	  could	  aid	  these	  providers	  in	  making	  important	  triage	  and	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disposition	  decisions,	  such	  as	  implementation	  of	  early	  goal-­‐directed	  therapy.	  	  This	  is	  a	   timely	   result	   given	   the	   recent	   publication	   of	   randomized	   control	   trials	   of	  protocolized	  and	  early	  goal-­‐directed	  therapy	  [10,	  11].	  	  Despite	  demonstrating	  a	  lack	  of	  superiority	  for	  protocolized	  and	  EGDT-­‐based	  care	  over	  usual	  care	  in	  severe	  sepsis	  and	   septic	   shock,	   these	   trials	   nevertheless	   leave	   open	   the	   question	   of	   whether	  certain	  subgroups	  could	  potentially	  benefit	  from	  an	  early	  hemodynamic	  monitoring	  and	  optimization	  approach.	  	  Without	  a	  firm	  answer	  to	  this	  question,	  clinicians	  who	  are	   wary	   of	   employing	   EGDT	   indiscriminately	   will	   be	   searching	   for	   a	   method	   to	  judiciously	  choose	  patients	  for	  these	  protocols.	  	  The	  classification	  system	  evaluated	  in	  this	  study	  may	  help	  to	  categorize	  patients	  for	  whom	  invasive	  monitoring	  should	  be	  considered,	  and	  could	  inform	  the	  design	  of	  future	  trials	  of	  EGDT.	  	  
Table 14.    Key outcomes by group. 
Variable	   Severe	  shock	  (n	  =	  42)	  
Hemo-­‐dynamic	  extremis	  (n	  =	  23)	  
Dysoxic	  shock	  (n	  =	  22)	   Vasoplegic	  shock	  (n	  =	  52)	  
Cryptic	  shock	  major	  (n	  =	  54)	  
Cryptic	  shock	  minor	  (n	  =	  138)	  
Severe	  sepsis	  w/o	  lactate	  elev.	  (n	  =	  180)	  
Incidence	  (%	  of	  full	  registry)	  	   9.4%	   5.2%	   4.9%	   11.7%	   12.1%	   30.9%	   40.4%	  
Primary	  outcome	   	  	   28-­‐day	  mortality	   14	  (33.3%)	   5	  (21.7%)	   11	  	  (50.0%)	   11	  	  (21.1%)	   10	  (18.5%)	   17	  	  (12.3%)	   13	  	  (7.2%)	  
Secondary	  outcomes	   	  	   Mechanical	  ventilation	   27	  	  (64.3%)	   10	  (43.5%)	   14	  	  (63.6%)	   27	  	  (51.9%)	   22	  	  (40.7%)	   36	  	  (26.1%)	   40	  	  (22.2%)	  	   Hospital	  vasopressor	  use	   42	  	  (100%)	  ϕ	   15	  (65.2%)	   22	  	  (100%)	  ϕ	   52	  	  (100%)	  ϕ	   16	  	  (29.6%)	   24	  	  (17.4%)	   19	  	  (10.6%)	  	   ICU	  admission	   40	  	  (95.2%)∆	   17	  (81.0%)	   20	  (90.9%)∆	   52	  	  (100%)	   45	  	  (83.3%)	   65	  	  (47.1%)	   82	  	  (45.6%)	  	   Number	  of	  organ	  dysfunctions*	   4.17	  	  ±	  2.12	   3.30	  ±	  2.08	  	   4.64	  	  ±	  2.40	   3.53	  	  ±	  1.87	   3.09	  	  ±	  1.95	   2.46	  	  ±	  1.77	   2.49	  	  ±	  1.27	  	   Mean	  APACHE	  II	  score	   24.43	  	  ±	  6.70	   23.39	  ±	  5.88	   26.95	  	  ±	  7.23	   21.71	  	  ±	  6.54	   20.85	  	  ±	  6.89	   16.89	  	  ±	  7.00	   17.57	  	  ±	  6.45	  	   Mean	  MEDS	  score	   13.19	  	  ±	  4.93	   12.04	  	  ±	  4.25	   14.05	  	  ±	  5.18	   13.48	  	  ±	  4.65	   10.48	  	  ±	  4.21	   10.75	  	  ±	  4.55	   10.89	  	  ±	  4.58	  
∆	  2	  patients	  died	  before	  transfer	  to	  ICU,	  ϕ	  Required	  by	  group	  definition,	  *	  Excludes	  hyperlactatemia.	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   The	  primary	  outcome	  of	  our	  study	  was	  28-­‐day	  mortality.	   	   In	   the	  univariate	  analysis,	   there	   was	   a	   dramatic	   and	   stepwise	   decrease	   in	   mortality	   over	   the	  classification	  system:	  50%	  in	  dysoxic	  shock,	  21.1%	  in	  vasoplegic	  shock,	  18%	  in	  the	  	  	  	  	  cryptic	   shock	   major,	   12.3%	   in	   cryptic	   shock	   minor,	   and	   7.2%	   in	   severe	   sepsis	  without	  hyperlactatemia.	   	  When	  controlled	  for	  age,	  source	  of	  infection,	  and	  certain	  comorbidities	   in	   the	   multivariate	   analysis,	   the	   calculated	   odd	   ratios	   for	   28-­‐day	  mortality	   were	   15.055	   (4.997-­‐45.354)	   for	   dysoxic	   shock,	   3.606	   (1.435-­‐9.063)	   for	  vasoplegic	   shock,	   3.771	   (1.458–9.756)	   for	   cryptic	   shock	  major,	   and	   1.929	   (0.875-­‐4.255)	  for	  cryptic	  shock	  minor.	  	  The	  group	  in	  severe	  sepsis	  without	  lactate	  elevation	  was	   used	   as	   the	   reference	   group	   for	   these	   calculations.	   	   The	  multivariate	   results	  reinforce	   the	   mortality	   trend	   seen	   in	   the	   univariate	   analysis	   and	   underscore	   the	  strength	  of	  both	  early	  vasopressor	  use	  and	  high	  lactate	  levels	  as	  risk	  factors	  in	  this	  patient	   population.	   	   There	   was	   also	   a	   trend	   towards	   an	   increased	   risk	   in	   cryptic	  shock	   minor	   over	   severe	   sepsis	   without	   lactate	   elevation,	   although	   this	   did	   not	  reach	  significance	  (p	  =	  0.1035).	  	  	   The	   trends	   in	   other	   severity	   indices,	   such	   as	   mean	   number	   of	   organ	  dysfunctions,	   the	  mean	   APACHE	   II	   score,	   and	   the	   rates	   of	  mechanical	   ventilation,	  roughly	  tracked	  with	  the	  28-­‐day	  mortality	  rates	  seen	  in	  the	  groups.	  	  By	  contrast,	  the	  only	   significant	   differences	   in	  mean	  MEDS	   scores	   occurred	   between	   vasopressor-­‐dependent	  subjects	  and	  normotensive	  subjects.	  	  Most	  likely,	  this	  is	  purely	  a	  result	  of	  the	  MEDS	  score	  criterion	  “septic	  shock,”	  which	  confers	  an	  additional	  3	  points	  to	  the	  score	  of	  each	  subject	  in	  the	  vasoplegic	  and	  dysoxic	  shock	  groups.	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   There	  was	  a	  significant	  difference	  in	  gender	  distribution	  between	  the	  groups;	  men	  formed	  54.5%	  of	  vasoplegic	  shock,	  42.3%	  of	  vasoplegic	  shock,	  61.1%	  of	  cryptic	  shock	   major,	   60.1%	   of	   cryptic	   shock	   minor,	   and	   42.2%	   of	   severe	   sepsis	   subjects	  without	   lactate	  elevation.	   	  As	   these	  results	  show,	   the	  groups	  with	  hyperlactatemia	  have	   a	   higher	   proportion	   of	  men.	   	   In	   our	   registry,	  men	   also	   had	   a	   slightly	   higher	  mean	   initial	   lactate	   level	   than	   women	   (2.94±2.30	   vs	   2.48±2.22,	   p	   =	   0.0315),	  although	  gender	  was	  not	  found	  to	  be	  significantly	  associated	  with	  28-­‐day	  mortality	  rates	   in	   the	   multivariate	   analysis.	   	   It	   is	   possible	   that	   men	   present	   with	   a	   worse	  degree	   of	   tissue	   hypoperfusion,	   produce	   more	   lactate	   constitutively	   (perhaps	  because	   of	   greater	   muscle	   mass)	   or	   fail	   to	   metabolize	   lactate	   as	   efficiently.	  	  However,	  another	  trial	  of	  1,814	  hospitalized	  patients,	  looking	  at	  disparities	  between	  sepsis	   treatment	  between	  men	  and	  women,	   found	  no	  differences	   in	   serum	   lactate	  measurements	   between	   men	   and	   women	   [132].	   	   The	   possibility	   of	   a	   gender	  disparity	  in	  lactate	  production	  or	  clearance	  warrants	  further	  study.	  	   A	   few	  differences	  were	   apparent	   in	   source	   of	   infection	   between	   groups	   on	  univariate	   analysis.	   	   Subjects	   in	   severe	   sepsis	  without	   lactate	   elevation	  were	   less	  likely	   to	   have	   an	   abdominal	   source	   of	   infection	   than	   the	   rest	   of	   included	   subjects	  (6.1%	   vs.	   14.7%,	   p	   =	   0.006),	   possibly	   since	   certain	   intra-­‐abdominal	   sources	   are	  associated	   with	   poorer	   outcomes	   [51].	   	   Pneumonia	   as	   a	   septic	   source	   was	   less	  common	   in	   cryptic	   shock	   major	   than	   cryptic	   shock	   minor	   (13.0%	   vs	   31.2%,	   p	   =	  0.01)	  or	  severe	  sepsis	  without	  lactate	  elevation	  (13.0%	  vs	  36.7%,	  p	  =	  0.001);	  given	  that	   pulmonary	   sources	   often	   increase	   risk	   of	   sepsis	   severity,	   this	   is	   a	   surprising	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finding	  that	  merits	  scrutiny.	  	  Pneumonia	  as	  a	  source	  of	  infection	  was	  not	  found	  to	  be	  associated	  with	  increased	  mortality	  risk	  in	  our	  logistic	  regression	  analysis.	  	   However,	   three	  other	   covariates	  of	   the	  multivariate	   analysis	  were	   found	   to	  be	  significantly	  associated	  with	  outcomes.	  	  Two	  were	  correlated	  with	  increased	  risk	  of	  death	  before	  28	  days:	   increasing	  age	   (with	  an	  OR	  of	  1.021	  per	  extra	  year),	   and	  previous	   history	   of	   cancer	   (OR	   of	   2.467).	   	   Both	   of	   these	   results	   conform	   to	   the	  known	  risks	  of	  advanced	  age	  and	  underlying	  cancer	  diagnosis	  on	  sepsis	  severity	  [3,	  31,	  36].	  	  The	  only	  covariate	  which	  correlated	  with	  a	  decreased	  risk	  of	  death	  before	  28	  days	  was	  the	  presence	  of	  a	  genitourinary	  source	  of	  infection	  (OR	  0.329);	  this	  is	  in	  keeping	  with	   literature	   showing	   that	   urosepsis	   is	   less	   deadly	   than	   other	   forms	   of	  sepsis	  [50].	  	  	  	  
Comparing	  dysoxic	  and	  vasoplegic	  shock	  In	  our	  study,	  the	  differences	  between	  the	  two	  categories	  of	  vasopressor-­‐dependent	  septic	   shock	   (dysoxic	   shock	   and	   vasoplegic	   shock)	   were	   particularly	   striking.	  	  Vasoplegic	  shock	  was	  more	  common	  than	  dysoxic	  shock	   in	  our	  study	  subjects	   (52	  vs.	  22,	  an	   incidence	  ratio	  of	  2.4	   to	  1).	   	   In	   the	  univariate	  analysis,	  28-­‐day	  mortality	  was	   much	   higher	   in	   dysoxic	   shock	   than	   in	   vasoplegic	   shock	   (50%	   vs.	   21%,	   p	   =	  0.0243),	  and	  this	  difference	  was	  maintained	  in	  the	  multivariate	  analysis	  (OR	  4.175,	  1.291-­‐13.508,	   p	   =	   0.0002).	   	   The	   difference	   in	   severity	   was	   also	   apparent	   when	  comparing	  other	  markers	  of	  increased	  risk;	  the	  dysoxic	  shock	  subjects	  had	  a	  higher	  shock	   index	   (1.4±0.41	   vs.	   1.09±0.35,	   p	   <	   0.0001),	   mean	   number	   of	   organ	  dysfunctions	   (4.64±2.40	   vs.	   3.53±1.87,	   p	   =	   0.0357),	   and	   mean	   APACHE	   II	   scores	  (26.95±7.23	   vs.	   21.71±6.54,	   p	   =	   0.0032)	   at	   first	   presentation.	   	   The	   rates	   of	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intubation	  in	  the	  ED	  and	  mechanical	  ventilation	  in	  the	  hospital	  were	  also	  higher	  in	  the	   dysoxic	   shock	   group,	   although	   these	   differences	   did	   not	   reach	   statistical	  significance.	   	   On	   the	   other	   hand,	   the	   initial	   mean	  MEDS	   scores	   were	   roughly	   the	  same	  between	  the	  two	  groups.	  	   Interestingly,	  there	  is	  some	  discrepancy	  between	  the	  use	  of	  vasopressors	  in	  dysoxic	   and	   vasoplegic	   shock.	   	   Dysoxic	   shock	   patients	   showed	   a	   trend	   towards	  requiring	  more	  vasopressor	  therapy	   in	  the	  ED;	  they	  had	  a	  higher	  mean	  number	  of	  agents	   started	   (2.3±1.2	   vs.	   1.8±0.9,	   p	   =	   0.0524)	   and	   were	   more	   likely	   than	  vasoplegic	   shock	   patients	   to	   be	   on	   multiple	   vasopressors	   (72.7%	   vs.	   48.1%,	   p	   =	  0.0734),	  although	  these	  trends	  were	  not	  significant.	  	  These	  data	  support	  the	  notion	  that	  dysoxic	   shock	  patients	   are	   less	   likely	   to	  have	   their	   blood	  pressure	   controlled	  with	   one	   vasopressor	   agent;	   ED	   clinicians	  may	   need	   to	   have	   a	   low	   threshold	   for	  adding	  a	  second	  agent	  in	  shock	  patients	  with	  high	  lactates,	  if	  MAP	  does	  not	  quickly	  improve	  after	  the	  start	  of	  the	  first	  agent.	  	   Our	   results	   concerning	   disease	   severity	   are	   in	   line	  with	   other	   studies	   that	  have	  compared	  septic	  shock	  patients	  with	  high	  and	  low	  lactates;	  however,	  some	  of	  the	   thresholds	   of	   lactate	   used	   in	   these	   studies	   differed.	   	   Dugas	   et	   al.	   divided	   123	  vasopressor-­‐dependent	   septic	   shock	   patients	   into	   three	   categories:	   non-­‐lactate	  expressors	   (initial	   lactate	  <2.5	  mmol/L),	   low	   lactate	  expressors	   (2.5-­‐4.0)	  and	  high	  lactate	   expressors	   (>4.0)	   [133].	   	   The	   first	   two	   categories,	   when	   combined,	   are	  consistent	  with	  our	   vasoplegic	   shock	   group,	  whereas	   the	   last	   is	   synonymous	  with	  our	  dysoxic	  shock	  group.	   	  The	  mortality	  rates	  for	  non-­‐lactate,	  low	  lactate,	  and	  high	  lactate	  expressors	  were	  20%,	  29%	  and	  43%,	  respectively,	  although	  the	  differences	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were	  not	  significant.	  	  Similarly,	  in	  their	  shock	  subgroup	  of	  196	  subjects,	  Mikkelsen	  et	  al.	   found	   that	  a	  high	   lactate	   level	   (>4.0	  mmol/L)	  and	  an	   intermediate	   lactate	   level	  (2.0-­‐4.0	  mmol/L)	   both	   correlated	  with	  mortality	   (OR	   4.87	   and	   3.27,	   respectively)	  when	  compared	  to	  overt	  septic	  shock	  patients	  with	   lactate	   levels	  below	  2	  mmol/L	  [75].	   	   Supporting	   these	   observed	   trends,	   a	   much	   larger	   study	   by	   Howell	   et	   al.	  classifying	   1,200	   hospitalized	   septic	   patients	   by	   initial	   lactate	   (<2.5,	   2.5-­‐4.0,	   and	  >4.0	  mmol/L)	   found	  that	   lactate	   levels	  continued	  to	  predict	  28-­‐day	  mortality	  even	  after	  stratification	  by	  initial	  blood	  pressures	  [124].	  	  	  	   Other	   studies	   have	   used	   lower	   lactate	   thresholds	   to	   subdivide	   vasoplegic	  from	  dysoxic	  shock	  patients.	  	  Sterling	  et	  al.	  stratified	  overt	  shock	  patients	  in	  the	  ED	  by	   a	   threshold	   lactate	   level	   of	   2.0	   mmol/L;	   in-­‐hospital	   mortality	   in	   their	   “tissue	  dysoxic	  shock”	  was	  significantly	  higher	  than	  in	  their	  “vasoplegic	  shock”	  group	  (26%	  vs.	   9%,	   respectively)	   [126].	   	   As	   a	   result	   of	   using	   a	   lower	   lactate	   threshold,	   their	  “tissue	   dysoxic	   shock”	   group	   substantially	   outnumbered	   their	   “vasoplegic	   shock”	  group	   (157	   vs.	   90	   patients,	   respectively).	   	   Likewise,	   in	   two	   back-­‐to-­‐back	   studies,	  Hernandez	  et	  al.	  similarly	  compared	  ICU	  overt	  shock	  patients	  with	  pre-­‐ICU	  low	  and	  high	   initial	   lactates,	   using	   the	   lactate	   threshold	   of	   2.5	   mmol/L	   [125,	   127].	   	   The	  mortality	   rates	   of	   their	   2011	   and	   2012	   cohorts	   of	   “overt	   shock	   without	  hyperlactatemia”	   were	   remarkably	   consistent	   (7.7%	   vs.	   7.9%,	   respectively);	  however,	  the	  mortality	  rates	  for	  the	  cohorts	  of	  “overt	  shock	  with	  hyperlactatemia”	  differed	  substantially	  (42.9%	  vs.	  20.9%,	  respectively).	  	  It	  is	  apparent	  that	  as	  a	  result	  of	   choosing	   a	   much	   lower	   threshold	   for	   lactate	   levels,	   “dysoxic	   shock”	   in	   these	  studies	  was	  both	  more	   common	  and	   less	  deadly	   than	   in	  our	  dysoxic	   shock	  group;	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the	  reverse	  trends	  are	  true	  when	  comparing	  their	  “vasoplegic	  shock”	  cohorts	  with	  our	   vasoplegic	   shock	   group.	   	   Furthermore,	   these	   three	   studies	   did	   not	   use	  vasopressor	  dependence	  as	  a	  criterion	  for	  shock.	  	  	   In	  sum,	  while	  definitions	  of	   lactate	  categories	   (high,	   intermediate,	   low)	  and	  the	   presenting	   disposition	   (hospitalized	   vs.	   emergency	   department)	   differ	  somewhat	   between	   studies,	   it	   seems	   that	   there	   is	   a	   consistent	   and	   reproducible	  trend	  between	  high	  lactates	  and	  mortality	  in	  overt	  septic	  shock	  patients.	  	  The	  most	  appropriate	  threshold	  for	  the	  initial	  lactate	  for	  risk-­‐stratification	  purposes	  remains	  unknown.	   	   In	   practice,	   stratification	   of	   patients	   into	   dysoxic	   and	   vasoplegic	   shock	  will	   not	   change	   treatment	   patterns	   or	   disposition	   decisions,	   as	   all	   overt	   shock	  patients	  should	  and	  will	  receive	  aggressive	  therapy	  to	  maintain	  blood	  pressure	  and	  will	   all	   be	   admitted	   to	   an	   intensive	   care	   unit.	   	   However,	   an	   understanding	   of	   the	  increased	  severity	  of	  dysoxic	  shock	  could	  help	  to	  inform	  prognostic	  discussions	  with	  family	  members	  and	  decisions	  regarding	  goals	  of	  care.	   	  Furthermore,	   the	  dramatic	  severity	  of	  dysoxic	   shock	  at	   initial	   presentation	  begs	   the	  question	  of	  whether	   this	  subgroup	  could	  conceivably	  benefit	   from	  early,	   invasive	  hemodynamic	  monitoring	  and	   optimization	   along	   the	   lines	   of	   EGDT.	   	   Although	   this	   question	  would	   be	   best	  answered	   through	   a	   randomized	   clinical	   trial,	   post-­‐hoc	   subgroup	   analyses	   of	   the	  ProCESS	  and	  ARISE	  trials,	  based	  on	  the	  definitions	  of	  vasoplegic	  and	  dysoxic	  shock,	  could	  conceivably	  yield	  interesting	  results.	  	  
Comparing	  cryptic	  shock	  to	  vasopressor-­‐dependent	  shock	  There	  were	   54	   subjects	   defined	   as	   having	   cryptic	   shock,	   a	   similar	   number	   to	   the	  vasoplegic	   shock	   group	   (52	   subjects)	   and	   more	   than	   twice	   the	   number	   of	   the	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dysoxic	   shock	  group	   (22	  subjects).	   	  Of	   the	  entire	   registry,	   the	  cryptic	   shock	  major	  group	  made	  up	  12.1%.	   	   This	   incidence	   is	   consistent	  with	   other	   studies	   looking	   at	  cryptic	  shock	  major.	  	  In	  a	  post-­‐hoc	  analysis	  of	  the	  original	  EGDT	  trial	  in	  2001,	  there	  were	   48	   subjects	   classified	   as	   being	   in	   “cryptic	   shock”	   (severe	   sepsis	   with	  normotension	  and	  a	  lactate	  >	  4mmol/L)	  of	  a	  total	  population	  of	  263	  (18.3%)	  [117].	  	  Similarly,	   in	  a	  study	   incorporating	  hospital	  and	  ED-­‐based	  patients	   in	  severe	  sepsis	  and	  septic	  shock,	  Ranzani	  et	  al.	   found	  a	  cryptic	  shock	  prevalence	  of	  12%	  [128].	   	   It	  seems	  from	  our	  data	  and	  others’	  that	  cryptic	  shock	  is	  only	  slightly	  less	  common	  than	  overt	   septic	   shock	   but	   far	   less	   common	   than	   other	   types	   of	   severe	   sepsis	   with	   a	  normal	  blood	  pressure.	  	  In	  a	  large	  database	  of	  over	  15,000	  patients	  in	  severe	  sepsis	  and	  septic	  shock,	  created	  by	  the	  Surviving	  Sepsis	  Campaign,	  cryptic	  shock	  patients	  made	   up	   just	   5.4%	   of	   patients,	   compared	   vasopressor-­‐dependent	   patients	   with	  lactate	   less	   than	   4.0	   mmol/L	   (49.5%)	   and	   with	   lactate	   greater	   than	   4.0	   mmol/L	  (16.6%)	  [116].	  	  It	  is	  important	  to	  note,	  however,	  that	  these	  data	  should	  not	  be	  taken	  as	  accurate	  measurements	  of	  incidence;	  the	  database	  was	  open	  to	  submission	  from	  over	   100	   centers	   and	  was	   significantly	   weighted	   towards	   vasopressor-­‐dependent	  patients	  (making	  up	  71.5%	  of	  the	  database	  subjects).	  	   The	   mortality	   rate	   of	   cryptic	   shock	   major	   in	   our	   study	   was	   18.5%,	  considerably	   lower	   than	   in	   the	   dysoxic	   shock	   group	   (50%,	   p	   =	   0.0098)	   but	   not	  statistically	  different	   from	   the	  vasoplegic	   shock	  mortality	   (21.1%,	  p	  =	  0.81);	   these	  differences	   persisted	   when	   controlling	   for	   other	   severity	   predictors	   in	   the	  multivariate	   analysis.	   	  Among	   the	   secondary	  outcomes,	   the	   similarity	   in	  outcomes	  between	  vasoplegic	  shock	  and	  cryptic	  shock	  major	  is	  striking;	  these	  two	  groups	  had	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roughly	  comparable	  mean	  number	  of	  organ	  dysfunctions	  (3.53±1.87	  vs.	  3.09±1.95,	  p	  =	  0.24),	  mean	  APACHE	  II	  scores	  (21.71±6.54	  vs.	  20.85±6.89,	  p	  =	  0.51),	  and	  the	  need	  for	  mechanical	   ventilation	   (51.9%	   vs.	   40.7%,	   p	   =	   0.33).	   	   However,	   the	   rate	   of	   ED	  intubation	   was	   higher	   in	   vasoplegic	   shock	   than	   cryptic	   shock	   major	   (32.7%	   vs.	  14.8%,	   p	   =	   0.0396).	   	   The	   mean	   MEDS	   scores	   were	   also	   significantly	   different	  (13.48±4.65	   vs.	   10.48±4.21,	   p	   =	   0.0007),	   but	   this	   is	   clearly	   a	   result	   of	   a	   single	  criterion	   difference	   (3	   points	   for	   “septic	   shock”)	   that	   discriminates	   between	   the	  groups	  by	  definition.	  	  It	  is	  interesting	  to	  note	  that	  of	  the	  54	  subjects	  who	  presented	  in	   cryptic	   shock	   major,	   16	   (or	   29.6%)	   required	   vasopressors	   during	   the	   first	   72	  hours	  of	  hospitalization;	  the	  mortality	  rate	  of	  these	  subjects	  was	  43.8%,	  whereas	  the	  mortality	  rate	   in	   those	  not	   treated	  with	   in-­‐hospital	  vasopressor	   therapy	  was	  5.6%	  (p	  =	  0.0016).	  	  No	  cryptic	  shock	  major	  subjects	  began	  vasopressors	  after	  72	  hours	  of	  hospitalization.	  	  These	  data	  support	  the	  notion	  that	  patients	  in	  cryptic	  shock	  major	  should	   be	   admitted	   to	   a	   high	   level	   of	   care,	   as	   indeed	   were	   most	   of	   our	   subjects	  (83.3%	  to	  ICU	  care).	  	  	   These	   data	   are	   consistent	   with	   other	   studies	   that	   have	   compared	   cryptic	  shock	  to	  overt	  septic	  shock.	  	  In	  the	  large	  database	  described	  above,	  Levy	  et	  al.	  found	  that	  cryptic	  shock	  major	  had	  a	  mortality	  rate	  of	  29.9%,	  comparable	  to	  the	  mortality	  rate	  of	  vasopressor-­‐dependent	  patients	  with	  lactates	  below	  4	  mmol/L	  (36.7%)	  and	  slightly	   lower	   than	   vasopressor-­‐dependent	   patients	   with	   lactates	   greater	   than	  4mmol/L	  (46.1%)	  [116].	  	  Puskarich	  et	  al.	  treated	  300	  cryptic	  shock	  and	  overt	  shock	  patients	  presenting	   to	   the	  ED	  with	  protocol-­‐based	  sepsis	   resuscitation	   [118].	   	  The	  in-­‐hospital	  mortality	  of	   the	  cryptic	   shock	  group	  was	  20%	  and	   the	  mortality	  of	   the	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overt	  shock	  group	  was	  19%;	  the	  mean	  lactate	  level	  of	  the	  overt	  shock	  group	  was	  2.6	  mmol/L,	   suggesting	   that	   most	   of	   these	   patients	   would	   have	   been	   categorized	   as	  “vasoplegic	  shock”	  in	  our	  classification	  scheme.	  	  	   In	   a	   more	   recent	   study,	   Hwang	   et	   al.	   compared	   outcomes	   in	   patients	  presenting	   to	   an	   ED	   with	   cryptic	   shock,	   overt	   shock	   (define	   by	   persistent	  hypotension	  despite	   fluid	   resuscitation),	   and	   cryptic-­‐to-­‐overt	   shock	   (cryptic	   shock	  which	  progressed	  to	  overt	  shock	  within	  72	  hours)	  [120].	  	  There	  were	  187,	  247,	  and	  157	   patients	   in	   these	   groups,	   respectively;	   their	   database	   contained	   a	   high	  proportion	  of	  patients	  presenting	  initially	  in	  cryptic	  shock	  compared	  to	  overt	  shock	  (58%	  vs.	  42%).	   	   80%	  of	   the	   subjects	   in	   the	   cryptic-­‐to-­‐overt	   shock	  group	   required	  vasopressors	  within	   the	   first	   24	   hours,	   and	   the	  mortality	   rates	   for	   cryptic	   shock,	  overt	  shock,	  and	  cryptic-­‐to-­‐overt	  shock	  were	  7.0%,	  21.9%,	  and	  27.4%,	  respectively.	  	  	  
Table	  15.	  	  Existing	  studies	  on	  cryptic	  shock	  major	  and	  minor.	  	   Author	   Size	  of	  study	   Incidence	   Mortality	  rate	  
Cryptic	  shock	  major	  	   Current	  study	   54	  subjects	   12.1%	   18.5%	  	   Donnino	  et	  al.	   48	  subjects	   18.3%	   39.6%	  	   Ranzani	  et	  al.	   162	  subjects	   8.3%	   35.2%	  	   Levy	  et	  al.	   811	  subjects	   5.4%	   29.9%	  	   Puskarich	  et	  al.	  *	   53	  subjects	   17.7%	   20.0%	  	   Huang	  et	  al.	  *	   344	  subjects	   58.2%	   16.3%	  
Cryptic	  shock	  minor	  	   Current	  study	   138	  subjects	   30.9%	   12.3%	  	   Tang	  et	  al.	   535	  subjects	   n/a∆	   1.1%	  	   Song	  et	  al.	   474	  subjects	   n/a∆	   10.1%	  *	  Studies	  only	  included	  septic	  shock	  and	  cryptic	  shock	  subjects.	  ∆	  	  Studies	  did	  not	  include	  other	  types	  of	  shock.	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These	   results	   are	   in	   keeping	   with	   our	   data,	   demonstrating	   that	   cryptic	   shock	  patients	  represent	  a	  subgroup	  not	  only	  with	  similarly	  poor	  outcomes	  as	  overt	  shock,	  but	   also	   with	   high	   potential	   for	   developing	   overt	   shock	   in	   the	   early	   stages	   of	  hospitalization.	  	   Despite	  the	  similarities	  in	  outcomes	  between	  cryptic	  shock	  major	  and	  types	  of	   overt	   shock,	   our	   data	   hint	   at	   differences	   in	   treatment.	   	   Cryptic	   shock	   major	  subjects	  were	  much	   less	   likely	   than	  vasoplegic	   shock	  patients	   to	   receive	   a	   central	  line	  placement	   (27.8%	  vs.	   94.2%,	  p	  <	  0.0001)	   or	   have	  EGDT	  documented	   in	   their	  chart	  (13.4%	  vs.	  38.0%,	  p	  =	  0.0035).	  	  In	  keeping	  with	  these	  results,	  Mikkelsen	  et	  al.	  similarly	   found	   that	   subjects	   meeting	   the	   lactate	   criterion	   rather	   than	   the	  hemodynamic	   criterion	   for	   EGDT	   resuscitation	   were	   much	   less	   likely	   to	   receive	  EGDT	  management	  [119].	  	  Cryptic	  shock	  major	  subjects	  received	  a	  lower	  volume	  of	  crystalloid	   during	   their	   ED	   stay,	   which	   is	   to	   be	   expected	   given	   their	   stable	  hemodynamics	  (3.0±1.64L	  vs.	  4.3±2.40L,	  p	  =	  0.0014).	  	  The	  mean	  time	  to	  antibiotics	  and	  mean	  ED	  length-­‐of-­‐stay	  were	  not	  statistically	  different.	  	  	  	   However,	   while	   every	   single	   vasoplegic	   shock	   patient	  was	   admitted	   to	   the	  ICU,	  only	  83.3%	  of	  cryptic	  shock	  major	  patients	  were	  directly	  admitted	  to	  the	  ICU;	  11.1%	   were	   sent	   to	   a	   floor	   bed	   from	   the	   ED.	   	   These	   data	   suggest	   that	   patients	  presenting	  in	  cryptic	  shock	  major	  are	  not	  considered	  by	  ED	  clinicians	  to	  be	  as	  sick	  as	  patients	  with	  refractory	  hypotension	  requiring	  vasopressors,	  despite	  similarly	  poor	  outcomes	   over	   the	   hospital	   stay.	   	   Given	   the	   relationships	   between	   dysoxic,	  vasoplegic,	   and	   cryptic	   shock	   major	   groups	   in	   terms	   of	   28-­‐day	   mortality,	   it	   is	  imperative	   for	   ED	   clinicians	   to	   consider	   both	   vasopressor	   dependence	   and	   initial	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lactate	  greater	  than	  4	  mmol/L	  as	  equivalent	  risk	  factors	  for	  a	  poor	  outcome	  in	  the	  hospital.	  	  
Comparing	  non-­‐vasopressor	  dependent	  subjects	  We	   subdivided	   non-­‐vasopressor-­‐dependent	   subjects	   into	   three	   groups:	   cryptic	  shock	   major	   (lactate	   >4mmol/L),	   cryptic	   shock	   minor	   (lactate	   2-­‐4	   mmol/L),	   and	  severe	   sepsis	   without	   lactate	   elevation	   (lactate	   <2mmol/L).	   	   Cryptic	   shock	  major	  was	  much	  less	  common	  than	  cryptic	  shock	  minor	  and	  severe	  sepsis	  without	  lactate	  elevation	   (54	   vs.	   138	   vs.	   180	   subjects,	   respectively).	   	   The	  mortality	   rates	   of	   these	  three	  groups	  were	  18.5%,	  12.3%,	  and	  7.2%;	  while	  demonstrating	  a	  clear	  trend,	  the	  difference	   was	   statistically	   significant	   only	   between	   cryptic	   shock	   major	   subjects	  and	   severe	   sepsis	   subjects	   without	   lactate	   elevation	   (p	   =	   0.02).	   	   Of	   372	   non-­‐vasopressor	  dependent	   subjects,	   49	   (13.2%)	  were	   started	  on	   vasopressors	  within	  72	   hours,	   and	   only	   10	   (2.7%)	   were	   started	   on	   vasopressors	   after	   72	   hours	   of	  admission.	   	   These	   data	   support	   the	   use	   of	   the	   72-­‐hour	   threshold	   used	   by	   other	  investigators	   [120,	   122,	   134]	   to	   capture	   the	   majority	   of	   hemodynamically-­‐stable	  septic	  patients	  who	  decompensate	  during	  their	  hospital	  stay.	  	   Comparing	   cryptic	   shock	  major	   to	   cryptic	   shock	  minor	   revealed	   significant	  differences	  in	  secondary	  outcomes.	   	  Cryptic	  shock	  major	  subjects	  were	  much	  more	  likely	  than	  cryptic	  shock	  minor	  subjects	  to	  be	  admitted	  to	  the	  ICU	  (83.3%	  vs.	  47.1%,	  p	   <	   0.0001),	   as	   well	   as	   having	   a	   higher	   mean	   number	   of	   organ	   dysfunctions	  (3.09±1.95	   vs.	   2.46±1.77,	   p	   =	  0.0325),	   a	   higher	   rate	   of	  AKI	   (59.3%	  vs.	   41.3%,	  p	  =	  0.0359),	   a	   higher	   rate	   of	   troponin	   elevation	   (40.7%	  vs.	   23.2%,	  p	  =	  0.0201),	   and	   a	  higher	  mean	   APACHE	   II	   score	   (20.85±6.89	   vs.	   16.89±7.00,	   p	   =	   0.0005).	   However,	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mean	   MEDS	   scores	   were	   not	   different	   between	   the	   two	   groups	   (10.48±4.21	   vs.	  10.75±4.55,	   p	   =	   0.71).	   	   In	   terms	   of	   critical	   care	   utilization,	   cryptic	   shock	   major	  subjects	   were	   more	   likely	   to	   receive	   vasopressors	   within	   72	   hours	   (29.6%	   vs.	  12.3%,	   p	   =	   0.0095)	   and	   trended	   towards	   a	   higher	   rate	   of	   mechanical	   ventilation	  during	   the	  hospital	   stay	   (40.7%	  vs.	   26.1%,	  p	  =	  0.0553)	   than	   their	   counterparts	   in	  cryptic	  shock	  minor.	  	  	  	   The	   differences	   between	   cryptic	   shock	   major	   and	   severe	   sepsis	   without	  lactate	   elevation	   were	   even	   starker.	   	   The	   28-­‐day	   mortality	   rate	   was	   significantly	  higher	  in	  cryptic	  shock	  major	  than	  in	  severe	  sepsis	  without	  lactate	  elevation	  (18.5%	  vs.	  7.2%,	  p	  =	  0.0201);	  the	  cryptic	  shock	  major	  group	  also	  had	  a	  higher	  mean	  number	  of	  organ	  dysfunctions	  (3.09±1.95	  vs.	  2.49±1.27,	  p	  <	  0.0001),	  rate	  of	  AKI	  (59.3%	  vs.	  30.0%,	  p	  =	  0.0002),	  mean	  APACHE	  II	  score	  (20.85±6.89	  vs.	  17.57±6.45,	  p	  =	  0.0014),	  rate	  of	  ICU	  admission	  (83.3%	  vs.	  45.6%,	  p	  <	  0.0001),	  rate	  of	  vasopressor	  use	  within	  72	  hours	  (29.6%	  vs.	  8.9%,	  p	  =	  0.0008),	  and	  rate	  of	  mechanical	  ventilation	  (40.7%	  vs.	  22.2%,	  p	  =	  0.0087).	  	  Cryptic	  shock	  major	  subjects	  received	  more	  fluid	  resuscitation	  in	  the	  ED	  (3.00±1.64L	  vs.	  2.31±1.78L,	  p	  =	  0.0117)	  and	  were	  more	  likely	  to	  receive	  dobutamine	   (9.3%	   vs.	   1.7%,	   p	   =	   0.0176)	   than	   subjects	   in	   severe	   sepsis	   without	  lactate	  elevation.	  	  	  	   Interestingly,	   there	   were	   even	   differences	   in	   initial	   vital	   signs	   between	  cryptic	   shock	   major	   subjects	   and	   the	   other	   non-­‐vasopressor	   dependent	   groups.	  	  Cryptic	  shock	  major	  subjects	  had	  a	  lower	  initial	  SBP	  (108.5±29.4	  vs.	  122.2±29.0,	  p	  =	  0.0038),	  higher	  initial	  HR	  (112.9±20.0	  vs.	  105.6±20.8,	  p	  =	  0.0283),	  and	  higher	  shock	  index	   (SI,	   1.12±0.38	   vs.	   0.91±0.28,	   p	   <0.0001)	   than	   cryptic	   shock	  minor	   subjects.	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These	  same	  vital	  signs	  were	  significantly	  different	  when	  compared	  between	  cryptic	  shock	   major	   and	   severe	   sepsis	   without	   lactate	   elevation:	   SBP	   (108.5±29.4	   vs.	  119.5±27.3,	   p	   =	   0.0114),	   HR	   (112.9±20.0	   vs.	   103.1	   ±	   23.4,	   p	   =	   0.0058),	   and	   SI	  (1.12±0.38	  vs.	  0.90±0.27,	  p	  <0.0001).	   	  These	  findings	  further	  implicate	  an	  elevated	  lactate	   as	   a	   possible	   sign	   of	   impending	   hemodynamic	   instability,	   and	   support	   the	  shock	  index	  as	  a	  marker	  of	  poor	  perfusion	  and	  potential	  for	  hemodynamic	  collapse.	  	   On	   the	   contrary,	   the	   groups	   with	   cryptic	   shock	   minor	   and	   severe	   sepsis	  without	   lactate	   elevation	   did	   not	   appear	   to	   have	   different	   outcomes.	   	   While	   the	  absolute	   rates	   of	  mechanical	   ventilation	   (26.1%	  vs.	   22.2%,	   p	   =	  0.43),	   vasopressor	  therapy	   (12.3%	   vs.	   8.9%,	   p	   =	   0.36),	   and	   28-­‐day	   mortality	   (12.3%	   vs.	   7.2%,	   p	   =	  0.175)	  appeared	  higher	  in	  cryptic	  shock	  minor	  subjects	  compared	  to	  severe	  sepsis	  without	   lactate	   elevation,	   none	   of	   these	   differences	   approached	   statistical	  significance.	   	  Mean	  APACHE	   II	   scores	   (16.89±7.00	  vs.	  17.57±6.45,	  p	  =	  0.37),	  mean	  MEDS	   scores	   (10.75±4.55	   vs.	   10.89±4.58,	   p	   =	   0.79),	   and	   mean	   number	   of	   organ	  dysfunctions	   (2.46±1.77	   vs.	   2.49±1.27,	   p	   =	   0.86)	   were	   likewise	   comparable.	   	   The	  only	   statistically-­‐significant	   difference	   between	   these	   groups	   was	   found	   in	   the	  prevalence	  of	  AKI	  (41.3%	  vs.	  30.0%,	  p	  =	  0.0436).	   	  Despite	  relatively	  high	  mortality	  rates	  compared	  to	  other	  conditions	  presenting	  through	  the	  ED,	  patients	  with	  cryptic	  shock	   minor	   and	   severe	   sepsis	   without	   lactate	   elevation	   are	   very	   frequently	  admitted	  to	  floor	  beds	  (42.8%	  and	  48.3%,	  respectively).	  	  Taken	  together,	  these	  data	  suggest	   that	   in	   our	   population	   of	   patients	   in	   severe	   sepsis,	   hyperlactatemia	   is	  equivalent	  to	  other	  types	  of	  organ	  dysfunction	  in	  terms	  of	  severity.	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   Our	  results	  are	  interesting	  in	  light	  of	  the	  increasing	  attention	  being	  paid	  the	  patient	   group	   characterized	   by	   normotension	   and	   a	   serum	   lactate	   level	   above	  normal	  but	  below	  the	  threshold	  for	  cryptic	  shock	  (>4.0	  mmol/L);	  this	  group,	  termed	  “cryptic	  shock	  minor”	  in	  our	  study,	  is	  also	  referred	  to	  as	  “preshock”	  by	  other	  groups.	  	  Howell	  et	  al.	  reported	  a	  mortality	  odds	  ratio	  of	  2.2	  for	  normotensive	  septic	  patients	  with	  lactates	  between	  2.5-­‐4.0	  when	  compared	  to	  patients	  with	  lactates	  <2.5mmol/L	  [124];	  this	  is	  similar	  to	  the	  odds	  ratio	  of	  2.0	  found	  by	  Mikkelsen	  et	  al.	  in	  their	  non-­‐shock	  subgroup	  analysis	  [75].	  	  In	  an	  observational	  study	  of	  535	  “preshock”	  patients,	  Tang	   et	   al.	   noted	   an	   in-­‐hospital	   mortality	   rate	   of	   only	   1.1%	   but	   high	   rates	   of	  vasopressor	   use	   (12.9%)	   and	  mechanical	   ventilation	   (13.3%)	   during	   the	   hospital	  stay	  [135].	  In	  another	  study	  of	  similar	  size,	  Song	  et	  al.	  studied	  hospital	  outcomes	  for	  474	  ED	  patients	  presenting	  in	  “preshock;”	  their	  mortality	  rate	  was	  10.1%,	  similar	  to	  our	   28-­‐day	  mortality	   rate	   of	   12.3%	   [121].	   	   Furthermore,	   15.4%	   of	   these	   patients	  were	  given	  vasopressors	  during	  their	  hospital	  stay,	  which	  is	  comparable	  to	  the	  rate	  of	  in-­‐hospital	  vasopressor	  usage	  in	  our	  cryptic	  shock	  minor	  population	  (17.4%).	  	  	   Thus,	  whereas	   there	  were	   few	   significant	   differences	   in	   outcomes	  between	  our	   cryptic	   shock	   minor	   group	   and	   the	   group	   in	   severe	   sepsis	   without	   lactate	  elevation,	  we	  do	  observe	  trends	  toward	  increased	  severity,	  and	  these	  trends	  are	  in	  keeping	  with	  the	  literature.	  	  Cryptic	  shock	  minor	  or	  “preshock”	  likely	  represents	  an	  at-­‐risk	   population	   with	   the	   potential	   for	   progression	   to	   either	   cryptic	   shock	   or	  vasopressor-­‐dependent	  shock	  early	  in	  the	  hospital	  stay,	  and	  so	  it	  will	  be	  important	  to	   discover	   features	   of	   these	   patients	   that	   are	  markers	   for	   this	   risk.	   	   The	   current	  literature	   suggests	   that	   such	   features	   may	   include	   altered	   mental	   status,	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hypotension,	   tachypnea,	   elevated	   BUN,	   and	   high	   organ	   dysfunction	   scores	   [121,	  135].	  	  	  	  
Comparison	  with	  a	  similar	  classification	  schema	  In	  contrast	   to	  many	  of	   the	  previously-­‐described	  studies	  recorded	   in	   the	   literature,	  which	   focused	   primarily	   on	   one	   or	   two	   of	   subclassifications	   of	   severe	   sepsis	   or	  septic	   shock	   individually,	   we	   incorporated	   the	   full	   spectrum	   of	   severe	   sepsis	   and	  septic	  shock	  patients	  in	  our	  analysis.	  	  The	  advantage	  to	  this	  approach	  is	  that	  it	  offers	  a	   more	   universal	   risk	   stratification	   system	   for	   severe	   sepsis	   and	   septic	   shock	  patients.	  	  	  To	  our	  knowledge,	  only	  one	  other	  study	  has	  attempted	  to	  create	  a	  similar	  comprehensive	   classification	   system	   by	   combining	   initial	   lactate	   levels	   with	   an	  assessment	   of	   hemodynamic	   stability	   [128].	   	   In	   a	   multicenter	   Brazilian	   study	  published	  after	  the	  initiation	  of	  our	  study,	  Ranzani	  et	  al.	  categorized	  1,948	  ED	  and	  hospitalized	  patients	  with	  severe	  sepsis	  and	  septic	  shock	  by	  lactate	  measurements	  and	  the	  presence	  of	  persistent	  hypotension	  despite	  adequate	  volume	  resuscitation.	  	  After	   categorization,	   there	   were	   219	   (12%)	   in	   dysoxic	   shock,	   549	   (28%)	   in	  vasoplegic	   shock,	   162	   (12%)	   in	   cryptic	   shock,	   and	   1,018	   (52%)	   in	   severe	   sepsis	  without	   hyperlactatemia.	   	   Their	   classification	   system	   utilized	   a	   high	   lactate	  threshold	   of	   >4	   mmol/L	   for	   their	   dysoxic	   and	   cryptic	   shock	   groups	   and	   did	   not	  include	  a	  cryptic	  shock	  minor	  category.	  	  The	  hospital	  mortality	  rates	  of	  each	  group	  were	   60.3%,	   48.1%,	   35.2%	   and	   16.8%,	   respectively,	   a	   mortality	   trend	   roughly	  comparable	   with	   our	   results.	   	   Additionally,	   the	   incidence	   of	   dysoxic	   (12%)	  compared	  to	  vasoplegic	  shock	  (28%)	  in	  this	  study	  was	  similar	  to	  our	  data.	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   However,	  there	  are	  several	  key	  differences	  between	  this	  study	  and	  our	  own.	  	  The	  study	  by	  Ranzani	  et	  al.	  did	  not	  perform	  a	  multivariate	  analysis,	  so	  it	  is	  difficult	  to	   determine	   if	   clinical	   confounders	   may	   have	   been	   partly	   responsible	   for	   their	  results.	  	  Their	  study	  also	  used	  the	  presence	  or	  absence	  of	  persistent	  hypotension	  as	  a	   criterion	   for	   classification,	   but	   it	   is	   unclear	   how	   exactly	   this	   definition	   was	  instituted.	   	   For	   example,	   only	   93%	   of	   their	   “vasoplegic	   shock”	   and	   98%	   of	   their	  “dysoxic	   shock”	   groups	   received	   “adequate	   volume	   expansion	   and	   vasopressor	   if	  necessary,”	   and	   the	   rate	   of	   vasopressor	   use	  was	   not	  mentioned	   for	   these	   groups.	  	  We	  chose	  to	  use	  a	  more	  definitive	  criterion	  (vasopressor	  use	  in	  the	  ED)	  to	  separate	  severe	   sepsis	   from	   septic	   shock	   patients,	   bearing	   in	   mind	   that	   our	   vasopressor-­‐dependent	  patients	  likely	  represent	  a	  sicker	  subset	  of	  the	  total	  septic	  shock	  group.	  	  This	   difference	   in	   definition	   may	   partly	   explain	   why	   a	   lower	   percentage	   of	   our	  registry	   subjects	   were	   classified	   as	   having	   overt	   septic	   shock	   (16.6%	   vs.	   39.4%).	  	  Another	   possibility	   is	   that	   their	   patients	   presented	   later	   or	   were	   diagnosed	   with	  sepsis	  at	  a	  later	  stage,	  leading	  to	  higher	  rates	  of	  septic	  shock.	  	   Furthermore,	  Ranzani	  et	  al.	  included	  patients	  presenting	  from	  inpatient	  units	  (both	   wards	   and	   ICUs)	   as	   well	   as	   from	   the	   emergency	   department;	   ED	   patients	  made	   up	   less	   than	   half	   of	   their	   total	   patient	   population.	   	   It	   is	   unclear	   from	   their	  study	  whether	  the	  incidence	  and	  mortality	  rate	  of	  various	  subgroups	  is	  affected	  by	  the	  location	  of	  diagnosis	  (ICU,	  ward	  or	  ED).	  	  By	  contrast,	  our	  classification	  system	  is	  the	   first	   to	   focus	   exclusively	   on	   septic	   patients	   diagnosed	   and	   managed	   in	   the	  emergency	  department.	   	   Lastly,	   although	   the	  mortality	   trends	  were	   similar	   across	  groups	  between	  our	   two	  populations,	   their	  mortality	   rates	  are	  significantly	  higher	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when	   directly	   compared	   to	   our	   corresponding	   group.	   This	   may	   be	   a	   result	   of	   a	  different	   septic	   patient	   population,	   a	   delayed	   time-­‐to-­‐diagnosis	   of	   sepsis,	   or	  differences	  in	  care	  in	  the	  hospitals	  from	  which	  their	  population	  was	  drawn.	  	  	  
Other	  high-­‐risk	  groups	  As	   an	   exploratory	   analysis	   of	   other	   septic	   patients	   considered	   at	   high	   risk,	   we	  evaluated	   incidence	   and	   outcomes	   for	   two	   other	   groups:	   subjects	   in	   severe	   shock	  (defined	   as	   requiring	   two	   or	   more	   vasopressor	   agents	   in	   the	   ED)	   and	   subjects	  presenting	   in	   hemodynamic	   extremis	   (initial	   SBP	   lower	   than	   70mmHg).	   	   The	  presentation	   of	   severe	   shock	   was	   frequently	   seen;	   in	   fact,	   the	   majority	   of	  vasopressor-­‐dependent	  shock	  subjects	  were	  treated	  with	  two	  or	  more	  vasopressors	  (42	   of	   74,	   or	   57%),	   suggesting	   that	   one	   vasopressor	   agent	   was	   not	   effective	   in	  controlling	  blood	  pressure	  for	  the	  majority	  of	  vasopressor-­‐dependent	  patients.	  	  The	  28-­‐day	  mortality	  rate	  for	  severe	  shock	  was	  33.3%;	  in	  comparing	  this	  with	  the	  50%	  mortality	   rate	   of	   the	   dysoxic	   shock	   group,	   it	   is	   surprising	   to	   note	   that	   an	   initial	  lactate	  >4.0	  mmol/L	  seems	  to	  confer	  a	  higher	  risk	   for	  death	   than	  the	  requirement	  for	   multiple	   vasopressors.	   	   In	   a	   further	   sub-­‐analysis,	   the	   16	   subjects	   in	   severe	  dysoxic	  shock	  showed	  a	  trend	  toward	  higher	  28-­‐day	  mortality	  than	  the	  26	  subjects	  in	   severe	  vasoplegic	   shock	   (50.0%	  vs.	  23.1%,	  p	  =	  0.098).	   	  These	  data	  suggest	   that	  even	   among	   the	   most	   hemodynamically-­‐unstable	   patients	   requiring	   multiple	  vasopressors,	   the	   initial	   lactate	   level	   may	   be	   used	   as	   a	   further	   risk	   stratifier.	  	  However,	   further	   comparisons	   between	   these	   groups	   were	   limited	   by	   the	   low	  sample	  sizes.	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   23	   subjects	  presented	   in	  hemodynamic	   extremis,	   representing	   just	  5.2%	  of	  all	   subjects.	   	   The	   initial	   lactate	   level	   in	   11	   (47.8%)	   of	   subjects	  was	   >4.0	  mmol/L,	  suggesting	   that	  a	  substantial	  minority	  of	   these	  patients	  have	  objective	  evidence	  of	  prolonged	   tissue	   hypoxia	   at	   presentation.	   	   A	   different	   set	   of	   11	   (47.8%)	   subjects	  required	  vasopressor	   therapy	   in	   the	  ED,	  and	  even	  more	  of	   these	  patients	   (65.2%)	  required	   vasopressor	   support	   early	   in	   the	   hospital	   course;	   this	   shows	   that	   initial	  resuscitation	  with	  fluids	  is	  commonly	  inadequate	  for	  hemodynamic	  stabilization	  in	  these	  patients.	  	  In	  fact,	  the	  28-­‐day	  mortality	  in	  this	  group	  (21.7%)	  seems	  equivalent	  to	  vasoplegic	  shock	  (21.1%)	  or	  cryptic	  shock	  major	  (18.5%),	  two	  groups	  for	  whom	  EGDT	   has	   been	   advocated;	   conceivably,	   patients	   presenting	   in	   hemodynamic	  extremis	   could	   also	   benefit	   from	   similar	   protocolized	   optimization	   of	   their	  hemodynamic	  status.	  	  To	  our	  knowledge,	  this	  is	  the	  first	  study	  to	  evaluate	  outcomes	  in	   this	   subgroup	   of	   sepsis	   patients;	   more	   research	   is	   certainly	   needed	   to	   better	  characterize	  this	  presentation	  of	  severe	  sepsis.	  	  
Limitations	  Subjects	   in	   the	  registry	  were	  prospectively	  evaluated	  by	  multiple	  clinicians	  during	  pre-­‐defined	  time	  periods;	  however,	  most	  ED	  clinicians	  working	  at	  the	  two	  sites	  were	  not	   affiliated	   with	   the	   registry,	   and	   thus	   the	   included	   patients	   represent	   a	   small	  subset	   of	   all	   septic	   patient	   seen	   at	   these	   two	   centers	   over	   the	   documented	   time	  period.	   	   Additionally,	   included	   patients	   were	   required	   to	   meet	   the	   1992	   clinical	  definition	   for	   sepsis	   (at	   least	   2	   of	   4	   SIRS	   criteria),	   a	   more	   stringent	   screening	  method	  than	  using	  the	  2001	  definition	  for	  sepsis	  (which	  allows	  for	  the	  presence	  of	  other	   clinical	   signs	   without	   positive	   SIRS).	   	   The	   chart	   extraction	   process	   was	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performed	   retrospectively	   by	   multiple	   investigators,	   opening	   the	   possibility	   for	  errors	   in	   chart	   extraction	   because	   of	   individual	   variation	   in	   data	   interpretation.	  	  However,	   comparison	   of	   over	   500	   overlapping	   data	   points	   showed	   greater	   than	  95%	  concordance	  between	  two	  separate	  investigators.	  	  Certain	  data	  points,	  such	  as	  arterial	  blood	  gas	  and	  CVP/ScvO2	  measurements,	  were	  not	  performed	  in	  all	  patients	  as	   care	   decisions	   were	   left	   to	   the	   treating	   providers;	   the	   lack	   of	   these	   data	   for	  certain	  subjects	  make	  the	  interpretation	  of	  patterns	  between	  groups	  difficult.	  	  	   In	  order	  to	  categorize	  patients	  appropriately	  by	  initial	  lactate	  level,	  we	  were	  forced	  to	  exclude	  75	  registry	  patients	  with	  no	  initial	  lactate	  drawn	  in	  the	  emergency	  department,	  and	  the	  exclusion	  of	   these	  patients	  could	  conceivably	  have	  biased	  the	  data.	  	  However,	  the	  mortality	  rate	  of	  the	  excluded	  group	  was	  comparable	  to	  severe	  sepsis	   without	   lactate	   elevation	   (6.7%	   vs.	   7.2%,	   p	   =	   1.00).	   Although	   sepsis	  guidelines	   would	   advocate	   checking	   an	   initial	   lactate	   on	   presentation	   in	   these	  patients,	   it	   is	   likely	   that	   they	   represent	   a	   low-­‐risk	   group	   whose	   inclusion	   in	   the	  classification	  would	  not	  have	  significantly	  altered	  the	  findings	  of	  our	  analysis.	  	  	   We	   chose	   to	   include	   all	   severe	   sepsis	   and	   septic	   shock	   subjects	   enrolled	  during	  the	  time	  period,	  in	  order	  to	  accurately	  estimate	  the	  relative	  incidences	  of	  our	  groups;	  however,	  this	  created	  large	  disparities	  in	  group	  size.	   	  There	  were	  very	  few	  subjects	   in	   the	  most	   severe	   subject	   groups	   (dysoxic	   shock	   and	   vasoplegic	   shock),	  and	  so	  stochastic	  events	  would	  have	  been	  more	  likely	  to	  influence	  results,	  especially	  if	   the	  results	  had	  no	  biological	  explanation	  (such	  as	  the	  low	  frequency	  of	  coronary	  artery	  disease	   in	  dysoxic	   shock	   subjects).	   	   Furthermore,	   it	   is	   likely	   that	   our	   study	  registry	  was	  underpowered	  to	  detect	  small	  mortality	  differences	  between	  the	  larger	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groups	   (cryptic	   shock	   minor	   and	   severe	   sepsis	   without	   lactate	   elevation,	   for	  example);	   other	   studies	  with	   similar	   outcome	   rates	   and	   larger	   sample	   sizes	   have	  found	  significant	  differences	  between	  these	  groups.	  	  Beyond	  the	  primary	  outcome	  of	  this	   study,	   the	   results	   of	   our	   comparisons	   are	   mainly	   hypothesis-­‐generating;	  therefore	  we	  statistically	  compared	  all	  results	  at	  a	  constant	  alpha	  level	  of	  0.05,	  and	  no	  correction	  was	  made	  for	  multiple	  comparisons.	  	  	  	  	   In	  the	  multivariate	  analysis,	  we	  chose	  to	  exclude	  certain	  variables	  known	  to	  influence	   severity,	   such	   as	   certain	   treatment	   characteristics	   (time-­‐to-­‐antibiotics,	  appropriate	   antibiotics,	   and	   timely	   use	   of	   vasopressors)	   as	   well	   as	   markers	   of	  severity	   such	   as	   number	   of	   organ	   dysfunctions	   or	   MEDS	   scores.	   	   In	   discussing	  whether	   to	   include	   treatment	   decisions,	   we	   reasoned	   that	   treatment	   decisions	  would	  mostly	   be	   influenced	   by	   severity	   of	   presentation;	   sicker	   patients	  would	   be	  more	   likely	   to	   receive	   timely	  and	  correct	   sepsis	  management,	   and	   this	  would	  bias	  the	   results	   in	   favor	   of	   a	   positive	   result	   (a	   type	   I	   error).	   	   Second,	   we	   decided	   not	  include	  other	  severity	  markers	  (such	  as	  the	  MEDS	  score	  or	  mean	  number	  of	  organ	  dysfunctions)	   in	  our	  multivariate	  analysis.	   	  Our	  reasoning	  was	   that	  we	  considered	  our	   classification	   system	   to	   be	   a	   simpler	   alternative	   rather	   than	   complimentary	  method	  to	  MEDS	  or	  APACHE	  II	  scoring	  for	  risk	  prediction.	  	  Furthermore,	  one	  of	  the	  criteria	   for	   the	   MEDS	   score	   (septic	   shock)	   was	   definitional	   to	   our	   classification	  system,	  and	  we	  accounted	  for	  two	  of	  the	  other	  MEDS	  criteria	  within	  the	  multivariate	  analysis	   (age	   and	   pulmonary	   source	   of	   infection).	   	   Nevertheless,	   the	   exclusion	   of	  these	   known	   severity	   indicators	   in	   the	  multivariate	   analysis	  may	  have	   biased	   our	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results.	   	   Lastly,	   the	   secondary	   outcomes	  were	   all	   assessed	   by	   univariate	   analysis,	  which	  increases	  the	  probability	  of	  confounding	  biases.	  
	  
Future	  Directions	  Future	  research	  in	  the	  realm	  of	  predicting	  severity	  in	  sepsis	  is	  urgently	  needed,	  with	  the	  objective	  of	  improving	  both	  prognostication	  and	  ultimately	  treatment	  decisions	  for	   the	   proximal	   phase	   provider.	   	   As	   we	   have	   shown,	   initial	   serum	   lactate	   levels	  confer	  a	  heterogeneity	  of	  outcomes	  on	  current	  definitions	  of	  vasopressor-­‐dependent	  shock	   and	   severe	   sepsis;	   it	   would	   be	   fruitful	   to	   perform	   subgroup	   analyses	   of	  previous	  observational	  and	  randomized	  control	  trials	  in	  order	  to	  determine	  possible	  subgroups	  (such	  as	  dysoxic	  shock	  or	  cryptic	  shock	  minor)	  who	  may	  have	  benefitted	  from	  a	  protocolized	  care	  or	  EGDT-­‐based	  strategy.	  	  Future	  trials	  could	  also	  use	  initial	  lactate	  levels	  and	  ED	  vasopressor	  use	  to	  inform	  the	  formation	  of	  a	  priori	  subgroups	  for	  the	  same	  purpose	  of	  defining	  treatment	  benefits.	  	  	   In	  this	  study,	  we	  employed	  a	  snapshot	  of	  the	  patient	  at	  time	  of	  presentation	  in	  order	  to	  evaluate	  distant	  hospital	  outcomes.	  	  However,	  as	  sepsis	  is	  a	  progressive	  process,	  it	  would	  be	  useful	  to	  examine	  these	  subgroups	  longitudinally	  through	  their	  hospital	  stay	  to	  determine	  the	  progression	  of	  disease.	  	  Further	  longitudinal	  analyses	  could	   include	   time	   to	   vasopressors,	   length-­‐of-­‐stay	   in	   the	   ICU	   and	   hospital,	   serum	  lactate	  trends,	   the	  rate	  of	   individual	  and	  cumulative	  organ	  failures	  (via	  daily	  SOFA	  scores),	   and	   a	   Kaplan-­‐Meier	   assessment	   of	   survival.	   	   It	   would	   be	   especially	  interesting	   to	   follow	   the	   clinical	   trajectories	   of	   the	   cryptic	   shock	  minor	   category,	  since	  a	   large	  percentage	  of	   these	   subjects	  may	  progress	   to	  either	   cryptic	   shock	  or	  vasopressor-­‐dependent	  shock.	  	  A	  determination	  of	  clinical	  or	  laboratory	  criteria	  that	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could	   predict	   risk	   of	   hemodynamic	   decompensation	   or	   death	   in	   the	   cryptic	   shock	  major	  and	  minor	  categories	  could	  also	  prove	  useful	  for	  risk	  stratification	  within	  this	  moderate-­‐risk	  group.	  	  Lastly,	  there	  is	  still	  much	  to	  be	  done	  to	  understand	  the	  clinical	  history	  as	  well	  as	  evaluate	  the	   laboratory	  characteristics	  and	  outcomes	  of	  patients	  presenting	  in	  hemodynamic	  extremis.	  	  
Conclusion	  Despite	  a	  wealth	  of	  knowledge	  on	   the	  determinants	  of	   severity	   in	   sepsis,	   a	   simple	  and	   accurate	  method	   of	   predicting	   risk	   in	   sepsis	   patients	   at	   time	   of	   presentation	  remains	  elusive.	  	  This	  study	  demonstrates	  that	  risk	  stratification	  can	  be	  performed	  in	   the	   hyperacute	   phase	   of	   care	   via	   categorizing	   septic	   patients	   by	   initial	   lactate	  levels,	  vasopressor	  use	  and	  organ	  dysfunction	  in	  the	  ED;	  this	  prognostication	  ability	  is	  maintained	  after	  controlling	  for	  major	  determinants	  of	  sepsis	  severity.	  	  	  	   Even	   among	   vasopressor-­‐dependent	   patients,	   presenting	   lactate	   levels	   can	  risk-­‐stratify	   patients;	   dysoxic	   shock	   exemplifies	   a	   more	   deadly	   presentation	   of	  septic	   shock	   that	   certainly	   warrants	   increased	   awareness	   and	   further	   study.	  	  Remarkably,	   vasoplegic	   shock	   is	   similar	   in	   both	   incidence	   and	   severity	   to	   cryptic	  shock	   major	   despite	   the	   former	   group’s	   dependence	   on	   early	   vasopressors.	   	   It	  appears	   that	   ED	   vasopressor	   use	   and	   initially	   high	   serum	   lactate	   levels	   confer	  roughly	  equal	  and	  additive	  risk	  of	  poor	  outcomes	  during	  the	  hospital	  stay.	   	  Lastly,	  patients	  presenting	   in	  cryptic	  shock	  minor	  seem	  to	  represent	  an	   intermediate-­‐risk	  group	   between	   cryptic	   shock	   major	   and	   other	   severe	   sepsis	   patients;	   this	   group	  presents	   a	   unique	   opportunity	   to	   study	   sepsis	   progression	   and	   evaluate	   future	  treatment	  strategies.	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   Our	   classification	   system	   for	   severe	   sepsis	   and	   septic	   shock	   may	   help	   to	  inform	   the	   design	   of	   future	   trials	   in	   the	   field	   of	   early	   sepsis	   management.	   	   An	  assessment	  of	  incidence	  for	  different	  presentations	  within	  severe	  sepsis	  and	  septic	  shock,	  as	  we	  performed	  in	  this	  study,	  will	  assist	  in	  determining	  the	  subgroup	  sizes	  necessary	  to	  answer	  questions	  of	  efficacy	  and	  power.	  	  Furthermore,	  stratification	  of	  future	  treatment	  trials	  by	  initial	  lactate	  levels	  and	  early	  vasopressor	  use	  could	  aid	  in	  discovering	   subsets	   of	   patients	   that	   may	   benefit	   from	   goal-­‐oriented	   resuscitative	  strategies.	   	   It	   is	   our	  hope	   that	   early	   and	  accurate	  prognostication	   in	   severe	   sepsis	  and	  septic	  shock	  will	  advance	  the	  cause	  of	  improving	  sepsis	  care	  in	  the	  future.	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Appendix:	  Data	  Collection	  Form	  
 
SHOCK INDEX IN SEVERE SEPSIS 
HIC # 0707002865      PT ID #_______________ 
 
Sex:  Male   Female  Age______________ 
1. EXCLUSION CRITERIA 
 Age <18 
 Pt with documented Comfort measures prior to, or during stay in ED 
 Sepsis (2 SIRS + Source and without organ failure)   
 Discharged to home 
 
2. SIRS (at least two of the following): 
 Temperature > 100.4 or < 96.8 degrees Celsius 
 Heart Rate > 90 beats per minute  
 Respiratory Rate > 20 breaths per minute or PCo2 less than 32 mm Hg 
 White Blood cell count > 12x10 or < 4x10 or > 10% immature neutrophils 
 
3. SOURCES (any one of the following): 
 WBC >10,000 or <4000 or >10% bands  
 Temp > 100.4 or < 96.8 
 Blood cultures drawn in ED    
 Antibiotics administered in ED 
 Documentation of presumed source of infection in ED- LOCATION: 
  PNA – Upper or Lower Respiratory by physical exam or Chest Xray 
  Genitourinary – by Urinalysis, physical exam or diagnostic study 
  Intra-Abdominal – peritonitis, abscess, or other suspected source 
  Soft Tissue – cellulitis, necrotizing fasciitis, abscess, or ulceration of skin  
  Other – (Ex—CNS, line, etc.) List:  ________________________  
 
4. END-ORGAN DYSFUNCTION (any one of the following): 
 Transient systolic BP <90 that responds to fluid resuscitation 
 Lactate level > 2mmol/mL 
 Unexplained acidosis (pH < 7.35) or a serum bicarbonate < 21 
 Altered mental status (change from baseline) 
 Platelets <150,000mm3 (no hx thrombocytopenia) 
 Elevation of bilirubin above normal or (direct or indirect) > than baseline 
 High coagulation factors (any elevation in absence of heparin or coumadin use) 
 Acute Renal Failure (Cr >0.5 from baseline, or abnormal if no baseline available) 
 Hypoxemia (oxygen saturation less than 90%) 
 Troponin elevation above baseline 
 Other – please list: ________________________ 
 
5. CLASSIFICATION (Highest classification at any point in ED) 
 Severe Sepsis (2 SIRS + Source+ Organ Failure) 
 Septic Shock (SBP < 90mmHg after IVF) 
 
6. Inclusion in Study: 
  Yes – meets all inclusion criteria and does not meet any exclusion criteria 
  No – does NOT meet all Inclusion Criteria, or meets any Exclusion Criteria 
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1.  TIME (24:00): ED Presentation: Triage VS (T0)  __ __ : __  __  
ED Discharge: Last RN note or VS (Tf)              __ __ : __  __ 
2. VITAL SIGNS (Initial to Discharge from ED or start of Vasopressor) 
 TIME SBP DBP HR Temp Pox RA, NC 
Initial        
Final      N/A N/A 
 
  TIME SBP DBP HR  TIME SBP DBP HR 
1     9     
2     10     
3     11     
4     12     
5     13     
6     14     
7     15     
8     16     
3. OTHER VITALS: (IN ED) 
Lowest SBP _________ Lowest DBP __________   Lowest MAP ____________ 
Highest Temp: __________degrees C or F Highest RR: __________ breaths/minute 
Lowest SaO2: __________ *on: __________ liters O2 by __________ 
4. GCS (Triage or scored from neuro exam) __________ 
5. FLUIDS (in ED) TIME START __ __ : __ __   
TRIAGE:_________  mL    +   ED ________ mL   =  TOTAL __________ mL 
 
6. ANTIBIOTICS  NO   YES-  TIME STARTED __ __: __ __  
 Vancomycin     Zosyn    Ciprofloxacin  Flagyl  Unasyn 
 Other(s)  ________________________________________ 
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7. CULTURES/SENSITIVITIES  Appropriate ED ABX Coverage  Inappropriate  
BLOOD                 NO   YES- TIME  __ __: __ __  
RESULTS:  n/a   No Growth ____________DATE:  __ __ / __ __ / __ __ 
URINE                 NO   YES- TIME  __ __: __ __  
RESULTS:  n/a   No Growth ____________DATE:  __ __ / __ __ / __ __ 
OTHER     NO   YES- TIME  __ __: __ __  
RESULTS:  n/a   No Growth ____________DATE:  __ __ / __ __ / __ __ 
8.  PAST MEDICAL HISTORY (from ED notes or discharge Summary) 
Nursing Home Residence   NO   YES 
 Liver Disease     CHF    EF__  No Echo   CAD  HTN  
 COPD   Asthma   ESRD   DM  ETOH 
 Immunocompromised (NOS)   HIV/AIDS  Cancer  Cancer w/ chemo 
  CVA/TIA  Alzheimers/Dementia/MR/Chronic AMS at baseline 
 Other Significant _______________________________________________ 
9.  LABORATORY DATA (Initial) 
WBC ______ Bands  ______% Hct  _____ Plt ______ 
Na  ______ Cl ______ BUN _____ 
K ______ HCO3 ______ Cr _____ Baseline Cr ______  
Bt ______ Bd ______ Trop _____ Albumin _____   
PT ______ INR ______ PTT _____  
10.  LACTATE (Value/Time) 
1st ED____/____   ED Peak____/____   1st Floor ____/____  Floor Peak____/____ 
11. ABG’s – INITIAL _____ /  _____ /  _____  /  _____    Time __ __ : __ __ 
  Lowest pH ______   Other P02____________________________________ 
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12. Early Goal Directed Therapy: Documented in Note   NO   YES 
a. Central Line Placed  NO  YES- TIME  __ __: __ __  
b. Initial ED CVP____ Peak ____  NO  YES-  TIME  __ __: __ __  
c. ScVo2 (VBG) ________  NO  YES-  TIME  __ __: __ __  
 1st 24 hours ______  ______  ______  ______  ______  ______ ______ 
 d. Vasopressors in ED  NO  YES- TIME  __ __: __ __ 
    Vasopressors in Hospital  NO  YES -    <72h        >72h  
  Norepinephrine     Dopamine  Other______________________ 
 e. Dobutamine in ED  NO  YES- TIME  __ __: __ __ 
    Dobutamine in Hospital  NO  YES -    <72h        >72h  
 
13. OTHER TREATMENTS: 
a. Corticosteroids  NO   YES-   IN ED   IN Floor 
b. Source Control   NO   YES-   IN ED   IN Floor  
 Type:     Line pulled  abscess drained   to OR   Other:_________ 
c. Mech. Vent    NO   YES-   IN ED    IN ICU 
d. Tight Glu Contr.   NO   YES  IN ED   
e. Blood Prod in ED  NO   YES-  Type ________________ 
f. Xigris   NO   YES-   IN ED  IN ICU 
14. DISPOSITION from ED 
 Admitted-   ICU   STEP DOWN  FLOOR  OR 
 Morgue   Other ____________  
15. OUTCOME   Survived hospital discharge  




16. ED Attending DIAGNOSES  
1) _______________ 2) ______________  3) _______________ 
17. FINAL HOSPITAL DIAGNOSES on DISCHARGE SUMMARY  
1) _______________ 2) ______________  3) ______________ 4) ________________ 
18. SEPSIS MIMIC   No  Yes           
19. EMCCM PT    No  Yes   
20. Patient on beta-blocker prior to presentation:          No  Yes   
 
